Worksheets

[10 bagger]

QMDT.. $0.0528..Polartec LLC to License Stay-Fresh(R) Antimicrobial Technology

Quick-Med Signs License With Polartec, LLC for Products Utilizing Stay Fresh Antimicrobial Technology

GAINESVILLE, FL -- (Marketwired) -- 08/27/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a license for a range of products and fields of use with Polartec LLC, a premium producer of textile solutions.

"We are very pleased to enter into this partnership with such a strongly positioned and technologically advanced partner as Polartec, whose leadership and innovation in performance textiles is recognized worldwide. Our Stay Fresh technology can permit Polartec to unlock added value in their product offerings, as well as access entire new segments with their performance fabrics, and strong network of industrial partners," said Bernd Liesenfeld, Quick-Med's President.

About Stay Fresh

Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly used in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to be utilized to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has also granted clearance to market an antibacterial medical textile based on Stay Fresh Technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously, with development of additional applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications, with consumer applications of Stay Fresh Technology having EPA registration for the treated articles, as well as an FDA clearance for an antibacterial medical textile product. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

About Polartec, LLC

Polartec, LLC is the premium producer of innovative textile solutions. Since inventing modern synthetic fleece in 1981, the engineers at Polartec have continued to push the limits of fabric technology. Today, Polartec supplies the world with the most advanced fabric innovations. Polartec products range from advanced lightweight wicking fabric, to insulation and weather protection textiles and are utilized by leading apparel brands, the U.S. military and other global militaries, flame resistance, work wear, and contract upholstery markets. For more information, visit polartec.com.

© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc.

============================================================

Quick-Med Technology, Inc. Receives Notice-of-Allowance for New NIMBUS Patent

New Poly-Electrolyte Complex (PEC) Patent Will Protect NIMBUS Antimicrobial Product Applications

GAINESVILLE, FL -- (Marketwired) -- 08/23/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has received a Notice-of-Allowance for an additional new U.S. patent that will protect its novel, non-leaching NIMBUS® antimicrobial technology.

The U.S. Patent and Trademark Office has allowed all 41 claims in Quick-Med Technologies' U.S. Patent Application No. 12/830,062 titled, "POLYELECTROLYTE COMPLEX FOR IMPARTING ANTIMICROBIAL PROPERTIES TO A SUBSTRATE." This new patent will provide protection for an improved method of preparing the company's NIMBUS antimicrobial products. The method utilizes a Poly-Electrolyte Complex, or PEC in which a negatively-charged (anionic) polymer is used to stabilize the active antimicrobial agent -- a positively-charged (cationic) polymer. This complex allows the NIMBUS polymer to be bonded to a wider variety of substrates, opening the door for new applications and products.

"The PEC method is an important improvement in the way we manufacture our NIMBUS materials," said Dr. William Toreki, one of the inventors of the method, and Quick-Med's Vice-President of Research & Development. "The PEC makes the antimicrobial component more adherent on a molecular level, and that makes it easier to attach it to the surfaces of bandages and wound dressings." The PEC method is currently in-use in commercial products such as the BIOGUARD® series of wound dressings sold by Derma Sciences, under license from Quick-Med. Quick-Med expects this new patent to issue in approximately 6 to 8 weeks from today, and it will remain in force until the year 2030.

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.

While NIMBUS antimicrobials remain at full strength, the active agent in most other antimicrobial technologies is depleted gradually while in use. These other antimicrobials carry the risk of irritation or interference with healing in products such as wound dressings and textile applications in which the treated material is next to or used on the skin. The bonding of an antimicrobial to a substrate is a paradigm shift from the current state-of-the-art which fosters release of the active agent. The value of a non-leaching antimicrobial is that it does not allow depletion of the active agent which can lead to damage to human skin or tissue cells such that they can cause irritation, delay healing and possibly initiate the development of bacterial resistance.

========================================================

Quick-Med Technologies Awarded NSF Grant to Develop Antimicrobial Coatings That Can Be Regenerated With Hydrogen Peroxide

Stay Fresh(R) Technology Competitively Selected by National Science Foundation for Development of Antimicrobial Surface Treatments

GAINESVILLE, FL -- (Marketwired) -- 05/30/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded grant IIP-1315379 by the National Science Foundation (NSF), titled: "Regenerable Antimicrobial Coatings Containing Zinc Oxide Binders for Hydrogen Peroxide Cleaning Solutions." Quick-Med's Stay Fresh® technology was competitively selected for this award under the Small Business Innovation Research (SBIR) program of NSF. The SBIR program, established by the U.S. Congress, supports scientific excellence and technological innovation through the investment of federal research funds by competitively awarding contracts and grants on the basis of scientific merit, commercial potential, and potential for societal impact by the supported research.

The Phase I objective of this research is to develop Regenerable Antimicrobial Coatings with long-lasting efficacy for use in medical instruments, devices, and hospital equipment and facilities. The same coatings will also have broad utility in the consumer, industrial, and institutional markets.

The coating technology is an extension of the highly effective Stay Fresh technology, sequestering Hydrogen Peroxide (HP) in zinc oxide particles incorporated into the coatings. Exposure of coated surfaces to commercially-available HP-containing cleaning products will cause binding of HP to the zinc oxide particles -- allowing HP to be sequestered within the coating after the surface has dried. This technology is designed to provide durable and long-lasting antimicrobial effect sufficient to reduce or eliminate the proliferation and spread of pathogenic organisms in between cleaning cycles. Additionally, the antimicrobial effect should be regenerated each time the surface is cleaned with peroxide-containing cleaning products.

The Phase I research grant is valued at about $150,000, and the performance period is from July 1, 2013 through December 31, 2013. The Phase 1 award also qualifies Quick-Med to apply for Phase 2, which can bring the total value close to $1M, and will develop the proof of concept to commercial readiness. "We are very pleased to have been competitively selected for this important advanced research program to develop antimicrobial coatings," said Bernd Liesenfeld, Quick-Med's President. "This award is a great validation of our Stay Fresh antimicrobial technology platform and will enable us to continue our development of products that help prevent microbial contamination, and pathogen transfer, particularly as focused on healthcare settings. We believe that this technology can be particularly helpful to aid infection control strategies in institutions housing vulnerable populations."

About Stay Fresh..

Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly utilized in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has granted clearance to market an antibacterial medical textile based on Stay Fresh technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously, with development of further applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

=============================================================
FDA Clears Stay-Fresh(R) Medical Textile Product

Quick-Med Receives 510k Clearance to Market Antibacterial Skinfold Management Device -- First Medical Product Utilizing Stay Fresh Technology

GAINESVILLE, FL -- (Marketwired) -- 05/29/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Food and Drug Administration (FDA) has issued clearance for distribution and marketing of a Stay Fresh® medical textile product. FDA granted 510k clearance for the Stay Fresh® antibacterial skinfold management textile, which provides durable protection against bacterial contamination for skinfold management in bariatric patients.

"We are very pleased to have received this clearance for both prescription (Rx) and Over-The-Counter (OTC) use," said Bernd Liesenfeld, Quick-Med's President. "This clearance represents a very powerful validation of our Stay Fresh technology, since the FDA review process is extremely meticulous and comprehensive; 510k clearance requires strong evidence of both effectiveness and of safety for users and care providers. Together with the existing EPA registration for Stay Fresh this provides strong regulatory support for our products already in development with partners, and for further products in our pipeline, both on the consumer and on the medical sides."

"Areas of skin-to-skin contact such as under breast folds or abdominal skin folds frequently develop redness, odor, and rashes due to increased moisture and friction that create an environment that promotes bacterial growth in the skin folds," said Professor Gregory Schultz, Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology at the University of Florida. "The Stay Fresh® antibacterial textile approved by the FDA provides an effective skin fold management system that will help manage moisture and bacterial pathogen growth for up to 5 days."

About Stay Fresh
Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly used in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to be utilized to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has granted clearance to market an antibacterial medical textile based on Stay Fresh Technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously, with development of additional applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

================================================

Quick-Med Technologies Awarded Contract to Develop Wound Healing Technology to Control Scar Contracture in Burn Patients

NIMBUS Technology Selected by Department of Defense for Advanced Wound Healing Technology SBIR Grant

GAINESVILLE, FL -- (Marketwired) -- 05/22/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded a contract by the U.S. Department of Defense for research on the "Development of Technologies to Control Scar Contracture after Burn Injuries." NIMBUS technology was competitively selected for this award under the Small Business Innovation Research (SBIR) program of the DoD Defense Health Program (DHP). The SBIR program, established by the U.S. Congress, supports scientific excellence and technological innovation through the investment of federal research funds by competitively awarding contracts on the basis of scientific merit and commercial potential.

The Phase I objective of this research is "to design a new innovative technology to intervene during the wound healing process, including inflammatory, proliferative and/or remodeling stages, to attenuate/control scar contracture and retain skin aesthetics following deep tissue burn injuries." The Phase I research contract is valued at about $150,000. Work starts immediately and is expected to take about 6 months. Follow-on phases of the award can bring the total value close to $1M, and will develop the proof of concept to commercial readiness.

"We are very pleased to have been competitively selected for this important advanced research program into dressings that can speed wound healing," said Bernd Liesenfeld, Quick-Med's President. "This award is a further validation of our NIMBUS antimicrobial technology platform and will enable us to continue our development a series of products that accelerate wound healing and help prevent microbial contamination."

The new research contract builds on Quick-Med's prior work developing a dressing that was shown to speed healing of vesicant (blister) injuries caused by chemical weapons (sulfur mustard gas). This previous research, which was conducted under Phase 1 and Phase 2 SBIR awards from the US Army, was presented at the 2011 Annual Meeting of the Wound Healing Society, where it received the top prize for Industrial Research and Development. This new award permits Quick-Med to extend that research to more directly address unmet commercial needs in treatments for the approximately 2.4 million thermal burns occurring annually in the US, with a dressing designed to reduce scarring and contracture in healing of severe burns. Part of the research will be conducted at the University of Florida's Institute for Wound Research.

"The NIMBUS super-absorbent polymer technology allows Quick-Med to develop a unique dressing that provides antimicrobial protection for the wound while also acting to minimize scar tissue formation, and inhibit matrix metalloproteinases to block contracture of tissues," said Professor Greg Schultz, Director of the Institute for Wound Research at the University of Florida. "This unique combination therapy should speed healing and reduce contraction of severe burns in our wounded warriors. It would also have extensive application for civilians with large burns."

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional and advanced wound care applications, both in the US and abroad. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by numerous U.S. patents and foreign counterparts. Additional applications currently under development include advanced wound dressings, medical adhesives, and catheters.
======================================================
From 8K filing:Item 1.01 Entry into a Material Definitive Agreement

The following discussion provides only a brief description of the document described below. The discussion is qualified in its entirety by the full text of the agreement, which is attached to this Current Report on Form 8-K as an exhibit.

On May 20, 2013, with an effective date as of May 13, 2013, Quick-Med Technologies, Inc. (the “Company” or "we") and the U.S. Army Medical Research and Material Command entered in to an agreement for the Company to provide Small Business Innovative Research (SBIR) Phase I research in “Development of Technologies the Control Scar Contracture after Burn Injuries”. The agreement provides payments to the Company of $149,999 over the period from May 15, 2013 through December 15, 2013.

Phase I is to determine the scientific or technical merit of ideas submitted to the U.S. Army by the Company. Phase II awards could be made in the government’s fiscal year 2014 (October 1, 2013 to September 30, 2014) if the approaches appear sufficiently promising as a result of Phase I and could cover 2-5 many years of effort over a period generally not to exceed 24 months.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits.

Exh. No. Description

10.1 Award/Contract between Quick-Med Technologies, Inc. and the U.S. Army Medical Research and Material Command effective as of May 13, 2013.

======================================================

FDA Clears Stay-Fresh(R) Medical Textile Product

Marketwire - May 29 08:00 EDT

Alert hits:OTC /qm
Company Symbols: OTC-PINK:QMDT

Quick-Med Receives 510k Clearance to Market Antibacterial Skinfold Management Device -- First Medical Product Utilizing Stay Fresh Technology

GAINESVILLE, FL -- (Marketwired) -- 05/29/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Food and Drug Administration (FDA) has issued clearance for distribution and marketing of a Stay Fresh® medical textile product. FDA granted 510k clearance for the Stay Fresh® antibacterial skinfold management textile, which provides durable protection against bacterial contamination for skinfold management in bariatric patients.

"We are very pleased to have received this clearance for both prescription (Rx) and Over-The-Counter (OTC) use," said Bernd Liesenfeld, Quick-Med's President. "This clearance represents a very powerful validation of our Stay Fresh technology, since the FDA review process is extremely meticulous and comprehensive; 510k clearance requires strong evidence of both effectiveness and of safety for users and care providers. Together with the existing EPA registration for Stay Fresh this provides strong regulatory support for our products already in development with partners, and for further products in our pipeline, both on the consumer and on the medical sides."

"Areas of skin-to-skin contact such as under breast folds or abdominal skin folds frequently develop redness, odor, and rashes due to increased moisture and friction that create an environment that promotes bacterial growth in the skin folds," said Professor Gregory Schultz, Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology at the University of Florida. "The Stay Fresh® antibacterial textile approved by the FDA provides an effective skin fold management system that will help manage moisture and bacterial pathogen growth for up to 5 days."

About Stay Fresh
Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly used in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to be utilized to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has granted clearance to market an antibacterial medical textile based on Stay Fresh Technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously, with development of additional applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

CONTACT: Quick-Med Technologies Bernd Liesenfeld
President [phone]
[e-mail]

Source: Quick-Med Technologies, Inc.

==================================================

Quick-Med Technologies Awarded Contract to Develop Wound Healing Technology to Control Scar Contracture in Burn Patients

NIMBUS Technology Selected by Department of Defense for Advanced Wound Healing Technology SBIR Grant

GAINESVILLE, FL -- (Marketwired) -- 05/22/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded a contract by the U.S. Department of Defense for research on the "Development of Technologies to Control Scar Contracture after Burn Injuries." NIMBUS technology was competitively selected for this award under the Small Business Innovation Research (SBIR) program of the DoD Defense Health Program (DHP). The SBIR program, established by the U.S. Congress, supports scientific excellence and technological innovation through the investment of federal research funds by competitively awarding contracts on the basis of scientific merit and commercial potential.

The Phase I objective of this research is "to design a new innovative technology to intervene during the wound healing process, including inflammatory, proliferative and/or remodeling stages, to attenuate/control scar contracture and retain skin aesthetics following deep tissue burn injuries." The Phase I research contract is valued at about $150,000. Work starts immediately and is expected to take about 6 months. Follow-on phases of the award can bring the total value close to $1M, and will develop the proof of concept to commercial readiness.

"We are very pleased to have been competitively selected for this important advanced research program into dressings that can speed wound healing," said Bernd Liesenfeld, Quick-Med's President. "This award is a further validation of our NIMBUS antimicrobial technology platform and will enable us to continue our development a series of products that accelerate wound healing and help prevent microbial contamination."

The new research contract builds on Quick-Med's prior work developing a dressing that was shown to speed healing of vesicant (blister) injuries caused by chemical weapons (sulfur mustard gas). This previous research, which was conducted under Phase 1 and Phase 2 SBIR awards from the US Army, was presented at the 2011 Annual Meeting of the Wound Healing Society, where it received the top prize for Industrial Research and Development. This new award permits Quick-Med to extend that research to more directly address unmet commercial needs in treatments for the approximately 2.4 million thermal burns occurring annually in the US, with a dressing designed to reduce scarring and contracture in healing of severe burns. Part of the research will be conducted at the University of Florida's Institute for Wound Research.

"The NIMBUS super-absorbent polymer technology allows Quick-Med to develop a unique dressing that provides antimicrobial protection for the wound while also acting to minimize scar tissue formation, and inhibit matrix metalloproteinases to block contracture of tissues," said Professor Greg Schultz, Director of the Institute for Wound Research at the University of Florida. "This unique combination therapy should speed healing and reduce contraction of severe burns in our wounded warriors. It would also have extensive application for civilians with large burns."

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional and advanced wound care applications, both in the US and abroad. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by numerous U.S. patents and foreign counterparts. Additional applications currently under development include advanced wound dressings, medical adhesives, and catheters.

============================================================
QUICK-MED TECHNOLOGIES, INC.
CONDENSED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2013 AND 2012
(UNAUDITED)

--------------------------------------------------------------------------------

3 months ended 9 months ended
March March
2013 2012 2013 2012

Revenues
Royalty and license fees $ 137,217 $ 117,867 $ 459,333 $ 319,604
Product sales 124,788 77,433 265,578 284,655
Research and development service - 3,000 - 113,000
Total revenues 262,005 198,300 724,911 717,259

Expenses:
Cost of sales 6,475 6,358 17,483 17,724
Research and development 117,942 210,235 405,639 683,889
General and administrative expenses (142,039 ) 210,712 262,411 742,443
Licensing and patent expenses 53,743 62,323 194,734 230,233
Depreciation and amortization 32,487 15,757 63,939 48,583
Total operating expenses 68,608 505,385 944,205 1,722,872

Operating profit (loss) 193,397 (307,085 ) (219,294 ) (1,005,613 )

Other income (expense):
Interest income 87 58 660 1,371
Interest expense (108,808 ) (111,819 ) (334,375 ) (338,153 )
Total other expense (108,721 ) (111,761 ) (333,715 ) (336,782 )

Profit (Loss) before provision (benefit) for income taxes 84,676 (418,846 ) (553,010 ) (1,342,395 )

Provision (benefit) for income taxes - - - -

Net loss $ 84,676 $ (418,846 ) $ (553,010 ) $ (1,342,395 )

Net loss per share - basic and diluted $ 0.00 $ (0.01 ) $ (0.01 ) $ (0.04 )

Weighted average common shares outstanding - basic and diluted 37,346,154 37,346,154 37,346,154 37,346,154

----------------------------------------------
8K announcement..
Item 1.01 Entry into a Material Definitive Agreement

The following discussion provides only a brief description of the document described below. The discussion is qualified in its entirety by the full text of the agreement, which is attached to this Current Report on Form 8-K as an exhibit.

On May 9, 2013, with an effective date as of April 1, 2013, Quick-Med Technologies, Inc. (the “Company” or "we") and VIRIDIS BioPharma Pvt. Ltd. entered into a Patent and Technology License Agreement (the "Agreement") to license our proprietary Nimbus® intellectual property.

Under the Agreement, we grant Viridis exclusive rights to use our proprietary Nimbus intellectual property in hydrophilic polyurethane foam for wound care applications and for securing intravenous tubings and catheters on products sold in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine, Uzbekistan, Russia and their territories and possessions.

In consideration for the execution of the Agreement, Viridis will pay a royalty of 7.5% on net sales for each product. The Agreement shall continue to be in effect for a term of five years from the effective date, unless terminated earlier for breach or bankruptcy.


The Agreement is in addition to the Patent and Technology License Agreement of July 26, 2010 (including Amendments 1-3) (“2010 Patent Agreement”). We also entered into a fourth amendment of the 2010 Patent Amendment on May 9, 2013 that extended the term of the 2010 Patent Agreement to March 31, 2018

There are no material relationships between the Company or its affiliates and any of the parties to the Agreement, other than with respect to this Agreement and the Agreement dated July 26, 2010 with amendments 1-4.

Item 9.01 Financial Statements and Exhibits


(c) Exhibits.

Exh. No. Description

10.1 Patent and License Agreement by and between Quick-Med Technologies, Inc. and VIRIDIS BioPharma Pvt. Ltd. effective as of April 1, 2013.

10.2 Amendment No. 4 to Patent and License Agreement by and between Quick-Med Technologies, Inc. and VIRIDIS BioPharma Pvt. Ltd. dated May 9, 2013.

===================================================

Quick-Med Engages Match Point Partners as Financial Advisor

Specialist Firm Expert in Healthcare Markets Served by QMT

GAINESVILLE, FL -- (Marketwired) -- 04/12/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company, announced that is that it has retained Match Point Partners to manage its investor and public relations programs. Match Point Partners is a New York based strategy and financial advisory firm that helps healthcare and technology companies manage and grow through inflection points and maximize long-term value.

"We are continuing the commercial expansion of our NIMBUS® and Stay Fresh® product lines with our US and international partners," said Quick-Med CFO Paul Jenssen. "We are excited to have the help of Match Point Partners to communicate our growth and increase our visibility with our partners and supporters."

"QMT is a highly innovative health care company that is bringing very exciting antimicrobial technologies to market," said J.D. Friedland, Founder and Senior Managing Director of Match Point. "Their products address the major public health concerns of drug-resistant bacteria in our communities, institutions, and even in our food industries. Match Point will be able to help communicate the value of these technologies better to the healthcare, consumer goods, and financial communities to improve public understanding of Quick-Med's value.

"Our work with Quick-Med reflects Match Point's approach to partner closely with our clients in a broad manner to help them achieve their financial and strategic objectives. We follow through on our commitment by working side by side with our clients at every step. This depth of collaboration helps to align client goals with our efforts and enhance company value."

About Match Point Partners LLC
Headquartered in New York City, Match Point Partners is a strategy and financial advisory firm that provides a unique blend of value-added strategic, operating and investment banking services to emerging middle market healthcare and technology firms. Our team of experienced entrepreneurs, bankers, and operators collaborate to develop and execute creative, innovative and often out-of-the-box solutions to help our clients achieve superior value. All securities are offered through Bridge Capital Associates, Inc., Member FINRA / SIPC. For more information, please visit www.mppartnersllc.com. ==================================================

Quick-Med Announces New Members Appointed to Its Board of Directors

Appointment of Dale Bergman and Paul Jenssen

GAINESVILLE, FL -- (Marketwire) -- 02/28/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the Board has appointed new members Dale Berman and Paul Jenssen effective February 28, 2013. These members fill vacancies left by departures of Major General George Friel, USA (Ret.), who served from 2000 to 2012, and J. Ladd Greeno, who served from 2007 to 2013.

Mr. Bergman, 57, has practiced corporate and securities law for over 25 years, with specialty in advising emerging and mid-market public companies in their growth. Since March 2011, he has been a partner in the Ft. Lauderdale office of Roetzel & Andress, LPA. From May 2009 to March 2011, he was a partner in the Ft. Lauderdale office of Arnstein & Lehr and from January 2004 to April 2009, he was a member of Kluger, Peretz, Kaplan & Berlin, P.L., a Miami-Florida based law firm. Mr. Bergman does not currently serve as a director of any reporting companies. Mr. Bergman, who is a member of the Florida and New York bars, holds a bachelor's degree from Columbia College of Columbia University and a J.D. from Harvard Law School. Quick-Med Technologies believes that his lengthy experience in advising emerging and mid-market public companies in their growth makes him a valuable addition to the board of directors. The board of directors expects to appoint Mr. Bergman to its audit committee.

Mr. Jenssen has served as Chief Financial Officer and Corporate Secretary for Quick-Med Technologies since January 10, 2013. He has over 35 years of experience in strategic planning, process improvement, finance and accounting. He started his career at Deloitte Touche (1978-1984) before becoming Treasurer at Associated Press (1984-1998). In addition to working as a consultant since 1998, he was the CFO, COO and a Senior Managing Director at Rothschild North America investment bank (1998-2006). From 2006 until the present, Mr. Jenssen was the President of Jenssen Consulting, a business involved in providing strategic planning, process improvement, finance and accounting related services. Mr. Jenssen does not serve as a director of any other reporting company. Mr. Jenssen is a CPA, has an MBA from Columbia University in New York and has held several securities licenses. The registrant believes that Mr. Jenssen's financial and investment banking experiences makes him a valuable addition to its board of directors.

===================================================

Quick-Med Technologies Appoints Paul H. Jenssen as Its Chief Financial Officer

GAINESVILLE, FL -- (Marketwire) -- 01/15/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT) announced today that its Board of Directors (the "Board") appointed Paul H. Jenssen as the Company's Chief Financial Officer and corporate secretary, effective as of January 10, 2013. He replaces Nam H. Nguyen, whom Quick-Med wishes to thank for his contributions and years of service, and who will provide active support for the transition.

Mr. Jenssen has 35 years of experience in strategic planning, process improvement, finance and accounting. He started his career at Deloitte Touche (1978-1984) before becoming Treasurer at Associated Press (1984-1998). In addition to working as a consultant since 1998, he was the CFO, COO and a Senior Managing Director at Rothschild North America investment bank (1998-2006). He is a CPA, has an MBA with highest honors from Columbia University in New York and has held several securities licenses. He is also an engaged member of the community and has worked in several teaching positions. Additional information can be found in the Company's current report on Form 8-K filed with the Securities and Exchange Commission and available on the Company's website.

"We are very excited to have Paul join our team at Quick-Med, as he brings terrific experiences to support our operational and investment needs. This completes the centralization of our operations to our Gainesville site, and will improve and simplify our ability to communicate with our clients and investors as a team" stated Bernd Liesenfeld, President of Quick-Med.

==================================================

Quick-Med Announces Update on Appointment of Director

GAINESVILLE, FL -- (Marketwire) -- 01/15/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today an update to a previous press release announcement. Quick-Med announced November 13, 2012 that John W. Sheets was appointed to join the board of directors of the company. Delays in receiving clearance from his employer's (Boston Scientific) corporate counsel have prevented Dr. Sheets from being able to join the company's board to date. As a result, Dr. Sheets' appointment as a board member has been rescinded by the company's board of directors at this time. Both Dr. Sheets and the company remain enthusiastic to work together and intend to do so as the situation permits.

====================================================

Quick-Med Announces First Commercial Sale of Advanced Dressings With NIMBUS(R) Technology

Viridis BioPharma Launches Microfoam(TM) Advanced Wound Care Dressings in India

GAINESVILLE, FL -- (Marketwire) -- 01/08/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that Viridis BioPharma Pvt. Ltd. has begun selling and shipping Microfoam™ dressings to customers. Microfoam is the first advanced wound care dressing to utilize Quick-Med's proprietary non-leaching NIMBUS® technology. Viridis received approval by the Food and Drug Administration of India in September 2011 to manufacture and market Microfoam wound dressings incorporating NIMBUS antimicrobial technology.

NIMBUS represents a next generation in wound care. This unique technology offers surgeons, wound care clinicians, infection control experts and primary care doctors an important new weapon against the transmission of such virulent bacteria as Methicillin-resistant Staphylococcus aureus (MRSA). It is the first non-leaching antimicrobial available in a wound dressing.

"It's exciting that this unique technology is now available in an advanced wound dressing format, in an emerging market," said Bernd Liesenfeld, Quick-Med's president. "India's large population, increasing investments in health care and fast growing wound care market represents a significant opportunity for Viridis to provide patients and caregivers with great a product, and to drive sales with our unique, value-added NIMBUS antimicrobial feature."

The NIMBUS technology is designed to prevent bacteria developing resistance, and avoid releasing toxic material into the wound, so there is no impeding the wound healing process. It is a novel antimicrobial technology: non-leaching and effective even in high concentrations of body fluids. NIMBUS technology is easy for the caregiver to implement as part of prophylactic care for patients at risk for infections.

As part of its commercialization efforts, Viridis BioPharma has sponsored clinical trials to demonstrate the efficacy of Microfoam dressings. "India tops the diabetes sufferers list as per World Health Organization (WHO) figures and consequently chronic diabetic wounds and ulcers. Quick-Med's NIMBUS Technology applied through Microfoam dressing shows remarkable relief in burn and wound cases and particularly in diabetic chronic wounds, as well as in venous and pressure ulcers, in an Indian clinical trial," commented Dr. Dilip Mehta, CEO of Viridis BioPharma Pvt. Ltd.

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.

About Viridis BioPharma Pvt. Ltd.
Through strategic associations with international pharmaceutical and biopharma companies, Viridis BioPharma Pvt. Ltd. commercializes products with therapeutic efficacy and growth potential in the Indian subcontinent and delivers a range of clinically-proven products to enable people to live better and more active lives. Viridis currently manufactures and markets a number of medical devices for companies, manufactured under license for B. Braun, American BioTech Labs, and Bhabha Atomic Research Center (BARC). For more information, see: www.viridisbiopharma.com

===================================================

USPTO Grants Quick-Med Tenth U.S. Patent for NIMBUS(R) Technology

New Patent Covers for NimbuDerm Hand Sanitizer and a Range of Other NIMBUS Antimicrobial Product Applications

GAINESVILLE, FL -- (Marketwire) -- 01/02/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded a tenth U.S. patent for its novel, non-leaching NIMBUS® antimicrobial technology.

The U.S. Patent and Trademark Office has granted Quick-Med Technologies U.S. Patent No. 8,343,523 titled, "Disinfectant with Durable Activity Based on Alcohol-Soluble Quaternary Ammonium Polymers and Copolymers." The new patent provides for a novel alcohol-soluble, water insoluble disinfectant for achieving a prolonged antimicrobial property to a variety of surfaces including skin. It covers the composition and method for several NIMBUS polyurethane quaternary applications including certain formulations of the Company's proprietary NimbuDerm™ hand sanitizer and a variety of NIMBUS applications including medical adhesives, foam wound dressings, sutures, catheters and other medical tubing.

"We are very pleased that the U.S. Patent Office has granted this tenth NIMBUS patent which further solidifies our leadership in non-leaching antimicrobial technology," said Bernd Liesenfeld, Quick-Med's president. "This new patent captures additional special characteristics of our unique NIMBUS technology and provides intellectual property protection for several key applications of our growing family of NIMBUS antimicrobial polymers."

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.

=========================================================

Quick-Med Technologies Announces Further Expansion of Its NIMBUS(R) Technology Global Patent Portfolio

New Patents in India and China Plus Notice of Allowance in Canada Expand International NIMBUS Intellectual Property Coverage


Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today advances in patent coverage in India, China, and Canada for the Company's novel, non-leaching NIMBUS® antimicrobial technology.

The State Intellectual Property of the People's Republic of China and the Patent Office of India have granted Quick-Med Technologies' pending patent entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers" in their respective jurisdictions. Additionally, the Canadian Intellectual Property Office has issued a "Notice of Allowance" for this pending patent in Canada. These new patents will significantly expand the international intellectual property coverage for NIMBUS.

The three new patents are similar to U.S. Patent No. 8,088,400, also entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers." They cover the Company's novel polyurethane-modified polycation, the newest member of the NIMBUS technology family of antimicrobials. NIMBUS technology encompasses the chemistry of antimicrobials that comprise a high charge density polycation that is built into the backbone of various polymers such as polyurethane in this case.

The new patents are key "composition-of-matter" patents that cover incorporation of a NIMBUS polycation into main chain of a urethane polymer. The physical state of the polyurethane polycation can be modified to alter the strength of the antimicrobial, the breathability of the film or coating and its flexibility or rigidity. The patents provide protection for various claims regarding the efficacy and durability of an antimicrobial polyurethane.

"This patent adds an exciting new dimension to our NIMBUS technology," says Dr. William Toreki, co-inventor and Quick-Med's vice president of Research & Development. "Our new polyurethane polycation has been licensed for medical adhesives and is well suited for a wide range of applications including films and coatings, catheters and other types of extruded tubing, and as a durable hand sanitizer."

"These NIMBUS patents are strategically important because they significantly expand the global coverage for our proprietary NIMBUS technology into exciting and emerging markets," said Dr. Bernd Liesenfeld, Quick-Med's president. "NIMBUS technology can make an important contribution to infection prevention programs in each of these markets."

NIMBUS technology provides efficacy against a broad range of both Gram-positive and Gram-negative bacteria. NIMBUS antimicrobials are not depleted in use, maintain effectiveness even in the presence of large amounts of blood or body fluids, and by design, pose no risk of bacteria developing resistance.

NIMBUS non-leaching antimicrobial technology was cleared by FDA in 2009 and is the only non-leaching antimicrobial technology available in wound dressings. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts.



© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.

[10 bagger]

=============================================================
Accelerize New Media, Inc. Reports Second Quarter 2013 Financial Results

Second Quarter Revenues Increased 75% Year Over Year to a Record $2,259,395, as Management Accelerates Investment in R&D and Sales Force

NEWPORT BEACH, CA -- (Marketwired) -- 08/13/13 -- Accelerize New Media, Inc. (OTCBB: ACLZ), owner and operator of CAKE, a highly-scalable enterprise Software-as-a-Service (SaaS) platform providing business intelligence to performance-based marketers -- from acquisition to conversion, today announced financial results for its fiscal second quarter ended June 30, 2013.

"New client additions and increased usage by existing clients led to another record quarter of revenue growth," said Brian Ross, Accelerize New Media, Inc. Chairman and CEO. "Our strong reputation and commitment to R&D excellence has enabled us to attract and hire top industry talent, while we continue to evaluate strategic alternatives to maximize shareholder value. We are confident that these R&D investments and sales force additions will result in ongoing market share gains, as the advertising industry embraces online performance-based marketing."

Financial Highlights for Q2 2013 vs. Q2 2012

Revenues: Total revenues for the quarter increased 75% from $1,294,720 to $2,259,395 year over year, driven by a 65% increase in the average number of clients and a 6% increase in the average monthly fee per client. We expect future revenues to be driven by organic growth, international expansion, and increased sales efforts.
Income from Continuing Operations: Despite a 33% quarterly increase in research and development and a 114% quarterly increase in SG&A expenses due to new sales hires to support our anticipated growth, we realized a positive income from continuing operations for the period of $20,177, compared to $21,752 a year ago. We anticipate income from continuing operations to improve as these R&D and SG&A investments begin to pay off later this year.
Balance Sheet: Cash and cash equivalents for the quarter increased from $45,040 to $906,640 year over year, and our working capital, which is $1,357,275 as of June 30, 2013, provides us with greater flexibility to invest in research and development and expand our sales force both domestically and internationally. We strive to maintain a balanced capital structure to support consistent long-term growth.
About Accelerize New Media, Inc.

Accelerize New Media, Inc. owns and operates CAKE, an enterprise SaaS (Software-as-a-Service) platform providing business intelligence to performance-based marketers from acquisition to conversion. With an easy-to-use interface and real-time reporting, performance-based marketers can quickly setup, manage, and optimize their campaigns. Seamless integration with external services through a robust API provides clients with a single dashboard that helps increase revenues, lower operational costs, and improve the ROIs of their campaigns.
ACCELERIZE NEW MEDIA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, December 31,
ASSETS 2013 2012
------------- -------------
(Unaudited) (1)
Current Assets:
Cash $ 906,640 $ 231,926
Accounts receivable, net 869,140 673,818
Other assets 100,517 42,783
------------- -------------
Total current assets 1,876,297 948,527

Property and equipment, net 90,876 52,297

Note receivable, net - 88,000
------------- -------------
Total assets $ 1,967,173 $ 1,088,824
============= =============

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
Accounts payable and accrued expenses $ 241,704 $ 284,526
Deferred revenues 51,255 24,616
Convertible notes payable and notes payable 226,063 299,325
------------- -------------
Total current liabilities 519,022 608,467

Total stockholders' equity 1,448,151 480,357
------------- -------------

Total liabilities and stockholders' equity $ 1,967,173 $ 1,088,824
============= =============

(1) Derived from audited financial statements



ACCELERIZE NEW MEDIA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three-month periods ended Six-month periods ended
June 30, June 30,
------------------------ ------------------------
2013 2012 2013 2012
----------- ----------- ----------- -----------
(Unaudited) (Unaudited) (Unaudited) (Unaudited)

Revenues: $ 2,259,395 $ 1,294,720 $ 4,422,802 $ 2,343,085

Operating expenses:
Cost of revenue 328,296 235,124 635,280 368,526
Research and
development 365,075 274,975 678,698 495,879
Selling, general and
administrative 1,532,430 717,161 2,895,053 1,586,867
----------- ----------- ----------- -----------
Total operating
expenses 2,225,801 1,227,260 4,209,031 2,451,272
----------- ----------- ----------- -----------

Operating income
(loss) 33,594 67,460 213,771 (108,187)

Other expenses (13,417) (45,708) (18,376) (99,088)
----------- ----------- ----------- -----------

Income (loss) from
continuing operations 20,177 21,752 195,395 (207,275)

Income (loss) from
discontinued
operations, net 38,611 27,444 100,361 (28,518)

Net income (loss) 58,788 49,196 295,756 (235,793)

Less dividends series A
and B preferred stock - - - 83,232
----------- ----------- ----------- -----------

Net income (loss)
attributable to common
stock $ 58,788 $ 49,196 $ 295,756 $ (152,561)
=========== =========== =========== ===========

Earnings per share:
Basic
Continuing operations $ 0.00 $ 0.00 $ 0.00 $ (0.00)
Discontinued
operations $ 0.00 $ 0.00 $ 0.00 $ (0.00)
----------- ----------- ----------- -----------
Net income (loss) per
share $ 0.00 $ 0.00 $ 0.01 $ (0.00)
=========== =========== =========== ===========

Diluted
Continuing operations $ 0.00 $ 0.00 $ 0.00 $ (0.00)
Discontinued
operations $ 0.00 $ 0.00 $ 0.00 $ (0.00)
----------- ----------- ----------- -----------
Net income (loss) per
share $ 0.00 $ 0.00 $ 0.00 $ (0.00)
=========== =========== =========== ===========


Basic weighted average
common shares
outstanding 56,644,643 55,719,575 56,337,069 48,923,639
=========== =========== =========== ===========
Diluted weighted average
common shares
outstanding 75,346,900 61,587,751 72,369,773 48,923,639
=========== =========== =========== ===========



ACCELERIZE NEW MEDIA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six-month periods ended
June 30,
--------------------------
2013 2012
------------ ------------
(Unaudited) (Unaudited)
Cash flows from operating activities:
Net income (loss) from continuing operations $ 195,395 $ (207,275)
Adjustments to reconcile net loss from
continuing operations to net cash provided by
operating activities: 412,477 132,539
Changes in operating assets and liabilities: (277,344) 64,778
------------ ------------
Net cash provided by (used in) continuing
operations 330,528 (9,958)
Net cash provided by discontinued operations - 15,383
------------ ------------
Net cash provided by operating activities 330,528 5,425
------------ ------------

Net cash provided by (used in) investing
activities 13,584 (11,022)
------------ ------------

Cash flows provided by (used in) financing
activities:
Principal repayments on notes payable (90,000) (180,000)
Proceeds from exercise of warrants and options 421,996 125,887
------------ ------------

Net cash provided by (used in) financing
activities 331,996 (54,113)
------------ ------------

Effect of exchange rate changes on cash (1,394) -
------------ ------------

Net increase (decrease) in cash 674,714 (59,710)

Cash, beginning of period 231,926 104,750
------------ ------------

Cash, end of period $ 906,640 $ 45,040
============ ============



Contact:

Brian Ross
Chairman & CEO
[phone]
Email Contact
www.accelerizenewmedia.com

=============================================================

Accelerize New Media Inc. Reports First Quarter 2013 Financial Results

First Quarter Revenues Jumped 106% Year Over Year to a Record $2,163,407, While Net Income From Continuing Operations Reached $175,218

NEWPORT BEACH, CA -- (Marketwired) -- 05/14/13 -- Accelerize New Media Inc. (OTCBB: ACLZ), owner and operator of Cake Marketing (www.cakemarketing.com), a highly scalable SaaS (Software-as-a-Service) platform providing a comprehensive and complete online tracking solution for advertisers -- from acquisition through conversion, today announced financial results for its fiscal first quarter ended March 31, 2013.

"Robust demand for the Cake Marketing platform led to a strong performance and start to 2013," said Accelerize New Media Inc. Chairman & CEO Brian Ross. "We are well positioned to grow revenues as brand advertisers and performance based marketers continue to adopt our technology, while utilizing our improved cash flows from operations have enabled us to accelerate sales and marketing initiatives and invest in product innovation."

Financial Highlights for Q1 2013 vs Q1 2012

Revenues: Total revenues increased 106% from $1,048,365 to $2,163,407 year over year, driven by a 75% increase in the average number of clients and an 18% increase in the average usage fees earned per client. We expect future revenues to be driven by ongoing organic growth, international expansion, and increased sales efforts.
Operating Income: Operating income reached $180,177, compared to an operating loss of $(175,647) year over year, due to higher revenues and contained expenses. We plan to continue managing our costs and scaling revenues to improve operating margins.
Net Income from Continuing Operations: Net income from continuing operations increased to $175,218, compared to a net loss of $(229,027) during the prior year period, due to growing revenues from a greater number of clients and higher average usage fees earned per client, as well as controlled expenses.
Cash Flow: Cash provided by continuing operations increased to $58,847, compared to net cash used in continuing operations of $(49,622) during the prior year period. The company invested $313,623 in ongoing research and development, and total operating expenses increased 62% to $1,983,230 to support our growth. Free cash flow, which amounts to cash flow from operations less capital expenditures, totaled $72,791.
About Accelerize New Media Inc.

Accelerize New Media, Inc. owns and operates Cake Marketing, a highly scalable SaaS (Software-as-a-Service) platform providing a comprehensive and complete online tracking solution for advertisers -- from acquisition through conversion. Easy-to-use wizards and real-time reporting guide users through every step of managing and optimizing campaigns. From traffic providers to advertisers, tracking to data distribution, Cake Marketing offers the most robust platform to manage your business and analyze the performance of your marketing relationships. Seamless integration with other services through a developed API eliminates bottlenecks while increasing ROI for advertisers.

ACCELERIZE NEW MEDIA INC. CONSOLIDATED BALANCE SHEETS
March 31, December 31,
2013 2012
(Unaudited) (Audited)
ASSETS
Current Assets:
Cash $ 357,389 $ 231,926
Accounts receivable, net of allowance for bad
debt of $40,224 and $18,208 838,306 673,818
Prepaid expenses and other assets 50,811 42,783
Total current assets 1,246,506 948,527

Property and equipment, net of accumulated
depreciation of $51,516 and $38,918 87,504 52,297
Note receivable, net of original issuance
discount of $50,111 and $62,000 81,889 88,000

Total assets $ 1,415,899 $ 1,088,824

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
Accounts payable and accrued expenses $ 218,521 $ 284,526
Deferred revenues 10,158 24,616
Convertible notes payable and accrued interest 176,244 176,244
Notes payable and accrued interest, net of debt
discount of $10,647 and $21,293 88,149 123,081
Total current liabilities 493,072 608,467

Stockholders' Equity
Common stock; $.001 par value; 100,000,000 shares
authorized; 56,195,105 and 55,992,605 issued and
outstanding 56,195 55,991
Additional paid-in capital 16,474,040 16,267,461
Accumulated deficit (15,606,12
7) (15,843,095)
Accumulated other comprehensive loss (1,281) 0

Total stockholders equity 922,827 480,357

Total liabilities and stockholders equity $ 1,415,899 $ 1,088,824

ACCELERIZE NEW MEDIA INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

Three-month periods
ended March 31,
2013 2012
(Unaudited) (Unaudited)

Revenue: $ 2,163,407 $ 1,048,365

Operating expenses:
Cost of revenue 306,984 133,402
Research and development 313,623 220,904
Selling, general and administrative 1,362,623 869,706
Total operating expenses 1,983,230 1,224,012

Operating income (loss) 180,177 (175,647)

Other income (expense):
Interest income 13,667 0
Interest expense (18,626) (53,380)
(4,959) (53,380)

Net income (loss) from continuing operations 175,218 (229,027)

Discontinued operations
Loss from discontinued operations 0 (55,962)
Gain from the disposal of discontinued operations 61,750 0
Net income (loss) from discontinued operations 61,750 (55,962)

Net income (loss) 236,968 (284,989)

Less dividends series A and B preferred stock 0 83,232

Net income (loss) attributable to common stock $ 236,968 $ (368,221)

Earnings per share:
Basic
Continuing operations $ 0.00 $ (0.01)
Discontinued operations 0.00 0.00
Net per share $ 0.00 $ (0.01)

Diluted
Continuing operations $ 0.00 $ (0.01)
Discontinued operations 0.00 0.00
Net per share $ 0.00 $ (0.01)


Basic weighted average common shares outstanding 56,158,216 42,139,371
Diluted weighted average common shares outstanding 69,394,505 42,139,371



ACCELERIZE NEW MEDIA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS



Three-month periods
ended March 31,
2013 2012
Cash flows from operating activities: (Unaudited) (Unaudited)

Net income (loss) from continuing operations $ 175,218 $ (229,027)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation and amortization 12,598 5,933
Amortization of debt discount 10,646 50,777
Amortization of original issuance discount (11,889) 0
Fair value of options 125,781 55,840
Changes in operating assets and liabilities:
Accounts receivable (164,488) (34,130)
Prepaid expenses 22 (15,745)
Other assets (8,315) (7,000)
Accrued interest (578) 196
Accounts payable and accrued expenses (65,690) 159,617
Deferred revenues (14,458) (36,083)
Net cash provided by (used in) continuing
operations 58,847 (49,622)
Net cash provided by (used in) discontinued
operations 61,750 (9,850)
Net cash provided by (used in) operating
activities 120,597 (59,472)

Cash flows used in investing activities:
Capital expenditures (47,806) (5,084)
Proceeds from sale of online marketing services
business 18,000 0

Net cash used in investing activities (29,806) (5,084)

Cash flows from financing activities:
Principal repayments on notes payable (45,000) (90,000)
Net proceeds from exercise of warrants 81,000 115,538

Net cash provided by financing activities 36,000 25,538

Effect of exchange rate changes on cash (1,328) 0

Net increase (decrease) in cash 125,463 (39,018)

Cash, beginning of period 231,926 104,750

Cash, end of period $ 357,389 $ 65,732

Supplemental disclosures of cash flow information:
Cash paid for interest $ 5,235 $ 17,912
Cash paid for income taxes $ - $ -

Non-cash investing and financing activities:
Conversion of preferred stock Series A to common
stock $ - $ 322,339
Conversion of preferred stock Series B to common
stock $ - $ 3,565,813
Conversion of note payable to common stock $ - $ 452,500
Preferred stock dividends $ - $ 83,232



Contact Information

Brian Ross
Chairman & CEO
[phone]
Email Contact
www.accelerizenewmedia.com

=============================================================
Accelerize New Media Inc. Engages SunTrust Robinson Humphrey as Strategic Financial Advisor

Accelerize New Media Inc. Explores Strategic Alternatives to Enhance Shareholder Value

NEWPORT BEACH, CA -- (Marketwired) -- 04/30/13 -- Accelerize New Media Inc. (OTCBB: ACLZ), owner and operator of Cake Marketing (www.cakemarketing.com), a highly scalable SaaS (Software-as-a-Service) platform providing comprehensive and complete online tracking solution for advertisers -- from acquisition through conversion -- today announced the engagement of SunTrust Robinson Humphrey, Inc., the full-service corporate and investment banking arm of SunTrust Banks, Inc. (NYSE: STI), to identify and consider a range of operational, financial, and strategic alternatives.

"Our company's significant growth and market opportunity has put us in a unique position to explore potential transactions to generate shareholder value," said Brian Ross, Chairman and CEO of Accelerize New Media Inc. "Teaming up with a full-service corporate and investment banking firm of SunTrust Robinson Humphrey's caliber is a testament that the company's recurring revenue business model is working and forms a sound base for the future. We look forward to working together with the SunTrust Robinson Humphrey team to identify ways to help fully realize our growth potential while utilizing cash flow to expand our business."

While undertaking this process, the Board and management team will remain highly focused on executing the company's operational plans.

There can be no assurances that the exploration of strategic alternatives will result in a transaction being entered into or consummated.

About SunTrust Robinson Humphrey

SunTrust Robinson Humphrey is the full-service corporate and investment banking arm of SunTrust Banks, Inc. and is headquartered in Atlanta, Georgia. It provides comprehensive capital raising, strategic advisory, risk management, and investment solutions to serve the needs of corporate clients across the nation. It also offers fixed income and equity research and sales and trading for institutional investors.

SunTrust Robinson Humphrey has extensive experience working with public and private companies of all sizes -- from emerging growth to the Fortune 500. While SunTrust Robinson Humphrey offers a complete array of solutions and advice for companies across all industries, it provides in-depth industry expertise and dedicated corporate and investment banking practices for certain core sectors, including business services, financial sponsors, building products, healthcare, consumer and retail, media and communications, energy, transportation, and financial services and technology.

More information on SunTrust Robinson Humphrey can be found at www.suntrustrh.com.

About Accelerize New Media, Inc.

Accelerize New Media, Inc. (OTCBB: ACLZ) owns and operates Cake Marketing, a highly scalable SaaS (Software-as-a-Service) platform providing a comprehensive and complete online tracking solution for advertisers -- from acquisition through conversion. Easy-to-use wizards and real-time reporting guide users through every step of managing and optimizing campaigns. From traffic providers to advertisers, tracking to data distribution, Cake Marketing offers the most robust platform to manage a business and analyze the performance of marketing relationships. Seamless integration with other services through a developed API eliminates bottlenecks while increasing ROI for advertisers.

=================================================

Accelerize New Media, Inc. Reports Record Revenues & Profits in 2012

Company Achieves Full Year Profitability With Triple Digit Revenue Growth in FY 2012

NEWPORT BEACH, CA -- (Marketwire) -- 03/07/13 -- Accelerize New Media Inc. (OTCBB: ACLZ), owner and operator of Cake Marketing(www.cakemarketing.com), a highly scalable SaaS (Software-as-a-Service) platform providing a comprehensive and complete online tracking solution for advertisers -- from acquisition through conversion, today announced financial results for its fiscal year ended December 31, 2012.

"Growing industry demand for our innovative SaaS platform and capitalizing on the true power of our recurring revenue business model enabled Accelerize to achieve its first full year of profitability, with record revenues that grew 146% year over year," said Accelerize New Media Inc. Chairman and CEO Brian Ross. "Given the increased number of new clients and greater usage among existing clients, we fully expect this momentum to continue through 2013 as we continue to scale our business both domestically and internationally."

"Reaching profitability was an important milestone, providing validation for our business model and enabling us to prudently reinvest in R&D and build shareholder value," added Mr. Ross. "With advertisers demanding a measurable return on investment for their marketing initiatives, we are confident that the R&D investments we have made and continue to make will result in ongoing and significant market share gains as the industry embraces performance-based marketing."

Financial Highlights for FY 2012

Revenues: Total revenues increased 146% from $2,363,073 to $5,800,622 year over year, driven organically by a 117% increase in the average number of clients and a 13% increase in the average usage fees charged per client. We expect future revenues to be driven by ongoing organic growth, international expansion, and increased sales efforts.
Operating Income: Operating income reached $380,937, compared to an operating loss of $(853,881) year-over-year, due to higher revenues and contained expenses. We plan to continue managing our costs and scaling revenues to improve operating margins.
Net Income: Net income increased to $492,948, compared to a loss of $(1,177,095), during the prior year period, due to revenues that grew faster than expenses.
Cash Flow: Cash provided by operations increased to $166,059 compared to cash used in operations of $(648,137) a year ago. Approximately $933,034 was invested in research and development. We continued to increase our expenditures to support our additional customers and the scope of our activities, which increased our total operating expenses from $3,216,954 in 2011 to $5,419,685 in 2012. Free cash flow, which amounts to cash flows from operations less capital expenditures, totaled $124,289 for 2012.
About Accelerize New Media, Inc.

Accelerize New Media, Inc. owns and operates Cake Marketing, a highly scalable SaaS (Software-as-a-Service) platform providing a comprehensive and complete online tracking solution for advertisers -- from acquisition through conversion. Easy-to-use wizards and real-time reporting guide users through every step of managing and optimizing campaigns. From traffic providers to advertisers, tracking to data distribution, Cake Marketing offers the most robust platform to manage your business and analyze the performance of your marketing relationships. Seamless integration with other services through a developed API eliminates bottlenecks while increasing ROI for advertisers.

ACCELERIZE NEW MEDIA, INC.
CONDENSED BALANCE SHEETS

December 31, December 31,
ASSETS 2012 2011
------------- -------------
(Unaudited)
Current Assets:
Cash $ 231,926 $ 104,750
Accounts receivable 673,818 357,770
Other assets 42,783 124,521
------------- -------------
Total current assets 948,527 587,041

Property and equipment 52,297 50,447
Other assets 88,000 3,351
------------- -------------
Total assets $ 1,088,824 $ 640,839
============= =============

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Liabilities:
Accounts payable and accrued expenses $ 284,526 $ 413,322
Other liabilities 24,616 75,242
Convertible notes payable and notes payable 299,325 1,041,590
------------- -------------
Total liabilities 608,467 1,530,154

Total stockholders' equity (deficit) 480,357 (889,315)
------------- -------------

Total liabilities and stockholders' equity
(deficit) $ 1,088,824 $ 640,839
============= =============


ACCELERIZE NEW MEDIA, INC.
CONDENSED STATEMENTS OF OPERATIONS

Years ended
December 31,
----------------------------
2012 2011
------------- -------------
(Unaudited)

Revenue: $ 5,800,622 $ 2,363,073

------------- -------------
Operating expenses 5,419,685 3,216,954
------------- -------------

Operating income (loss) 380,937 (853,881)

------------- -------------
Interest expense, net (165,822) (316,939)
------------- -------------

Net income (loss) from continuing operations 215,115 (1,170,820)
------------- -------------

Net income (loss) from discontinued operations 277,833 (6,275)
------------- -------------

Net income (loss) $ 492,948 $ (1,177,095)
------------- -------------

Less dividends series A and B preferred stock (83,231) (373,842)
------------- -------------

Net income (loss) attributable to common stock $ 409,717 $ (1,550,937)
============= =============

Earnings per share:
Basic
Continuing operations $ 0.00 $ (0.04)
Discontinued operations $ 0.01 $ (0.00)
------------- -------------
Net per share $ 0.01 $ (0.04)
============= =============

Diluted
Continuing operations $ 0.00 $ (0.04)
Discontinued operations $ 0.00 $ (0.00)
------------- -------------
Net per share $ 0.01 $ (0.04)
============= =============


Basic weighted average common shares
outstanding 52,439,242 37,376,270
============= =============
Diluted weighted average common shares
outstanding 59,467,356 37,376,270
============= =============





ACCELERIZE NEW MEDIA, INC.
CONDENSED STATEMENTS OF CASH FLOWS

Years ended
December 31,
----------------------------
2012 2011
------------- -------------
(Unaudited)
Cash flows from operating activities:
Net income (loss) from continuing operations $ 215,115 $ (1,170,820)
Adjustments to reconcile net income (loss)
from continuing operations to net cash
provided by (used in) operating activities:
Depreciation and amortization 144,839 158,397
Fair value of options, warrants, &
inducements 278,487 491,956
Changes in operating assets and liabilities:
Accounts receivable (316,048) (265,299)
Accounts payable and accrued expenses (128,798) 118,329
Other (55,673) 59,699
------------- -------------
Net cash provided by (used in) continuing
operations 137,922 (607,738)
Net cash provided by (used in) discontinued
operations 28,137 (40,399)
------------- -------------
Net cash provided by (used in) operating
activities 166,059 (648,137)
------------- -------------

Cash flows from investing activities:
Proceeds from sale of discontinued
operations 242,000 36,621
Capital expenditures (41,770) (54,963)
------------- -------------

Net cash provided by (used in) investing
activities 200,230 (18,342)
------------- -------------

Cash flows from financing activities:
Proceeds (repayments) from notes payable,
net (365,000) 500,000
Proceeds from exercise of warrants 125,887 199,626
Other - (20,000)
------------- -------------

Net cash (used in) provided by financing
activities (239,113) 679,626
------------- -------------

Net increase in cash 127,176 13,147

Cash, beginning of year 104,750 91,603
------------- -------------

Cash, end of year $ 231,926 $ 104,750
============= =============
Investor Contact
Brian Ross
Chairman & CEO
[phone]
Email Contact
www.accelerizenewmedia.com


Source: Accelerize New Media, Inc.

[10 bagger]

TOOT.. $0.13 ,, Company just turning the corner and reports Earnings for the first time.. Other companies like Cheesecake factory Have started the same way.. I like the fact that they have turned the corner and things can/could/should only get better from here.. hank

The Tootie Pie Story, as it exists today, began in 2004 when Don Merrill, our President & CEO, read an article about Ruby Lorraine “Tootie” Feagan in the newspaper. The article told of Tootie’s many awards and how she had been featured in numerous publications; singing the praises of her wonderful pies. The article also said that Tootie wanted to sell her little Medina, Texas bakery and retire. Seeing an opportunity, Mr. Merrill contacted Tootie and arranged a meeting, where he tasted for the first time, Tootie’s famous six pound “Original Apple” Pie. From that meeting, the foundation of the Tootie Pie Company was formed.

Tootie Pie Company, Inc. was incorporated on June 16, 2005. In September 2005, the Company purchased all of Tootie’s pie recipes, customer lists, the right to the “Tootie Pie” name, and the related baking equipment, and building located in Medina, TX. Tootie became an employee and shareholder of the newly formed company but has since retired and hung up her apron to see her dream come to life. Tootie is still a shareholder and major force in the Tootie Pie Company today.

Because of her past experience working with her mother, Bobbie Keese, Tootie’s daughter, became our VP of Baking Operations and is responsible for running our baking operations and ensuring that our pies meet the same high quality standards set by Tootie.

Today the Tootie Pie Company is headquartered and operates out of Boerne, Texas. The Company bakes and sells magnificent, handmade pies through three basic sales channels: retail, corporate and wholesale. The retail segment serves individual consumers through in-store sales, orders via telephone and Internet on the Company’s website. The corporate segment serves businesses that purchase pies as a way to promote their company through client and employee appreciation programs. The wholesale segment is made up of regional and national broad-line foodservice distributors who purchase pies and then resell them to their customers.

==================================================================
Tootie Pie Company Records 19% Net Profit

SAN ANTONIO, TX., Feb. 19, 2013 -- Tootie Pie Company, Inc. (OTC: TOOT) reported a net profit of $266,828, or 19%, on revenues of $1,401,393 for the period ending December 31, 2012, versus a net profit of $233,494, or 19%, on revenues of $1,252,588 for the period ending December 31, 2011.

"Our Tootie Pie Gourmet Cafes continue to perform very well," reported Don L. Merrill, Jr. President & CEO. "Due to capital constraints, we were only able to add two Cafes this past year. I trust our recently hired investment banking firm, Midtown Partners, will help us continue our Cafe expansion strategy at a quicker pace going forward."

Year to date sales, which includes the important holiday season, were up 17% to $2,783,190 for the nine months ending December 31, 2012 versus $2,369,340 for the same period in 2011.

Gross profit increased to $1,057,459 for the period, versus $987,692 for the same period in 2011. Operating expenses increased slightly to $790,256 for the current period, up from $754,526 for the same period in 2011. Gross margin held steady at 75% for the period, versus 79% for the same period in 2011.

About Tootie Pie Co.

Tootie Pie Company bakes and sells high-quality, handmade pies through three basic sales channels: retail, corporate and wholesale. The retail segment serves individual customers through sales in its Tootie Pie Gourmet Cafes, in-store sales, orders via telephone and internet on the Company's website. The corporate segment serves businesses that purchase pies as a way to promote their company through client and employee appreciation programs. The wholesale segment is made up of national and regional broad line grocery and foodservice distributors who purchase pies and then resell them through their respective sales distribution channels. Tootie Pie Company is a public company traded on the OTC markets under the symbol "TOOT." For additional information or to receive correspondence from Tootie Pie Company, please visit www.tootiepieco.com.

Forward-Looking Statements
Contact:
Carla Carter
Investor Relations
210.737.6600
[e-mail]

===============================================================
Tootie Pie Hires Investment Banker

SAN ANTONIO, Feb. 14, 2013 - Tootie Pie Company, Inc. (OTC: TOOT) announced that it has retained the services of MidTown Partners & Co, LLC, a New York City based investment banking firm.

"We are seeing a relatively sudden amount of outside direct investment interest in our Company," said Don Merrill , President & CEO. "As a result, we decided to engage one of those parties, MidTown Partners, to help us determine the best course of action to take Tootie Pie Company to the next level."

"We think the Tootie Pie Company is uniquely positioned as a brand that has definite scalability," said John R. Clarke , Managing Director. "We have clients who recognize what management has accomplished with Tootie Pie and are prepared to help them take the Company to the next level."

About Tootie Pie Co.

Tootie Pie Company bakes and sells high-quality, handmade pies through three basic sales channels: retail, corporate and wholesale. The retail segment serves individual customers through sales in its Tootie Pie Gourmet Cafes, in-store sales, orders via telephone and internet on the Company's website. The corporate segment serves businesses that purchase pies as a way to promote their company through client and employee appreciation programs. The wholesale segment is made up of national and regional broad line grocery and foodservice distributors who purchase pies and then resell them through their respective sales distribution channels. Tootie Pie Company is a public company traded on the OTC markets under the symbol "TOOT." For additional information or to receive correspondence from Tootie Pie Company, please visit www.tootiepieco.com.

About Midtown Partners & Co, LLC.

Founded in 2004, Midtown Partners, has become a leading independent investment bank, providing mergers and acquisitions advisory (M&A), business valuation, strategic consulting services, and capital raising capabilities to lower middle market businesses. A strong team with proven track records; 100+ years of combined experience, raising in excess of $1 billion; ranked among Top 5 Most Active Placement Agents from 2004 to 2009 and raised in excess of $400 million for public and private companies from 2005-2012.

Contact:
Carla Carter
Investor Relations
210.737.6600
[e-mail]

SOURCE Tootie Pie Company, Inc.

==============================================================
Tootie Pie in H-E-B Plus! Stores

SAN ANTONIO, Nov. 20, 2012 -- Tootie Pie Company, Inc. (OTCQB: TOOT) is pleased to announce that its pies will once again be carried in at least 25 H-E-B plus! stores in Houston, Austin, Dallas and San Antonio, TX during the upcoming holiday season.

"We are happy to once again be in H-E-B for the holiday season," said Don Merrill, President & CEO. "By being in mostly H-E-B plus! stores, it gives us great exposure in some of the best metropolitan areas in the state."

About H-E-B

Renowned for its innovation and community service, H-E-B, with sales of more than $18 billion, operates 337 stores in Texas and Mexico. The company is recognized for its fresh food, quality products, convenient services, and a commitment to environmental responsibility and sustainability. It strives to provide the best customer experience at every day low prices. Based in San Antonio, H-E-B employs more than 80,000 Partners and serves millions of customers in more than 150 communities. For more information, visit www.heb.com.

About Tootie Pie Co.

Tootie Pie Company bakes and sells high-quality, handmade pies through three basic sales channels: retail, corporate and wholesale. The retail segment serves individual customers through sales in its Tootie Pie Gourmet Cafes, in-store sales, orders via telephone and internet on the Company's website. The corporate segment serves businesses that purchase pies as a way to promote their company through client and employee appreciation programs. The wholesale segment is made up of national and regional broad line grocery and foodservice distributors who purchase pies and then resell them through their respective sales distribution channels. Tootie Pie Company is a public company traded on the OTCQB market under the symbol "TOOT." For additional information or to receive correspondence from Tootie Pie Company, please visit www.tootiepieco.com.

===============================================================
Tootie Pie Company Quarterly Sales Up 22%

SAN ANTONIO, Nov. 16, 2012 -- Tootie Pie Company, Inc. (OTCQB: TOOT) reported sales jumped 22% to $769,345, for the quarter ending September 30, 2012, versus $630,601 for same period in 2011.


EBITDA (and other non cash items) amounted to a gain of $23,033 for the period, versus an EBITDA (and other non cash items) loss of $66,882 for the same period in 2011.

"This is the first time we have been basically cash flow break even for the two quarters prior to our big holiday season," reported Don L. Merrill, Jr. President & CEO. "An increase in higher margin retail sales, coupled with our continued efforts to hold the line on expenses, continues to improve our bottom line."

=================================================================
Tootie Pie Company Quarterly Sales Up 26%

http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=17925
================================================================
Tootie Pie Company Annual Revenues Up 35%Retail Sales Jump 88%

SAN ANTONIO – Tootie Pie Company, Inc. (OTCQB:TOOT) reported that annual revenue jumped 35%, to $2,732,858 for fiscal year ending March, 2012, versus $2,027,547 for March, 2011.

“We made a significant investment in our Tootie Pie Gourmet Cafes in the last couple of years and that investment is paying off,” reported Don L. Merrill, Jr. President & CEO. “Our Cafés are doing well and we are very excited about the upcoming holiday pie season.”

Cash Flow (EBIDTA and other non cash items) improved 33% to a loss of $363,116 for the year ending March 31, 2012, versus $539,752 for the same period in 2011.

“Retail sales jumped 88%, which contributed to a nice improvement to our bottom line,” Merrill continued. “I expect these trends to continue into our current year and I believe we have the components in place to achieve profitability.”

Gross Profit came in at a record $1,697,382 for the year, up 26% from $1,251,798 for the prior year. Net loss, which includes depreciation, amortization and other noncash items, improved 21% to $861,262 for the twelve months ending March 31, 2012, versus $1,094,001 for the twelve months in 2011. The improvement was principally due to a reduction in non-recurring start up related and operating expenses incurred to open, staff and operate additional Café locations, as well as an 87.8% increase in higher margin retail sales, coming primarily through our Cafés.

==================================================================Tootie Pie Company April Same Store Sales Up 30%

SAN ANTONIO, May 9, 2012 -- Tootie Pie Company, Inc. (OTCQB: TOOT) announced that April 2012 same-store sales for its Tootie Pie Gourmet Cafes were up 30% over April 2011. The Company also extended its consecutive sales increases to 30 months with sales increases in April.

"Our new fiscal year is off to a very good start," said Don Merrill, President & CEO. "We continue to be pleased with how well our Tootie Pie Gourmet Cafes are performing and look forward to adding more of them."

The Company currently owns and operates six Tootie Pie Gourmet Cafes in San Antonio, Austin, Fredericksburg and Dallas (Frisco), TX. The Company recently announced the acquisition of what will be its seventh Cafe, located in the Villages of Allen, in Allen, TX.

=================================================================
Tootie Pie Company Acquires Seventh Cafe


http://www.prnewswire.com/news-releases/tootie-pie-company-acquires-seventh-cafe-147904195.html

===============================================================
Tootie Pie Company Secures $ 1 Million Credit Line

http://www.prnewswire.com/news-releases/tootie-pie-company-secures--1-million-credit-line-147733795.html

===============================================================
Tootie Pie Company March Same Store Sales Up 33%

SAN ANTONIO, April 5, 2012 /PRNewswire/ -- Tootie Pie Company, Inc. (OTCQB: TOOT) announced that March 2012 same-store sales for its Tootie Pie Gourmet Cafes were up 33% over March 2011. The Company also extended its consecutive sales increases to 29 months with sales increases in March.

"March marks the end of our fiscal year and it's great to finish the year strong," said Don Merrill, President & CEO. "Our aggressive growth model, featuring our Tootie Pie Gourmet Cafes, continues to meet or exceed our expectations as we head into a new year."

The Company currently owns and operates six Tootie Pie Gourmet Cafes in San Antonio, Austin, Fredericksburg and Dallas (Frisco), TX.


==============================================================

Tootie Pie Company Directors Up Stake in Company

SAN ANTONIO, March 27, 2012 /PRNewswire/ -- Tootie Pie Company, Inc. (OTCQB: TOOT) is pleased to announce that all five members of its Board of Directors increased their individual investment in Tootie Pie Company, the Company reported in a filing with the US Securities and Exchange Commission on Form 8K dated March 26, 2012.

"We are all pleased with the direction the Company is going, especially with our Tootie Pie Gourmet Cafes," said David Strolle, Board Member/Secretary. "We are expressing our support by increasing our individual investments in the Company."

The Company recently announced the opening of its sixth Tootie Pie Gourmet Cafe, located at the Village at Westlake Shopping Center: 701 Capitol of Texas Highway and Bee Caves Road in Austin, TX.

About Tootie Pie Co.

Tootie Pie Company bakes and sells high-quality, handmade pies through three basic sales channels: retail, corporate and wholesale. The retail segment serves individual customers through sales in its Tootie Pie Gourmet Cafes, in-store sales, orders via telephone and internet on the Company's website. The corporate segment serves businesses that purchase pies as a way to promote their company through client and employee appreciation programs. The wholesale segment is made up of national and regional broad line grocery and foodservice distributors who purchase pies and then resell them through their respective sales distribution channels. Tootie Pie Company is a public company traded on the OTCQB market under the symbol "TOOT." For additional information or to receive correspondence from Tootie Pie Company, please visit www.tootiepieco.com.

[10 bagger]

opps

[10 bagger]

CPHMF

37,164 $3.65 4.1255 10.47% $135,648.60 $153,320.08 $17,671.48
TEXC

331,748 $0.1248 3.62% $41,402.15 $53,079.68 $11,677.53
GLMB

449,618 0.13 3.99% $49,457.98 $58,450.34 $8,992.36
ASNB

607,853 0.08 3.32% $42,549.71 $48,628.24 $6,078.53
BNLB

362,948 0.107 2.65% $33,391.22 $38,835.44 $5,444.22
KLYG

147,546 0.118 1.19% $12,688.96 $17,410.43 $4,721.47
PAOS

23,136 0.25 0.39% $3,303.82 $5,784.00 $2,480.18
PBSV

9,111 1.10 0.68% $9,111.00 $10,022.10 $911.10
HIIT

103,464 0.25 1.77% $25,741.84 $25,866.00 $124.16
TPNL

77,631 $0.25 0.25 1.32% $19,407.75 $19,407.75 $0.00
CASH
LookUp
576,602 1.00 39.36% $576,602.00 $576,602.00
TOOT

12,605 0.15 0.13% $2,836.12 $1,890.75 -$945.38
BOLL

12,300 0.91 0.76% $12,300.00 $11,193.00 -$1,107.00
CONX

45,078 0.2148 0.66% $10,818.72 $9,682.75 -$1,135.97
SPCBF

19,234 0.2488 0.33% $6,154.88 $4,785.42 -$1,369.46
DTRK

53,409 0.6401 2.33% $36,852.21 $34,187.10 -$2,665.11
VSTI

327,533 0.1199 2.68% $42,579.29 $39,271.21 -$3,308.08
ADTY

40,600 0.15 0.42% $9,744.00 $6,090.00 -$3,654.00
ENSV

29,275 1.00 2.00% $36,593.75 $29,275.00 -$7,318.75
CIBH

129,625 0.538 4.76% $77,775.00 $69,738.25 -$8,036.75
GAMR

201,792 0.38 5.23% $88,586.69 $76,680.96 -$11,905.73
SPND

41,338 3.33 9.40% $152,950.60 $137,655.54 -$15,295.06
LVWD

132,864 0.28 2.54% $58,991.62 $37,201.92 -$21,789.70

[10 bagger]

05/03/13 9:31 AM EDT Buy 28888 CONX Executed @ $0.19 Details | Edit
05/03/13 9:31 AM EDT Buy 8263 CONX Executed @ $0.19 Details | Edit
05/02/13 3:52 PM EDT Sell 1000 HIIT Executed @ $0.2788 Details | Edit
05/02/13 3:17 PM EDT Buy 10000 TEXC Executed @ $0.118 Details | Edit
05/02/13 3:16 PM EDT Sell 1500 HIIT Executed @ $0.2788 Details | Edit
05/02/13 3:11 PM EDT Buy 12888 PBSV Executed @ $1 Details | Edit
05/02/13 1:59 PM EDT Buy 9349 SPCBF Executed @ $0.2529 Details | Edit
05/02/13 12:22 PM EDT Sell 14000 HIIT Executed @ $0.26 Details | Edit
05/02/13 11:55 AM EDT Sell 13000 HIIT Executed @ $0.2588 Details | Edit
05/02/13 10:09 AM EDT Sell 15288 ENSV Executed @ $1.28 Details | Edit
05/02/13 9:48 AM EDT Sell 100 ENSV Executed @ $1.31 Details | Edit
05/02/13 9:32 AM EDT Sell 3500 HIIT Executed @ $0.2588 Details | Edit
05/02/13 9:31 AM EDT Sell 2000 HIIT Executed @ $0.2588 Details | Edit
05/02/13 9:31 AM EDT Sell 2500 HIIT Executed @ $0.2588 Details | Edit
05/02/13 9:30 AM EDT Sell 6387 ENSV Executed @ $1.2 Details | Edit
05/01/13 3:44 PM EDT Buy 2600 TOOT Executed @ $0.2008 Details | Edit
05/01/13 2:33 PM EDT Sell 7576 HIIT Executed @ $0.25 Details | Edit
05/01/13 2:06 PM EDT Buy 1846 DTRK Executed @ $0.67 Details | Edit
05/01/13 1:53 PM EDT Sell 4000 DTRK Executed @ $0.7388 Details | Edit
05/01/13 1:09 PM EDT Sell 6300 ENSV Executed @ $1.25 Details | Edit
05/01/13 1:09 PM EDT Sell 1200 ENSV Executed @ $1.25 Details | Edit
05/01/13 12:42 PM EDT Sell 1387 DTRK Executed @ $0.75 Details | Edit
05/01/13 12:18 PM EDT Sell 10000 HIIT Executed @ $0.2494 Details | Edit
05/01/13 11:06 AM EDT Sell 2000 HIIT Executed @ $0.2494 Details | Edit
05/01/13 9:47 AM EDT Sell 8000 LVWD Executed @ $0.42 Details | Edit
05/01/13 9:47 AM EDT Sell 100 LVWD Executed @ $0.43 Details | Edit
05/01/13 9:38 AM EDT Sell 100 DTRK Executed @ $0.7888 Details | Edit

[10 bagger]

05/31/13 3:10 PM EDT Sell 2430 DTRK Executed @ $0.64 Details | Edit
05/31/13 3:10 PM EDT Sell 2745 DTRK Executed @ $0.64 Details | Edit
05/31/13 2:59 PM EDT Sell 90 DTRK Executed @ $0.68 Details | Edit
05/31/13 2:35 PM EDT Sell 100 DTRK Executed @ $0.68 Details | Edit
05/31/13 2:13 PM EDT Sell 300 DTRK Executed @ $0.68 Details | Edit
05/31/13 2:03 PM EDT Sell 385 DTRK Executed @ $0.68 Details | Edit
05/31/13 1:00 PM EDT Sell 200 DTRK Executed @ $0.68 Details | Edit
05/31/13 12:16 PM EDT Buy 16388 SPCBF Executed @ $0.22 Details | Edit
05/31/13 12:16 PM EDT Buy 12500 SPCBF Executed @ $0.2208 Details | Edit
05/31/13 11:44 AM EDT Sell 1000 SPCBF Executed @ $0.2488 Details | Edit
05/31/13 11:43 AM EDT Sell 4000 SPCBF Executed @ $0.2488 Details | Edit
05/31/13 10:54 AM EDT Sell 1200 SPCBF Executed @ $0.2488 Details | Edit
05/31/13 10:24 AM EDT Buy 16500 BNLB Executed @ $0.1 Details | Edit
05/31/13 10:22 AM EDT Sell 1000 QMDT Executed @ $0.118 Details | Edit
05/31/13 10:18 AM EDT Sell 800 SPCBF Executed @ $0.2488 Details | Edit
05/31/13 10:05 AM EDT Sell 200 DTRK Executed @ $0.7 Details | Edit
05/31/13 10:05 AM EDT Sell 1000 DTRK Executed @ $0.68 Details | Edit
05/31/13 10:01 AM EDT Sell 25000 BNLB Executed @ $0.105 Details | Edit
05/31/13 10:00 AM EDT Buy 2888 ENSV Executed @ $1.08 Details | Edit
05/31/13 9:53 AM EDT Sell 500 DTRK Executed @ $0.65 Details | Edit
05/31/13 9:53 AM EDT Sell 5000 DTRK Executed @ $0.65 Details | Edit
05/31/13 9:53 AM EDT Sell 2000 DTRK Executed @ $0.65 Details | Edit
05/31/13 9:51 AM EDT Sell 5000 DTRK Executed @ $0.66 Details | Edit
05/31/13 9:40 AM EDT Sell 7615 DTRK Executed @ $0.68 Details | Edit
05/31/13 9:40 AM EDT Sell 85 DTRK Executed @ $0.7 Details | Edit
05/31/13 9:40 AM EDT Sell 12300 DTRK Executed @ $0.695 Details | Edit
05/30/13 3:37 PM EDT Sell 4000 SPCBF Executed @ $0.2388 Details | Edit
05/30/13 3:02 PM EDT Buy 2100 CONX Executed @ $0.2018 Details | Edit
05/30/13 3:01 PM EDT Buy 34888 CONX Executed @ $0.2018 Details | Edit
05/30/13 1:55 PM EDT Buy 1900 CONX Executed @ $0.2018 Details | Edit
05/30/13 1:49 PM EDT Sell 1000 QMDT Executed @ $0.118 Details | Edit
05/30/13 1:30 PM EDT Buy 10000 QMDT Executed @ $0.1028 Details | Edit
05/30/13 1:27 PM EDT Buy 5711 QMDT Executed @ $0.1028 Details | Edit
05/30/13 1:27 PM EDT Sell 115 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:25 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:24 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:22 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:19 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:17 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:15 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:13 PM EDT Sell 1000 PXFG Executed @ $0.25 Details | Edit
05/30/13 12:47 PM EDT Buy 12000 KLYG Executed @ $0.116 Details | Edit
05/30/13 11:45 AM EDT Buy 800 ENSV Executed @ $1 Details | Edit
05/30/13 11:40 AM EDT Buy 2900 ENSV Executed @ $1 Details | Edit
05/30/13 9:35 AM EDT Buy 1888 SPCBF Executed @ $0.22 Details | Edit
05/29/13 11:53 AM EDT Buy 7000 SPCBF Executed @ $0.2228 Details | Edit
05/29/13 11:11 AM EDT Buy 300 ITSI Executed @ $0.9428 Details | Edit
05/29/13 9:59 AM EDT Buy 5000 QMDT Executed @ $0.08 Details | Edit
05/29/13 9:58 AM EDT Buy 10000 QMDT Executed @ $0.08 Details | Edit
05/29/13 9:55 AM EDT Buy 8500 ICTL Executed @ $0.6308 Details | Edit
05/29/13 9:52 AM EDT Buy 2192 QMDT Executed @ $0.0628 Details | Edit
05/29/13 9:46 AM EDT Buy 5100 ITSI Executed @ $0.9528 Details | Edit
05/29/13 9:43 AM EDT Sell 400 WPCS Executed @ $4.0601 Details | Edit
05/29/13 9:43 AM EDT Sell 100 WPCS Executed @ $4.06 Details | Edit
05/28/13 3:28 PM EDT Buy 6388 LVWD Executed @ $0.2318 Details | Edit
05/28/13 2:59 PM EDT Buy 1500 LVWD Executed @ $0.2318 Details | Edit
05/28/13 2:37 PM EDT Buy 6206 TEXC Executed @ $0.1508 Details | Edit
05/28/13 2:10 PM EDT Sell 1810 DTRK Executed @ $0.72 Details | Edit
05/28/13 1:55 PM EDT Sell 400 DTRK Executed @ $0.72 Details | Edit
05/28/13 1:54 PM EDT Sell 8900 DTRK Executed @ $0.72 Details | Edit
05/28/13 11:56 AM EDT Buy 500 LVWD Executed @ $0.26 Details | Edit
05/28/13 11:38 AM EDT Sell 951 ICTL Executed @ $0.7 Details | Edit
05/28/13 10:50 AM EDT Buy 5000 LVWD Executed @ $0.2318 Details | Edit
05/28/13 10:13 AM EDT Buy 30200 TEXC Executed @ $0.15 Details | Edit
05/28/13 10:13 AM EDT Buy 2300 TEXC Executed @ $0.15 Details | Edit
05/28/13 10:12 AM EDT Buy 100 TEXC Executed @ $0.1495 Details | Edit
05/28/13 9:52 AM EDT Buy 18888 LVWD Executed @ $0.2308 Details | Edit
05/28/13 9:30 AM EDT Sell 4000 ICTL Executed @ $0.7 Details | Edit
05/24/13 1:30 PM EDT Buy 12888 ENSV Executed @ $0.9628 Details | Edit
05/24/13 11:00 AM EDT Buy 300 CPHMF Executed @ $4.165 Details | Edit
05/24/13 11:00 AM EDT Buy 88 CPHMF Executed @ $4.166 Details | Edit
05/24/13 11:00 AM EDT Buy 100 CPHMF Executed @ $4.165 Details | Edit
05/23/13 3:13 PM EDT Buy 88 CPHMF Executed @ $4.077 Details | Edit
05/23/13 3:13 PM EDT Buy 400 CPHMF Executed @ $4.077 Details | Edit
05/23/13 3:13 PM EDT Buy 200 CPHMF Executed @ $4.077 Details | Edit
05/23/13 3:13 PM EDT Buy 200 CPHMF Executed @ $4.077 Details | Edit
05/23/13 3:00 PM EDT Buy 700 WPCS Executed @ $0.3701 Details | Edit
05/23/13 2:34 PM EDT Buy 2850 QMDT Executed @ $0.0508 Details | Edit
05/23/13 1:44 PM EDT Sell 43430 APNX Executed @ $0.1288 Details | Edit
05/23/13 11:02 AM EDT Sell 550 ASNB Executed @ $0.0888 Details | Edit
05/23/13 10:36 AM EDT Buy 10000 QMDT Executed @ $0.0528 Details | Edit
05/23/13 9:53 AM EDT Sell 300 ASNB Executed @ $0.0888 Details | Edit
05/23/13 9:38 AM EDT Sell 5000 BNLB Executed @ $0.1102 Details | Edit
05/23/13 9:32 AM EDT Buy 1100 ICTL Executed @ $0.63 Details | Edit
05/23/13 9:32 AM EDT Buy 3000 ICTL Executed @ $0.63 Details | Edit
05/22/13 3:32 PM EDT Buy 8888 KLYG Executed @ $0.0868 Details | Edit
05/22/13 2:34 PM EDT Buy 12888 ICTL Executed @ $0.62 Details | Edit
05/22/13 2:29 PM EDT Buy 12888 ICTL Executed @ $0.62 Details | Edit
05/22/13 2:27 PM EDT Buy 12000 ICTL Executed @ $0.63 Details | Edit
05/22/13 1:31 PM EDT Buy 7388 ENSV Executed @ $1.04 Details | Edit
05/22/13 1:15 PM EDT Buy 1500 ENSV Executed @ $1.04 Details | Edit
05/22/13 1:11 PM EDT Buy 7388 ICTL Executed @ $0.7028 Details | Edit
05/21/13 3:51 PM EDT Buy 6998 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:51 PM EDT Buy 6000 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:51 PM EDT Buy 50000 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:50 PM EDT Buy 1 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:49 PM EDT Buy 5001 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:45 PM EDT Sell 20000 SPCBF Executed @ $0.2588 Details | Edit
05/21/13 3:17 PM EDT Buy 9160 QMDT Executed @ $0.0428 Details | Edit
05/21/13 2:40 PM EDT Buy 2988 ENSV Executed @ $1.1 Details | Edit
05/21/13 2:16 PM EDT Buy 20000 SPCBF Executed @ $0.2228 Details | Edit
05/21/13 1:56 PM EDT Buy 5900 ENSV Executed @ $1.1 Details | Edit
05/21/13 1:48 PM EDT Sell 300 ENSV Executed @ $1.13 Details | Edit
05/21/13 1:32 PM EDT Sell 2000 SPCBF Executed @ $0.2588 Details | Edit
05/21/13 12:45 PM EDT Sell 1500 SPCBF Executed @ $0.2588 Details | Edit
05/21/13 11:56 AM EDT Buy 8888 ICTL Executed @ $0.75 Details | Edit
05/21/13 11:02 AM EDT Buy 4489 ENSV Executed @ $1.11 Details | Edit
05/21/13 10:34 AM EDT Sell 12500 SPCBF Executed @ $0.2588 Details | Edit
05/21/13 9:32 AM EDT Buy 1500 ICTL Executed @ $0.69 Details | Edit
05/20/13 3:44 PM EDT Buy 1005 QMDT Executed @ $0.0428 Details | Edit
05/20/13 3:34 PM EDT Buy 500 ENSV Executed @ $1.14 Details | Edit
05/20/13 3:20 PM EDT Buy 5000 ENSV Executed @ $1.14 Details | Edit
05/20/13 2:42 PM EDT Buy 2139 ASNB Executed @ $0.0678 Details | Edit
05/20/13 2:23 PM EDT Buy 12000 GLMB Executed @ $0.1228 Details | Edit
05/20/13 1:23 PM EDT Sell 10000 ASNB Executed @ $0.0828 Details | Edit
05/20/13 1:05 PM EDT Buy 4888 ENSV Executed @ $1.14 Details | Edit
05/20/13 12:57 PM EDT Sell 5000 GLMB Executed @ $0.13 Details | Edit
05/20/13 12:56 PM EDT Sell 13000 GLMB Executed @ $0.13 Details | Edit
05/20/13 12:51 PM EDT Sell 13000 GLMB Executed @ $0.13 Details | Edit
05/20/13 12:49 PM EDT Buy 3000 ENSV Executed @ $1.18 Details | Edit
05/20/13 12:27 PM EDT Sell 20208 ASNB Executed @ $0.078 Details | Edit
05/20/13 12:24 PM EDT Sell 10000 ASNB Executed @ $0.078 Details | Edit
05/20/13 12:09 PM EDT Sell 7000 BNLB Executed @ $0.115 Details | Edit
05/20/13 9:59 AM EDT Sell 5000 BNLB Executed @ $0.115 Details | Edit
05/20/13 9:36 AM EDT Sell 8496 GLMB Executed @ $0.13 Details | Edit
05/17/13 3:58 PM EDT Buy 8900 BNLB Executed @ $0.112 Details | Edit
05/17/13 3:53 PM EDT Buy 1000 ENSV Executed @ $1.13 Details | Edit
05/17/13 3:44 PM EDT Sell 250 ITSI Executed @ $0.98 Details | Edit
05/17/13 2:24 PM EDT Sell 1287 ENSV Executed @ $1.17 Details | Edit
05/17/13 2:08 PM EDT Sell 5601 TPNL Executed @ $0.212 Details | Edit
05/17/13 12:20 PM EDT Buy 28364 SPCBF Executed @ $0.2158 Details | Edit
05/17/13 12:06 PM EDT Sell 1000 TPNL Executed @ $0.24 Details | Edit
05/17/13 10:00 AM EDT Sell 5000 PBSV Executed @ $1.03 Details | Edit
05/17/13 9:51 AM EDT Buy 1500 ITSI Executed @ $0.95 Details | Edit
05/17/13 9:51 AM EDT Buy 4000 ITSI Executed @ $0.95 Details | Edit
05/17/13 9:50 AM EDT Sell 12888 PBSV Executed @ $1.03 Details | Edit
05/17/13 9:44 AM EDT Sell 8587 TPNL Executed @ $0.24 Details | Edit
05/17/13 9:44 AM EDT Sell 320 TPNL Executed @ $0.24 Details | Edit
05/17/13 9:35 AM EDT Sell 3413 TPNL Executed @ $0.24 Details | Edit
05/17/13 9:31 AM EDT Sell 2500 TPNL Executed @ $0.24 Details | Edit
05/17/13 9:30 AM EDT Sell 3960 TPNL Executed @ $0.24 Details | Edit
05/16/13 3:48 PM EDT Sell 7000 TPNL Executed @ $0.24 Details | Edit
05/16/13 1:45 PM EDT Buy 37500 BNLB Executed @ $0.1108 Details | Edit
05/16/13 12:15 PM EDT Sell 68000 BNLB Executed @ $0.1145 Details | Edit
05/16/13 12:12 PM EDT Sell 6257 TEXC Executed @ $0.14 Details | Edit
05/16/13 12:12 PM EDT Sell 21212 TEXC Executed @ $0.14 Details | Edit
05/16/13 12:07 PM EDT Sell 28788 TEXC Executed @ $0.14 Details | Edit
05/16/13 11:48 AM EDT Sell 41000 BNLB Executed @ $0.112 Details | Edit
05/16/13 10:20 AM EDT Sell 8000 BNLB Executed @ $0.1098 Details | Edit
05/16/13 10:20 AM EDT Sell 17000 BNLB Executed @ $0.1098 Details | Edit
05/16/13 9:45 AM EDT Sell 250 TPNL Executed @ $0.248 Details | Edit
05/16/13 9:45 AM EDT Buy 38888 BNLB Executed @ $0.1008 Details | Edit
05/15/13 3:59 PM EDT Buy 200 CPHMF Executed @ $3.697 Details | Edit
05/15/13 3:57 PM EDT Sell 100 LVWD Executed @ $0.33 Details | Edit
05/15/13 3:55 PM EDT Sell 3500 LVWD Executed @ $0.32 Details | Edit
05/15/13 3:54 PM EDT Sell 5000 LVWD Executed @ $0.32 Details | Edit
05/15/13 3:54 PM EDT Sell 5000 LVWD Executed @ $0.32 Details | Edit
05/15/13 3:53 PM EDT Sell 4000 LVWD Executed @ $0.31 Details | Edit
05/15/13 3:51 PM EDT Sell 4500 LVWD Executed @ $0.31 Details | Edit
05/15/13 3:51 PM EDT Sell 7500 LVWD Executed @ $0.31 Details | Edit
05/15/13 3:51 PM EDT Sell 8000 LVWD Executed @ $0.311 Details | Edit
05/15/13 1:51 PM EDT Sell 5000 TPNL Executed @ $0.245 Details | Edit
05/15/13 1:47 PM EDT Sell 13000 TPNL Executed @ $0.245 Details | Edit
05/15/13 1:03 PM EDT Sell 6100 TPNL Executed @ $0.24 Details | Edit
05/15/13 1:01 PM EDT Sell 17900 TPNL Executed @ $0.24 Details | Edit
05/15/13 12:59 PM EDT Sell 1000 TPNL Executed @ $0.258 Details | Edit
05/15/13 12:59 PM EDT Sell 2000 TPNL Executed @ $0.255 Details | Edit
05/15/13 12:30 PM EDT Sell 22000 GLMB Executed @ $0.12 Details | Edit
05/15/13 11:05 AM EDT Sell 916 BNLB Executed @ $0.102 Details | Edit
05/15/13 11:05 AM EDT Sell 31000 BNLB Executed @ $0.102 Details | Edit
05/15/13 10:37 AM EDT Sell 45000 BNLB Executed @ $0.1023 Details | Edit
05/15/13 10:02 AM EDT Sell 21026 HIIT Executed @ $0.24 Details | Edit
05/15/13 9:53 AM EDT Sell 2500 HIIT Executed @ $0.22 Details | Edit
05/15/13 9:53 AM EDT Sell 5000 HIIT Executed @ $0.22 Details | Edit
05/15/13 9:53 AM EDT Sell 20000 HIIT Executed @ $0.222 Details | Edit
05/15/13 9:51 AM EDT Sell 2500 HIIT Executed @ $0.23 Details | Edit
05/15/13 9:50 AM EDT Sell 2500 HIIT Executed @ $0.23 Details | Edit
05/15/13 9:49 AM EDT Sell 2500 HIIT Executed @ $0.2339 Details | Edit
05/15/13 9:47 AM EDT Sell 18300 HIIT Executed @ $0.24 Details | Edit
05/14/13 11:44 AM EDT Buy 500 GAMR Executed @ $0.38 Details | Edit
05/14/13 10:26 AM EDT Sell 24640 CONX Executed @ $0.1527 Details | Edit
05/14/13 10:26 AM EDT Sell 5000 CONX Executed @ $0.1601 Details | Edit
05/14/13 10:26 AM EDT Sell 5000 CONX Executed @ $0.16 Details | Edit
05/14/13 10:24 AM EDT Sell 5000 CONX Executed @ $0.16 Details | Edit
05/14/13 9:51 AM EDT Sell 5000 CONX Executed @ $0.1717 Details | Edit
05/14/13 9:51 AM EDT Sell 10000 CONX Executed @ $0.1717 Details | Edit
05/14/13 9:51 AM EDT Sell 6825 CONX Executed @ $0.175 Details | Edit
05/14/13 9:51 AM EDT Sell 5000 CONX Executed @ $0.1751 Details | Edit
05/14/13 9:50 AM EDT Sell 4600 CONX Executed @ $0.183 Details | Edit
05/14/13 9:50 AM EDT Sell 7499 CONX Executed @ $0.1752 Details | Edit
05/13/13 2:59 PM EDT Buy 399 ENSV Executed @ $1.04 Details | Edit
05/13/13 1:58 PM EDT Buy 20000 TOOT Executed @ $0.1418 Details | Edit
05/13/13 1:08 PM EDT Buy 18994 TEXC Executed @ $0.12 Details | Edit
05/13/13 12:49 PM EDT Sell 5014 ENSV Executed @ $1.1 Details | Edit
05/13/13 12:49 PM EDT Sell 50 ENSV Executed @ $1.11 Details | Edit
05/13/13 12:49 PM EDT Sell 3000 ENSV Executed @ $1.1 Details | Edit
05/13/13 12:48 PM EDT Sell 300 ENSV Executed @ $1.11 Details | Edit
05/13/13 12:48 PM EDT Sell 100 ENSV Executed @ $1.12 Details | Edit
05/13/13 12:47 PM EDT Sell 100 ENSV Executed @ $1.12 Details | Edit
05/13/13 12:47 PM EDT Sell 1800 ENSV Executed @ $1.12 Details | Edit
05/13/13 12:46 PM EDT Sell 500 ENSV Executed @ $1.12 Details | Edit
05/13/13 10:47 AM EDT Buy 5000 DTRK Executed @ $0.8 Details | Edit
05/13/13 9:41 AM EDT Buy 12888 GAMR Executed @ $0.35 Details | Edit
05/10/13 2:20 PM EDT Sell 1388 CONX Executed @ $0.2268 Details | Edit
05/10/13 12:42 PM EDT Buy 40000 HIIT Executed @ $0.2458 Details | Edit
05/10/13 12:09 PM EDT Sell 9000 HIIT Executed @ $0.278 Details | Edit
05/10/13 11:47 AM EDT Sell 1600 HIIT Executed @ $0.278 Details | Edit
05/10/13 11:42 AM EDT Buy 10488 TOOT Executed @ $0.1828 Details | Edit
05/10/13 11:38 AM EDT Buy 29257 BNLB Executed @ $0.095 Details | Edit
05/10/13 11:36 AM EDT Buy 8436 BNLB Executed @ $0.095 Details | Edit
05/10/13 11:33 AM EDT Sell 1000 HIIT Executed @ $0.278 Details | Edit
05/10/13 11:24 AM EDT Buy 38888 CONX Executed @ $0.2108 Details | Edit
05/10/13 9:36 AM EDT Buy 7200 TEXC Executed @ $0.1158 Details | Edit
05/09/13 3:56 PM EDT Buy 8800 TOOT Executed @ $0.1728 Details | Edit
05/09/13 3:55 PM EDT Buy 390 SPND Executed @ $3.7 Details | Edit
05/09/13 2:03 PM EDT Buy 776 DTRK Executed @ $0.88 Details | Edit
05/09/13 12:18 PM EDT Buy 3888 ENSV Executed @ $1.1 Details | Edit
05/09/13 12:08 PM EDT Sell 10000 SPCBF Executed @ $0.2688 Details | Edit
05/09/13 12:06 PM EDT Sell 3000 SPCBF Executed @ $0.2688 Details | Edit
05/09/13 11:22 AM EDT Buy 500 DTRK Executed @ $0.9 Details | Edit
05/09/13 10:59 AM EDT Buy 1674 DTRK Executed @ $0.9 Details | Edit
05/09/13 10:40 AM EDT Buy 9500 TOOT Executed @ $0.1828 Details | Edit
05/09/13 10:08 AM EDT Buy 5000 TEXC Executed @ $0.1158 Details | Edit
05/09/13 10:00 AM EDT Buy 100 TOOT Executed @ $0.1828 Details | Edit
05/09/13 9:43 AM EDT Buy 14888 SPCBF Executed @ $0.2518 Details | Edit
05/08/13 3:01 PM EDT Buy 5000 DTRK Executed @ $0.95 Details | Edit
05/08/13 2:40 PM EDT Sell 2275 VSTI Executed @ $0.11 Details | Edit
05/08/13 2:36 PM EDT Sell 5000 VSTI Executed @ $0.11 Details | Edit
05/08/13 2:32 PM EDT Sell 5000 HIIT Executed @ $0.254 Details | Edit
05/08/13 2:32 PM EDT Sell 4350 HIIT Executed @ $0.254 Details | Edit
05/08/13 2:31 PM EDT Sell 6000 VSTI Executed @ $0.11 Details | Edit
05/08/13 1:32 PM EDT Buy 100 CPHMF Executed @ $4.079 Details | Edit
05/08/13 1:32 PM EDT Buy 100 CPHMF Executed @ $4.079 Details | Edit
05/08/13 1:32 PM EDT Buy 200 CPHMF Executed @ $4.079 Details | Edit
05/08/13 11:56 AM EDT Sell 421 VSTI Executed @ $0.1 Details | Edit
05/08/13 11:25 AM EDT Sell 4000 VSTI Executed @ $0.1 Details | Edit
05/08/13 10:53 AM EDT Sell 4000 VSTI Executed @ $0.1 Details | Edit
05/08/13 10:52 AM EDT Sell 1770 VSTI Executed @ $0.1 Details | Edit
05/08/13 10:52 AM EDT Sell 2000 VSTI Executed @ $0.1 Details | Edit
05/08/13 10:51 AM EDT Sell 100 VSTI Executed @ $0.102 Details | Edit
05/08/13 10:51 AM EDT Sell 10000 VSTI Executed @ $0.11 Details | Edit
05/08/13 10:32 AM EDT Buy 3888 ENSV Executed @ $1.18 Details | Edit
05/08/13 10:18 AM EDT Buy 227 SPCBF Executed @ $0.2408 Details | Edit
05/08/13 10:08 AM EDT Sell 11200 HIIT Executed @ $0.2455 Details | Edit
05/08/13 10:06 AM EDT Sell 11600 HIIT Executed @ $0.2455 Details | Edit
05/08/13 10:03 AM EDT Sell 12200 HIIT Executed @ $0.25 Details | Edit
05/08/13 9:53 AM EDT Buy 2500 DTRK Executed @ $0.95 Details | Edit
05/08/13 9:53 AM EDT Buy 2500 DTRK Executed @ $0.948 Details | Edit
05/07/13 3:18 PM EDT Buy 1000 DTRK Executed @ $0.8028 Details | Edit
05/07/13 3:13 PM EDT Buy 100 DTRK Executed @ $0.8028 Details | Edit
05/07/13 3:05 PM EDT Buy 3788 ENSV Executed @ $1.22 Details | Edit
05/07/13 3:05 PM EDT Buy 100 ENSV Executed @ $1.22 Details | Edit
05/07/13 1:19 PM EDT Buy 4000 KLYG Executed @ $0.0868 Details | Edit
05/07/13 1:18 PM EDT Sell 7500 HIIT Executed @ $0.28 Details | Edit
05/07/13 1:16 PM EDT Sell 7500 HIIT Executed @ $0.28 Details | Edit
05/07/13 12:41 PM EDT Sell 8300 DTRK Executed @ $1.01 Details | Edit
05/07/13 12:41 PM EDT Sell 10000 DTRK Executed @ $1.01 Details | Edit
05/07/13 12:40 PM EDT Sell 5000 DTRK Executed @ $1.01 Details | Edit
05/07/13 12:24 PM EDT Sell 5788 DTRK Executed @ $0.8688 Details | Edit
05/07/13 12:09 PM EDT Buy 3000 SPCBF Executed @ $0.2408 Details | Edit
05/07/13 12:05 PM EDT Buy 9100 SPCBF Executed @ $0.2408 Details | Edit
05/07/13 12:05 PM EDT Buy 4098 DTRK Executed @ $0.8028 Details | Edit
05/07/13 11:59 AM EDT Buy 500 VSTI Executed @ $0.1495 Details | Edit
05/07/13 11:53 AM EDT Buy 12888 CONX Executed @ $0.2258 Details | Edit
05/07/13 10:43 AM EDT Sell 6500 CONX Executed @ $0.225 Details | Edit
05/07/13 10:16 AM EDT Buy 20 CPHMF Executed @ $4.101 Details | Edit
05/07/13 10:16 AM EDT Buy 100 CPHMF Executed @ $4.101 Details | Edit
05/07/13 10:13 AM EDT Sell 21500 RCVA Executed @ $0.025 Details | Edit
05/07/13 9:48 AM EDT Sell 2500 CONX Executed @ $0.225 Details | Edit
05/07/13 9:40 AM EDT Sell 200 ASNB Executed @ $0.0798 Details | Edit
05/06/13 3:56 PM EDT Buy 47288 HIIT Executed @ $0.2528 Details | Edit
05/06/13 3:44 PM EDT Buy 1600 HIIT Executed @ $0.2528 Details | Edit
05/06/13 3:19 PM EDT Sell 30000 HIIT Executed @ $0.282 Details | Edit
05/06/13 3:18 PM EDT Sell 2500 HIIT Executed @ $0.284 Details | Edit
05/06/13 2:00 PM EDT Sell 5000 ASNB Executed @ $0.0798 Details | Edit
05/06/13 12:35 PM EDT Sell 1508 DTRK Executed @ $0.78 Details | Edit
05/06/13 12:34 PM EDT Buy 5583 TOOT Executed @ $0.2008 Details | Edit
05/06/13 12:28 PM EDT Buy 37400 HIIT Executed @ $0.2842 Details | Edit
05/06/13 12:27 PM EDT Buy 2600 HIIT Executed @ $0.2842 Details | Edit
05/06/13 12:27 PM EDT Buy 24888 HIIT Executed @ $0.293 Details | Edit
05/06/13 12:27 PM EDT Buy 24000 HIIT Executed @ $0.293 Details | Edit
05/06/13 12:10 PM EDT Sell 1000 DTRK Executed @ $0.78 Details | Edit
05/06/13 11:37 AM EDT Buy 3600 PBSV Executed @ $1.03 Details | Edit
05/06/13 11:34 AM EDT Buy 1400 PBSV Executed @ $1.03 Details | Edit
05/06/13 11:04 AM EDT Sell 700 DTRK Executed @ $0.78 Details | Edit
05/06/13 10:26 AM EDT Sell 350 DTRK Executed @ $0.78 Details | Edit
05/06/13 10:13 AM EDT Sell 2800 ENSV Executed @ $1.28 Details | Edit
05/06/13 10:09 AM EDT Sell 1888 ENSV Executed @ $1.28 Details | Edit
05/06/13 9:52 AM EDT Buy 650 TOOT Executed @ $0.2008 Details | Edit
05/06/13 9:45 AM EDT Sell 2000 ETCIA Executed @ $0.16 Details | Edit
05/03/13 3:43 PM EDT Buy 90 DTRK Executed @ $0.7328 Details | Edit
05/03/13 3:43 PM EDT Buy 4700 DTRK Executed @ $0.73 Details | Edit
05/03/13 1:56 PM EDT Buy 48 ENSV Executed @ $1.29 Details | Edit
05/03/13 1:38 PM EDT Buy 1540 ENSV Executed @ $1.29 Details | Edit
05/03/13 1:34 PM EDT Buy 1300 ENSV Executed @ $1.29 Details | Edit
05/03/13 12:08 PM EDT Sell 20000 HIIT Executed @ $0.297 Details | Edit
05/03/13 12:01 PM EDT Buy 1888 ENSV Executed @ $1.29 Details | Edit
05/03/13 11:57 AM EDT Buy 50 TOOT Executed @ $0.2008 Details | Edit
05/03/13 11:52 AM EDT Sell 10000 HIIT Executed @ $0.297 Details | Edit
05/03/13 10:05 AM EDT Buy 11000 SPCBF Executed @ $0.2529 Details | Edit
05/03/13 9:55 AM EDT Sell 16388 HIIT Executed @ $0.2728 Details | Edit
05/03/13 9:31 AM EDT Buy 28888 CONX Executed @ $0.19 Details | Edit
05/03/13 9:31 AM EDT Buy 8263 CONX Executed @ $0.19 Details | Edit
05/02/13 3:52 PM EDT Sell 1000 HIIT Executed @ $0.2788 Details | Edit
05/02/13 3:17 PM EDT Buy 10000 TEXC Executed @ $0.118 Details | Edit
05/02/13 3:16 PM EDT Sell 1500 HIIT Executed @ $0.2788 Details | Edit
05/02/13 3:11 PM EDT Buy 12888 PBSV Executed @ $1 Details | Edit
05/02/13 1:59 PM EDT Buy 9349 SPCBF Executed @ $0.2529 Details | Edit
05/02/13 12:22 PM EDT Sell 14000 HIIT Executed @ $0.26 Details | Edit
05/02/13 11:55 AM EDT Sell 13000 HIIT Executed @ $0.2588 Details | Edit
05/02/13 10:09 AM EDT Sell 15288 ENSV Executed @ $1.28 Details | Edit
05/02/13 9:48 AM EDT Sell 100 ENSV Executed @ $1.31 Details | Edit
05/02/13 9:32 AM EDT Sell 3500 HIIT Executed @ $0.2588 Details | Edit
05/02/13 9:31 AM EDT Sell 2000 HIIT Executed @ $0.2588 Details | Edit
05/02/13 9:31 AM EDT Sell 2500 HIIT Executed @ $0.2588 Details | Edit
05/02/13 9:30 AM EDT Sell 6387 ENSV Executed @ $1.2 Details | Edit
05/01/13 3:44 PM EDT Buy 2600 TOOT Executed @ $0.2008 Details | Edit
05/01/13 2:33 PM EDT Sell 7576 HIIT Executed @ $0.25 Details | Edit
05/01/13 2:06 PM EDT Buy 1846 DTRK Executed @ $0.67 Details | Edit
05/01/13 1:53 PM EDT Sell 4000 DTRK Executed @ $0.7388 Details | Edit
05/01/13 1:09 PM EDT Sell 6300 ENSV Executed @ $1.25 Details | Edit
05/01/13 1:09 PM EDT Sell 1200 ENSV Executed @ $1.25 Details | Edit
05/01/13 12:42 PM EDT Sell 1387 DTRK Executed @ $0.75 Details | Edit
05/01/13 12:18 PM EDT Sell 10000 HIIT Executed @ $0.2494 Details | Edit
05/01/13 11:06 AM EDT Sell 2000 HIIT Executed @ $0.2494 Details | Edit
05/01/13 9:47 AM EDT Sell 8000 LVWD Executed @ $0.42 Details | Edit
05/01/13 9:47 AM EDT Sell 100 LVWD Executed @ $0.43 Details | Edit
05/01/13 9:38 AM EDT Sell 100 DTRK Executed @ $0.7888 Details | Edit
04/30/13 3:08 PM EDT Sell 7301 ENSV Executed @ $1.23 Details | Edit
04/30/13 2:36 PM EDT Sell 100 ENSV Executed @ $1.23 Details | Edit
04/30/13 2:03 PM EDT Sell 500 ENSV Executed @ $1.24 Details | Edit
04/30/13 12:40 PM EDT Sell 4276 DTRK Executed @ $0.6988 Details | Edit
04/30/13 12:34 PM EDT Sell 612 DTRK Executed @ $0.6988 Details | Edit
04/30/13 12:07 PM EDT Buy 110 SPND Executed @ $3.7 Details | Edit
04/30/13 11:59 AM EDT Sell 100 HIIT Executed @ $0.2494 Details | Edit
04/30/13 11:20 AM EDT Sell 15000 HIIT Executed @ $0.2494 Details | Edit
04/30/13 11:06 AM EDT Sell 15700 ETCIA Executed @ $0.17 Details | Edit
04/30/13 11:03 AM EDT Sell 22300 ETCIA Executed @ $0.17 Details | Edit
04/30/13 10:54 AM EDT Sell 5000 ETCIA Executed @ $0.183 Details | Edit
04/30/13 10:24 AM EDT Buy 6720 DTRK Executed @ $0.65 Details | Edit
04/30/13 10:03 AM EDT Buy 838 SPCBF Executed @ $0.2529 Details | Edit
04/30/13 10:02 AM EDT Buy 8162 SPCBF Executed @ $0.2529 Details | Edit
04/30/13 9:55 AM EDT Buy 4162 SPCBF Executed @ $0.2528 Details | Edit
04/30/13 9:54 AM EDT Buy 6162 SPCBF Executed @ $0.2528 Details | Edit

[10 bagger]

05/31/13 3:10 PM EDT Sell 2430 DTRK Executed @ $0.64 Details | Edit
05/31/13 3:10 PM EDT Sell 2745 DTRK Executed @ $0.64 Details | Edit
05/31/13 2:59 PM EDT Sell 90 DTRK Executed @ $0.68 Details | Edit
05/31/13 2:35 PM EDT Sell 100 DTRK Executed @ $0.68 Details | Edit
05/31/13 2:13 PM EDT Sell 300 DTRK Executed @ $0.68 Details | Edit
05/31/13 2:03 PM EDT Sell 385 DTRK Executed @ $0.68 Details | Edit
05/31/13 1:00 PM EDT Sell 200 DTRK Executed @ $0.68 Details | Edit
05/31/13 12:16 PM EDT Buy 16388 SPCBF Executed @ $0.22 Details | Edit
05/31/13 12:16 PM EDT Buy 12500 SPCBF Executed @ $0.2208 Details | Edit
05/31/13 11:44 AM EDT Sell 1000 SPCBF Executed @ $0.2488 Details | Edit
05/31/13 11:43 AM EDT Sell 4000 SPCBF Executed @ $0.2488 Details | Edit
05/31/13 10:54 AM EDT Sell 1200 SPCBF Executed @ $0.2488 Details | Edit
05/31/13 10:24 AM EDT Buy 16500 BNLB Executed @ $0.1 Details | Edit
05/31/13 10:22 AM EDT Sell 1000 QMDT Executed @ $0.118 Details | Edit
05/31/13 10:18 AM EDT Sell 800 SPCBF Executed @ $0.2488 Details | Edit
05/31/13 10:05 AM EDT Sell 200 DTRK Executed @ $0.7 Details | Edit
05/31/13 10:05 AM EDT Sell 1000 DTRK Executed @ $0.68 Details | Edit
05/31/13 10:01 AM EDT Sell 25000 BNLB Executed @ $0.105 Details | Edit
05/31/13 10:00 AM EDT Buy 2888 ENSV Executed @ $1.08 Details | Edit
05/31/13 9:53 AM EDT Sell 500 DTRK Executed @ $0.65 Details | Edit
05/31/13 9:53 AM EDT Sell 5000 DTRK Executed @ $0.65 Details | Edit
05/31/13 9:53 AM EDT Sell 2000 DTRK Executed @ $0.65 Details | Edit
05/31/13 9:51 AM EDT Sell 5000 DTRK Executed @ $0.66 Details | Edit
05/31/13 9:40 AM EDT Sell 7615 DTRK Executed @ $0.68 Details | Edit
05/31/13 9:40 AM EDT Sell 85 DTRK Executed @ $0.7 Details | Edit
05/31/13 9:40 AM EDT Sell 12300 DTRK Executed @ $0.695 Details | Edit
05/30/13 3:37 PM EDT Sell 4000 SPCBF Executed @ $0.2388 Details | Edit
05/30/13 3:02 PM EDT Buy 2100 CONX Executed @ $0.2018 Details | Edit
05/30/13 3:01 PM EDT Buy 34888 CONX Executed @ $0.2018 Details | Edit
05/30/13 1:55 PM EDT Buy 1900 CONX Executed @ $0.2018 Details | Edit
05/30/13 1:49 PM EDT Sell 1000 QMDT Executed @ $0.118 Details | Edit
05/30/13 1:30 PM EDT Buy 10000 QMDT Executed @ $0.1028 Details | Edit
05/30/13 1:27 PM EDT Buy 5711 QMDT Executed @ $0.1028 Details | Edit
05/30/13 1:27 PM EDT Sell 115 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:25 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:24 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:22 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:19 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:17 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:15 PM EDT Sell 1000 QMDT Executed @ $0.12 Details | Edit
05/30/13 1:13 PM EDT Sell 1000 PXFG Executed @ $0.25 Details | Edit
05/30/13 12:47 PM EDT Buy 12000 KLYG Executed @ $0.116 Details | Edit
05/30/13 11:45 AM EDT Buy 800 ENSV Executed @ $1 Details | Edit
05/30/13 11:40 AM EDT Buy 2900 ENSV Executed @ $1 Details | Edit
05/30/13 9:35 AM EDT Buy 1888 SPCBF Executed @ $0.22 Details | Edit
05/29/13 11:53 AM EDT Buy 7000 SPCBF Executed @ $0.2228 Details | Edit
05/29/13 11:11 AM EDT Buy 300 ITSI Executed @ $0.9428 Details | Edit
05/29/13 9:59 AM EDT Buy 5000 QMDT Executed @ $0.08 Details | Edit
05/29/13 9:58 AM EDT Buy 10000 QMDT Executed @ $0.08 Details | Edit
05/29/13 9:55 AM EDT Buy 8500 ICTL Executed @ $0.6308 Details | Edit
05/29/13 9:52 AM EDT Buy 2192 QMDT Executed @ $0.0628 Details | Edit
05/29/13 9:46 AM EDT Buy 5100 ITSI Executed @ $0.9528 Details | Edit
05/29/13 9:43 AM EDT Sell 400 WPCS Executed @ $4.0601 Details | Edit
05/29/13 9:43 AM EDT Sell 100 WPCS Executed @ $4.06 Details | Edit
05/28/13 3:28 PM EDT Buy 6388 LVWD Executed @ $0.2318 Details | Edit
05/28/13 2:59 PM EDT Buy 1500 LVWD Executed @ $0.2318 Details | Edit
05/28/13 2:37 PM EDT Buy 6206 TEXC Executed @ $0.1508 Details | Edit
05/28/13 2:10 PM EDT Sell 1810 DTRK Executed @ $0.72 Details | Edit
05/28/13 1:55 PM EDT Sell 400 DTRK Executed @ $0.72 Details | Edit
05/28/13 1:54 PM EDT Sell 8900 DTRK Executed @ $0.72 Details | Edit
05/28/13 11:56 AM EDT Buy 500 LVWD Executed @ $0.26 Details | Edit
05/28/13 11:38 AM EDT Sell 951 ICTL Executed @ $0.7 Details | Edit
05/28/13 10:50 AM EDT Buy 5000 LVWD Executed @ $0.2318 Details | Edit
05/28/13 10:13 AM EDT Buy 30200 TEXC Executed @ $0.15 Details | Edit
05/28/13 10:13 AM EDT Buy 2300 TEXC Executed @ $0.15 Details | Edit
05/28/13 10:12 AM EDT Buy 100 TEXC Executed @ $0.1495 Details | Edit
05/28/13 9:52 AM EDT Buy 18888 LVWD Executed @ $0.2308 Details | Edit
05/28/13 9:30 AM EDT Sell 4000 ICTL Executed @ $0.7 Details | Edit
05/24/13 1:30 PM EDT Buy 12888 ENSV Executed @ $0.9628 Details | Edit
05/24/13 11:00 AM EDT Buy 300 CPHMF Executed @ $4.165 Details | Edit
05/24/13 11:00 AM EDT Buy 88 CPHMF Executed @ $4.166 Details | Edit
05/24/13 11:00 AM EDT Buy 100 CPHMF Executed @ $4.165 Details | Edit
05/23/13 3:13 PM EDT Buy 88 CPHMF Executed @ $4.077 Details | Edit
05/23/13 3:13 PM EDT Buy 400 CPHMF Executed @ $4.077 Details | Edit
05/23/13 3:13 PM EDT Buy 200 CPHMF Executed @ $4.077 Details | Edit
05/23/13 3:13 PM EDT Buy 200 CPHMF Executed @ $4.077 Details | Edit
05/23/13 3:00 PM EDT Buy 700 WPCS Executed @ $0.3701 Details | Edit
05/23/13 2:34 PM EDT Buy 2850 QMDT Executed @ $0.0508 Details | Edit
05/23/13 1:44 PM EDT Sell 43430 APNX Executed @ $0.1288 Details | Edit
05/23/13 11:02 AM EDT Sell 550 ASNB Executed @ $0.0888 Details | Edit
05/23/13 10:36 AM EDT Buy 10000 QMDT Executed @ $0.0528 Details | Edit
05/23/13 9:53 AM EDT Sell 300 ASNB Executed @ $0.0888 Details | Edit
05/23/13 9:38 AM EDT Sell 5000 BNLB Executed @ $0.1102 Details | Edit
05/23/13 9:32 AM EDT Buy 1100 ICTL Executed @ $0.63 Details | Edit
05/23/13 9:32 AM EDT Buy 3000 ICTL Executed @ $0.63 Details | Edit
05/22/13 3:32 PM EDT Buy 8888 KLYG Executed @ $0.0868 Details | Edit
05/22/13 2:34 PM EDT Buy 12888 ICTL Executed @ $0.62 Details | Edit
05/22/13 2:29 PM EDT Buy 12888 ICTL Executed @ $0.62 Details | Edit
05/22/13 2:27 PM EDT Buy 12000 ICTL Executed @ $0.63 Details | Edit
05/22/13 1:31 PM EDT Buy 7388 ENSV Executed @ $1.04 Details | Edit
05/22/13 1:15 PM EDT Buy 1500 ENSV Executed @ $1.04 Details | Edit
05/22/13 1:11 PM EDT Buy 7388 ICTL Executed @ $0.7028 Details | Edit
05/21/13 3:51 PM EDT Buy 6998 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:51 PM EDT Buy 6000 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:51 PM EDT Buy 50000 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:50 PM EDT Buy 1 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:49 PM EDT Buy 5001 VSTI Executed @ $0.0928 Details | Edit
05/21/13 3:45 PM EDT Sell 20000 SPCBF Executed @ $0.2588 Details | Edit
05/21/13 3:17 PM EDT Buy 9160 QMDT Executed @ $0.0428 Details | Edit
05/21/13 2:40 PM EDT Buy 2988 ENSV Executed @ $1.1 Details | Edit
05/21/13 2:16 PM EDT Buy 20000 SPCBF Executed @ $0.2228 Details | Edit
05/21/13 1:56 PM EDT Buy 5900 ENSV Executed @ $1.1 Details | Edit
05/21/13 1:48 PM EDT Sell 300 ENSV Executed @ $1.13 Details | Edit
05/21/13 1:32 PM EDT Sell 2000 SPCBF Executed @ $0.2588 Details | Edit
05/21/13 12:45 PM EDT Sell 1500 SPCBF Executed @ $0.2588 Details | Edit
05/21/13 11:56 AM EDT Buy 8888 ICTL Executed @ $0.75 Details | Edit
05/21/13 11:02 AM EDT Buy 4489 ENSV Executed @ $1.11 Details | Edit
05/21/13 10:34 AM EDT Sell 12500 SPCBF Executed @ $0.2588 Details | Edit
05/21/13 9:32 AM EDT Buy 1500 ICTL Executed @ $0.69 Details | Edit
05/20/13 3:44 PM EDT Buy 1005 QMDT Executed @ $0.0428 Details | Edit
05/20/13 3:34 PM EDT Buy 500 ENSV Executed @ $1.14 Details | Edit
05/20/13 3:20 PM EDT Buy 5000 ENSV Executed @ $1.14 Details | Edit
05/20/13 2:42 PM EDT Buy 2139 ASNB Executed @ $0.0678 Details | Edit
05/20/13 2:23 PM EDT Buy 12000 GLMB Executed @ $0.1228 Details | Edit
05/20/13 1:23 PM EDT Sell 10000 ASNB Executed @ $0.0828 Details | Edit
05/20/13 1:05 PM EDT Buy 4888 ENSV Executed @ $1.14 Details | Edit
05/20/13 12:57 PM EDT Sell 5000 GLMB Executed @ $0.13 Details | Edit
05/20/13 12:56 PM EDT Sell 13000 GLMB Executed @ $0.13 Details | Edit
05/20/13 12:51 PM EDT Sell 13000 GLMB Executed @ $0.13 Details | Edit
05/20/13 12:49 PM EDT Buy 3000 ENSV Executed @ $1.18 Details | Edit
05/20/13 12:27 PM EDT Sell 20208 ASNB Executed @ $0.078 Details | Edit
05/20/13 12:24 PM EDT Sell 10000 ASNB Executed @ $0.078 Details | Edit
05/20/13 12:09 PM EDT Sell 7000 BNLB Executed @ $0.115 Details | Edit
05/20/13 9:59 AM EDT Sell 5000 BNLB Executed @ $0.115 Details | Edit
05/20/13 9:36 AM EDT Sell 8496 GLMB Executed @ $0.13 Details | Edit
05/17/13 3:58 PM EDT Buy 8900 BNLB Executed @ $0.112 Details | Edit
05/17/13 3:53 PM EDT Buy 1000 ENSV Executed @ $1.13 Details | Edit
05/17/13 3:44 PM EDT Sell 250 ITSI Executed @ $0.98 Details | Edit
05/17/13 2:24 PM EDT Sell 1287 ENSV Executed @ $1.17 Details | Edit
05/17/13 2:08 PM EDT Sell 5601 TPNL Executed @ $0.212 Details | Edit
05/17/13 12:20 PM EDT Buy 28364 SPCBF Executed @ $0.2158 Details | Edit
05/17/13 12:06 PM EDT Sell 1000 TPNL Executed @ $0.24 Details | Edit
05/17/13 10:00 AM EDT Sell 5000 PBSV Executed @ $1.03 Details | Edit
05/17/13 9:51 AM EDT Buy 1500 ITSI Executed @ $0.95 Details | Edit
05/17/13 9:51 AM EDT Buy 4000 ITSI Executed @ $0.95 Details | Edit
05/17/13 9:50 AM EDT Sell 12888 PBSV Executed @ $1.03 Details | Edit
05/17/13 9:44 AM EDT Sell 8587 TPNL Executed @ $0.24 Details | Edit
05/17/13 9:44 AM EDT Sell 320 TPNL Executed @ $0.24 Details | Edit
05/17/13 9:35 AM EDT Sell 3413 TPNL Executed @ $0.24 Details | Edit
05/17/13 9:31 AM EDT Sell 2500 TPNL Executed @ $0.24 Details | Edit
05/17/13 9:30 AM EDT Sell 3960 TPNL Executed @ $0.24 Details | Edit
05/16/13 3:48 PM EDT Sell 7000 TPNL Executed @ $0.24 Details | Edit
05/16/13 1:45 PM EDT Buy 37500 BNLB Executed @ $0.1108 Details | Edit
05/16/13 12:15 PM EDT Sell 68000 BNLB Executed @ $0.1145 Details | Edit
05/16/13 12:12 PM EDT Sell 6257 TEXC Executed @ $0.14 Details | Edit
05/16/13 12:12 PM EDT Sell 21212 TEXC Executed @ $0.14 Details | Edit
05/16/13 12:07 PM EDT Sell 28788 TEXC Executed @ $0.14 Details | Edit
05/16/13 11:48 AM EDT Sell 41000 BNLB Executed @ $0.112 Details | Edit
05/16/13 10:20 AM EDT Sell 8000 BNLB Executed @ $0.1098 Details | Edit
05/16/13 10:20 AM EDT Sell 17000 BNLB Executed @ $0.1098 Details | Edit
05/16/13 9:45 AM EDT Sell 250 TPNL Executed @ $0.248 Details | Edit
05/16/13 9:45 AM EDT Buy 38888 BNLB Executed @ $0.1008 Details | Edit
05/15/13 3:59 PM EDT Buy 200 CPHMF Executed @ $3.697 Details | Edit
05/15/13 3:57 PM EDT Sell 100 LVWD Executed @ $0.33 Details | Edit
05/15/13 3:55 PM EDT Sell 3500 LVWD Executed @ $0.32 Details | Edit
05/15/13 3:54 PM EDT Sell 5000 LVWD Executed @ $0.32 Details | Edit
05/15/13 3:54 PM EDT Sell 5000 LVWD Executed @ $0.32 Details | Edit
05/15/13 3:53 PM EDT Sell 4000 LVWD Executed @ $0.31 Details | Edit
05/15/13 3:51 PM EDT Sell 4500 LVWD Executed @ $0.31 Details | Edit
05/15/13 3:51 PM EDT Sell 7500 LVWD Executed @ $0.31 Details | Edit
05/15/13 3:51 PM EDT Sell 8000 LVWD Executed @ $0.311 Details | Edit
05/15/13 1:51 PM EDT Sell 5000 TPNL Executed @ $0.245 Details | Edit
05/15/13 1:47 PM EDT Sell 13000 TPNL Executed @ $0.245 Details | Edit
05/15/13 1:03 PM EDT Sell 6100 TPNL Executed @ $0.24 Details | Edit
05/15/13 1:01 PM EDT Sell 17900 TPNL Executed @ $0.24 Details | Edit
05/15/13 12:59 PM EDT Sell 1000 TPNL Executed @ $0.258 Details | Edit
05/15/13 12:59 PM EDT Sell 2000 TPNL Executed @ $0.255 Details | Edit
05/15/13 12:30 PM EDT Sell 22000 GLMB Executed @ $0.12 Details | Edit
05/15/13 11:05 AM EDT Sell 916 BNLB Executed @ $0.102 Details | Edit
05/15/13 11:05 AM EDT Sell 31000 BNLB Executed @ $0.102 Details | Edit
05/15/13 10:37 AM EDT Sell 45000 BNLB Executed @ $0.1023 Details | Edit
05/15/13 10:02 AM EDT Sell 21026 HIIT Executed @ $0.24 Details | Edit
05/15/13 9:53 AM EDT Sell 2500 HIIT Executed @ $0.22 Details | Edit
05/15/13 9:53 AM EDT Sell 5000 HIIT Executed @ $0.22 Details | Edit
05/15/13 9:53 AM EDT Sell 20000 HIIT Executed @ $0.222 Details | Edit
05/15/13 9:51 AM EDT Sell 2500 HIIT Executed @ $0.23 Details | Edit
05/15/13 9:50 AM EDT Sell 2500 HIIT Executed @ $0.23 Details | Edit
05/15/13 9:49 AM EDT Sell 2500 HIIT Executed @ $0.2339 Details | Edit
05/15/13 9:47 AM EDT Sell 18300 HIIT Executed @ $0.24 Details | Edit
05/14/13 11:44 AM EDT Buy 500 GAMR Executed @ $0.38 Details | Edit
05/14/13 10:26 AM EDT Sell 24640 CONX Executed @ $0.1527 Details | Edit
05/14/13 10:26 AM EDT Sell 5000 CONX Executed @ $0.1601 Details | Edit
05/14/13 10:26 AM EDT Sell 5000 CONX Executed @ $0.16 Details | Edit
05/14/13 10:24 AM EDT Sell 5000 CONX Executed @ $0.16 Details | Edit
05/14/13 9:51 AM EDT Sell 5000 CONX Executed @ $0.1717 Details | Edit
05/14/13 9:51 AM EDT Sell 10000 CONX Executed @ $0.1717 Details | Edit
05/14/13 9:51 AM EDT Sell 6825 CONX Executed @ $0.175 Details | Edit
05/14/13 9:51 AM EDT Sell 5000 CONX Executed @ $0.1751 Details | Edit
05/14/13 9:50 AM EDT Sell 4600 CONX Executed @ $0.183 Details | Edit
05/14/13 9:50 AM EDT Sell 7499 CONX Executed @ $0.1752 Details | Edit
05/13/13 2:59 PM EDT Buy 399 ENSV Executed @ $1.04 Details | Edit
05/13/13 1:58 PM EDT Buy 20000 TOOT Executed @ $0.1418 Details | Edit
05/13/13 1:08 PM EDT Buy 18994 TEXC Executed @ $0.12 Details | Edit
05/13/13 12:49 PM EDT Sell 5014 ENSV Executed @ $1.1 Details | Edit
05/13/13 12:49 PM EDT Sell 50 ENSV Executed @ $1.11 Details | Edit
05/13/13 12:49 PM EDT Sell 3000 ENSV Executed @ $1.1 Details | Edit
05/13/13 12:48 PM EDT Sell 300 ENSV Executed @ $1.11 Details | Edit
05/13/13 12:48 PM EDT Sell 100 ENSV Executed @ $1.12 Details | Edit
05/13/13 12:47 PM EDT Sell 100 ENSV Executed @ $1.12 Details | Edit
05/13/13 12:47 PM EDT Sell 1800 ENSV Executed @ $1.12 Details | Edit
05/13/13 12:46 PM EDT Sell 500 ENSV Executed @ $1.12 Details | Edit
05/13/13 10:47 AM EDT Buy 5000 DTRK Executed @ $0.8 Details | Edit
05/13/13 9:41 AM EDT Buy 12888 GAMR Executed @ $0.35 Details | Edit
05/10/13 2:20 PM EDT Sell 1388 CONX Executed @ $0.2268 Details | Edit
05/10/13 12:42 PM EDT Buy 40000 HIIT Executed @ $0.2458 Details | Edit
05/10/13 12:09 PM EDT Sell 9000 HIIT Executed @ $0.278 Details | Edit
05/10/13 11:47 AM EDT Sell 1600 HIIT Executed @ $0.278 Details | Edit
05/10/13 11:42 AM EDT Buy 10488 TOOT Executed @ $0.1828 Details | Edit
05/10/13 11:38 AM EDT Buy 29257 BNLB Executed @ $0.095 Details | Edit
05/10/13 11:36 AM EDT Buy 8436 BNLB Executed @ $0.095 Details | Edit
05/10/13 11:33 AM EDT Sell 1000 HIIT Executed @ $0.278 Details | Edit
05/10/13 11:24 AM EDT Buy 38888 CONX Executed @ $0.2108 Details | Edit
05/10/13 9:36 AM EDT Buy 7200 TEXC Executed @ $0.1158 Details | Edit
05/09/13 3:56 PM EDT Buy 8800 TOOT Executed @ $0.1728 Details | Edit
05/09/13 3:55 PM EDT Buy 390 SPND Executed @ $3.7 Details | Edit
05/09/13 2:03 PM EDT Buy 776 DTRK Executed @ $0.88 Details | Edit
05/09/13 12:18 PM EDT Buy 3888 ENSV Executed @ $1.1 Details | Edit
05/09/13 12:08 PM EDT Sell 10000 SPCBF Executed @ $0.2688 Details | Edit
05/09/13 12:06 PM EDT Sell 3000 SPCBF Executed @ $0.2688 Details | Edit
05/09/13 11:22 AM EDT Buy 500 DTRK Executed @ $0.9 Details | Edit
05/09/13 10:59 AM EDT Buy 1674 DTRK Executed @ $0.9 Details | Edit
05/09/13 10:40 AM EDT Buy 9500 TOOT Executed @ $0.1828 Details | Edit
05/09/13 10:08 AM EDT Buy 5000 TEXC Executed @ $0.1158 Details | Edit
05/09/13 10:00 AM EDT Buy 100 TOOT Executed @ $0.1828 Details | Edit
05/09/13 9:43 AM EDT Buy 14888 SPCBF Executed @ $0.2518 Details | Edit
05/08/13 3:01 PM EDT Buy 5000 DTRK Executed @ $0.95 Details | Edit
05/08/13 2:40 PM EDT Sell 2275 VSTI Executed @ $0.11 Details | Edit
05/08/13 2:36 PM EDT Sell 5000 VSTI Executed @ $0.11 Details | Edit
05/08/13 2:32 PM EDT Sell 5000 HIIT Executed @ $0.254 Details | Edit
05/08/13 2:32 PM EDT Sell 4350 HIIT Executed @ $0.254 Details | Edit
05/08/13 2:31 PM EDT Sell 6000 VSTI Executed @ $0.11 Details | Edit
05/08/13 1:32 PM EDT Buy 100 CPHMF Executed @ $4.079 Details | Edit
05/08/13 1:32 PM EDT Buy 100 CPHMF Executed @ $4.079 Details | Edit
05/08/13 1:32 PM EDT Buy 200 CPHMF Executed @ $4.079 Details | Edit
05/08/13 11:56 AM EDT Sell 421 VSTI Executed @ $0.1 Details | Edit
05/08/13 11:25 AM EDT Sell 4000 VSTI Executed @ $0.1 Details | Edit
05/08/13 10:53 AM EDT Sell 4000 VSTI Executed @ $0.1 Details | Edit
05/08/13 10:52 AM EDT Sell 1770 VSTI Executed @ $0.1 Details | Edit
05/08/13 10:52 AM EDT Sell 2000 VSTI Executed @ $0.1 Details | Edit
05/08/13 10:51 AM EDT Sell 100 VSTI Executed @ $0.102 Details | Edit
05/08/13 10:51 AM EDT Sell 10000 VSTI Executed @ $0.11 Details | Edit
05/08/13 10:32 AM EDT Buy 3888 ENSV Executed @ $1.18 Details | Edit
05/08/13 10:18 AM EDT Buy 227 SPCBF Executed @ $0.2408 Details | Edit
05/08/13 10:08 AM EDT Sell 11200 HIIT Executed @ $0.2455 Details | Edit
05/08/13 10:06 AM EDT Sell 11600 HIIT Executed @ $0.2455 Details | Edit
05/08/13 10:03 AM EDT Sell 12200 HIIT Executed @ $0.25 Details | Edit
05/08/13 9:53 AM EDT Buy 2500 DTRK Executed @ $0.95 Details | Edit
05/08/13 9:53 AM EDT Buy 2500 DTRK Executed @ $0.948 Details | Edit
05/07/13 3:18 PM EDT Buy 1000 DTRK Executed @ $0.8028 Details | Edit
05/07/13 3:13 PM EDT Buy 100 DTRK Executed @ $0.8028 Details | Edit
05/07/13 3:05 PM EDT Buy 3788 ENSV Executed @ $1.22 Details | Edit
05/07/13 3:05 PM EDT Buy 100 ENSV Executed @ $1.22 Details | Edit
05/07/13 1:19 PM EDT Buy 4000 KLYG Executed @ $0.0868 Details | Edit
05/07/13 1:18 PM EDT Sell 7500 HIIT Executed @ $0.28 Details | Edit
05/07/13 1:16 PM EDT Sell 7500 HIIT Executed @ $0.28 Details | Edit
05/07/13 12:41 PM EDT Sell 8300 DTRK Executed @ $1.01 Details | Edit
05/07/13 12:41 PM EDT Sell 10000 DTRK Executed @ $1.01 Details | Edit
05/07/13 12:40 PM EDT Sell 5000 DTRK Executed @ $1.01 Details | Edit
05/07/13 12:24 PM EDT Sell 5788 DTRK Executed @ $0.8688 Details | Edit
05/07/13 12:09 PM EDT Buy 3000 SPCBF Executed @ $0.2408 Details | Edit
05/07/13 12:05 PM EDT Buy 9100 SPCBF Executed @ $0.2408 Details | Edit
05/07/13 12:05 PM EDT Buy 4098 DTRK Executed @ $0.8028 Details | Edit
05/07/13 11:59 AM EDT Buy 500 VSTI Executed @ $0.1495 Details | Edit
05/07/13 11:53 AM EDT Buy 12888 CONX Executed @ $0.2258 Details | Edit
05/07/13 10:43 AM EDT Sell 6500 CONX Executed @ $0.225 Details | Edit
05/07/13 10:16 AM EDT Buy 20 CPHMF Executed @ $4.101 Details | Edit
05/07/13 10:16 AM EDT Buy 100 CPHMF Executed @ $4.101 Details | Edit
05/07/13 10:13 AM EDT Sell 21500 RCVA Executed @ $0.025 Details | Edit
05/07/13 9:48 AM EDT Sell 2500 CONX Executed @ $0.225 Details | Edit
05/07/13 9:40 AM EDT Sell 200 ASNB Executed @ $0.0798 Details | Edit
05/06/13 3:56 PM EDT Buy 47288 HIIT Executed @ $0.2528 Details | Edit
05/06/13 3:44 PM EDT Buy 1600 HIIT Executed @ $0.2528 Details | Edit
05/06/13 3:19 PM EDT Sell 30000 HIIT Executed @ $0.282 Details | Edit
05/06/13 3:18 PM EDT Sell 2500 HIIT Executed @ $0.284 Details | Edit
05/06/13 2:00 PM EDT Sell 5000 ASNB Executed @ $0.0798 Details | Edit
05/06/13 12:35 PM EDT Sell 1508 DTRK Executed @ $0.78 Details | Edit
05/06/13 12:34 PM EDT Buy 5583 TOOT Executed @ $0.2008 Details | Edit
05/06/13 12:28 PM EDT Buy 37400 HIIT Executed @ $0.2842 Details | Edit
05/06/13 12:27 PM EDT Buy 2600 HIIT Executed @ $0.2842 Details | Edit
05/06/13 12:27 PM EDT Buy 24888 HIIT Executed @ $0.293 Details | Edit
05/06/13 12:27 PM EDT Buy 24000 HIIT Executed @ $0.293 Details | Edit
05/06/13 12:10 PM EDT Sell 1000 DTRK Executed @ $0.78 Details | Edit
05/06/13 11:37 AM EDT Buy 3600 PBSV Executed @ $1.03 Details | Edit
05/06/13 11:34 AM EDT Buy 1400 PBSV Executed @ $1.03 Details | Edit
05/06/13 11:04 AM EDT Sell 700 DTRK Executed @ $0.78 Details | Edit
05/06/13 10:26 AM EDT Sell 350 DTRK Executed @ $0.78 Details | Edit
05/06/13 10:13 AM EDT Sell 2800 ENSV Executed @ $1.28 Details | Edit
05/06/13 10:09 AM EDT Sell 1888 ENSV Executed @ $1.28 Details | Edit
05/06/13 9:52 AM EDT Buy 650 TOOT Executed @ $0.2008 Details | Edit
05/06/13 9:45 AM EDT Sell 2000 ETCIA Executed @ $0.16 Details | Edit
05/03/13 3:43 PM EDT Buy 90 DTRK Executed @ $0.7328 Details | Edit
05/03/13 3:43 PM EDT Buy 4700 DTRK Executed @ $0.73 Details | Edit
05/03/13 1:56 PM EDT Buy 48 ENSV Executed @ $1.29 Details | Edit
05/03/13 1:38 PM EDT Buy 1540 ENSV Executed @ $1.29 Details | Edit
05/03/13 1:34 PM EDT Buy 1300 ENSV Executed @ $1.29 Details | Edit
05/03/13 12:08 PM EDT Sell 20000 HIIT Executed @ $0.297 Details | Edit
05/03/13 12:01 PM EDT Buy 1888 ENSV Executed @ $1.29 Details | Edit
05/03/13 11:57 AM EDT Buy 50 TOOT Executed @ $0.2008 Details | Edit
05/03/13 11:52 AM EDT Sell 10000 HIIT Executed @ $0.297 Details | Edit
05/03/13 10:05 AM EDT Buy 11000 SPCBF Executed @ $0.2529 Details | Edit

[10 bagger]

QMDT.. $0.06 Looks like a keeper to me.. If earnings continue to ramp up higher prices ahead..hank
------------------------------
From 8K filing:Item 1.01 Entry into a Material Definitive Agreement

The following discussion provides only a brief description of the document described below. The discussion is qualified in its entirety by the full text of the agreement, which is attached to this Current Report on Form 8-K as an exhibit.

On May 20, 2013, with an effective date as of May 13, 2013, Quick-Med Technologies, Inc. (the “Company” or "we") and the U.S. Army Medical Research and Material Command entered in to an agreement for the Company to provide Small Business Innovative Research (SBIR) Phase I research in “Development of Technologies the Control Scar Contracture after Burn Injuries”. The agreement provides payments to the Company of $149,999 over the period from May 15, 2013 through December 15, 2013.

Phase I is to determine the scientific or technical merit of ideas submitted to the U.S. Army by the Company. Phase II awards could be made in the government’s fiscal year 2014 (October 1, 2013 to September 30, 2014) if the approaches appear sufficiently promising as a result of Phase I and could cover 2-5 many years of effort over a period generally not to exceed 24 months.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits.

Exh. No. Description

10.1 Award/Contract between Quick-Med Technologies, Inc. and the U.S. Army Medical Research and Material Command effective as of May 13, 2013.

-------------------------------------------
FDA Clears Stay-Fresh(R) Medical Textile Product

Marketwire - May 29 08:00 EDT

Alert hits:OTC /qm
Company Symbols: OTC-PINK:QMDT

Quick-Med Receives 510k Clearance to Market Antibacterial Skinfold Management Device -- First Medical Product Utilizing Stay Fresh Technology

GAINESVILLE, FL -- (Marketwired) -- 05/29/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Food and Drug Administration (FDA) has issued clearance for distribution and marketing of a Stay Fresh® medical textile product. FDA granted 510k clearance for the Stay Fresh® antibacterial skinfold management textile, which provides durable protection against bacterial contamination for skinfold management in bariatric patients.

"We are very pleased to have received this clearance for both prescription (Rx) and Over-The-Counter (OTC) use," said Bernd Liesenfeld, Quick-Med's President. "This clearance represents a very powerful validation of our Stay Fresh technology, since the FDA review process is extremely meticulous and comprehensive; 510k clearance requires strong evidence of both effectiveness and of safety for users and care providers. Together with the existing EPA registration for Stay Fresh this provides strong regulatory support for our products already in development with partners, and for further products in our pipeline, both on the consumer and on the medical sides."

"Areas of skin-to-skin contact such as under breast folds or abdominal skin folds frequently develop redness, odor, and rashes due to increased moisture and friction that create an environment that promotes bacterial growth in the skin folds," said Professor Gregory Schultz, Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology at the University of Florida. "The Stay Fresh® antibacterial textile approved by the FDA provides an effective skin fold management system that will help manage moisture and bacterial pathogen growth for up to 5 days."

About Stay Fresh
Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly used in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to be utilized to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has granted clearance to market an antibacterial medical textile based on Stay Fresh Technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously, with development of additional applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications, with consumer applications of Stay Fresh Technology having EPA registration for the treated articles, as well as an FDA clearance for an antibacterial medical textile product. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc.

CONTACT: Quick-Med Technologies Bernd Liesenfeld
President [phone]
[e-mail]

Source: Quick-Med Technologies, Inc.

------------------------------------------------
Quick-Med Technologies Awarded Contract to Develop Wound Healing Technology to Control Scar Contracture in Burn Patients

NIMBUS Technology Selected by Department of Defense for Advanced Wound Healing Technology SBIR Grant

GAINESVILLE, FL -- (Marketwired) -- 05/22/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded a contract by the U.S. Department of Defense for research on the "Development of Technologies to Control Scar Contracture after Burn Injuries." NIMBUS technology was competitively selected for this award under the Small Business Innovation Research (SBIR) program of the DoD Defense Health Program (DHP). The SBIR program, established by the U.S. Congress, supports scientific excellence and technological innovation through the investment of federal research funds by competitively awarding contracts on the basis of scientific merit and commercial potential.

The Phase I objective of this research is "to design a new innovative technology to intervene during the wound healing process, including inflammatory, proliferative and/or remodeling stages, to attenuate/control scar contracture and retain skin aesthetics following deep tissue burn injuries." The Phase I research contract is valued at about $150,000. Work starts immediately and is expected to take about 6 months. Follow-on phases of the award can bring the total value close to $1M, and will develop the proof of concept to commercial readiness.

"We are very pleased to have been competitively selected for this important advanced research program into dressings that can speed wound healing," said Bernd Liesenfeld, Quick-Med's President. "This award is a further validation of our NIMBUS antimicrobial technology platform and will enable us to continue our development a series of products that accelerate wound healing and help prevent microbial contamination."

The new research contract builds on Quick-Med's prior work developing a dressing that was shown to speed healing of vesicant (blister) injuries caused by chemical weapons (sulfur mustard gas). This previous research, which was conducted under Phase 1 and Phase 2 SBIR awards from the US Army, was presented at the 2011 Annual Meeting of the Wound Healing Society, where it received the top prize for Industrial Research and Development. This new award permits Quick-Med to extend that research to more directly address unmet commercial needs in treatments for the approximately 2.4 million thermal burns occurring annually in the US, with a dressing designed to reduce scarring and contracture in healing of severe burns. Part of the research will be conducted at the University of Florida's Institute for Wound Research.

"The NIMBUS super-absorbent polymer technology allows Quick-Med to develop a unique dressing that provides antimicrobial protection for the wound while also acting to minimize scar tissue formation, and inhibit matrix metalloproteinases to block contracture of tissues," said Professor Greg Schultz, Director of the Institute for Wound Research at the University of Florida. "This unique combination therapy should speed healing and reduce contraction of severe burns in our wounded warriors. It would also have extensive application for civilians with large burns."

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional and advanced wound care applications, both in the US and abroad. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by numerous U.S. patents and foreign counterparts. Additional applications currently under development include advanced wound dressings, medical adhesives, and catheters.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc.

-------------------------------------------
QUICK-MED TECHNOLOGIES, INC.
CONDENSED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2013 AND 2012
(UNAUDITED)

--------------------------------------------------------------------------------

3 months ended 9 months ended
March March
2013 2012 2013 2012

Revenues
Royalty and license fees $ 137,217 $ 117,867 $ 459,333 $ 319,604
Product sales 124,788 77,433 265,578 284,655
Research and development service - 3,000 - 113,000
Total revenues 262,005 198,300 724,911 717,259

Expenses:
Cost of sales 6,475 6,358 17,483 17,724
Research and development 117,942 210,235 405,639 683,889
General and administrative expenses (142,039 ) 210,712 262,411 742,443
Licensing and patent expenses 53,743 62,323 194,734 230,233
Depreciation and amortization 32,487 15,757 63,939 48,583
Total operating expenses 68,608 505,385 944,205 1,722,872

Operating profit (loss) 193,397 (307,085 ) (219,294 ) (1,005,613 )

Other income (expense):
Interest income 87 58 660 1,371
Interest expense (108,808 ) (111,819 ) (334,375 ) (338,153 )
Total other expense (108,721 ) (111,761 ) (333,715 ) (336,782 )

Profit (Loss) before provision (benefit) for income taxes 84,676 (418,846 ) (553,010 ) (1,342,395 )

Provision (benefit) for income taxes - - - -

Net loss $ 84,676 $ (418,846 ) $ (553,010 ) $ (1,342,395 )

Net loss per share - basic and diluted $ 0.00 $ (0.01 ) $ (0.01 ) $ (0.04 )

Weighted average common shares outstanding - basic and diluted 37,346,154 37,346,154 37,346,154 37,346,154

----------------------------------------------
8K announcement..
Item 1.01 Entry into a Material Definitive Agreement

The following discussion provides only a brief description of the document described below. The discussion is qualified in its entirety by the full text of the agreement, which is attached to this Current Report on Form 8-K as an exhibit.

On May 9, 2013, with an effective date as of April 1, 2013, Quick-Med Technologies, Inc. (the “Company” or "we") and VIRIDIS BioPharma Pvt. Ltd. entered into a Patent and Technology License Agreement (the "Agreement") to license our proprietary Nimbus® intellectual property.

Under the Agreement, we grant Viridis exclusive rights to use our proprietary Nimbus intellectual property in hydrophilic polyurethane foam for wound care applications and for securing intravenous tubings and catheters on products sold in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine, Uzbekistan, Russia and their territories and possessions.

In consideration for the execution of the Agreement, Viridis will pay a royalty of 7.5% on net sales for each product. The Agreement shall continue to be in effect for a term of five years from the effective date, unless terminated earlier for breach or bankruptcy.


The Agreement is in addition to the Patent and Technology License Agreement of July 26, 2010 (including Amendments 1-3) (“2010 Patent Agreement”). We also entered into a fourth amendment of the 2010 Patent Amendment on May 9, 2013 that extended the term of the 2010 Patent Agreement to March 31, 2018

There are no material relationships between the Company or its affiliates and any of the parties to the Agreement, other than with respect to this Agreement and the Agreement dated July 26, 2010 with amendments 1-4.

Item 9.01 Financial Statements and Exhibits


(c) Exhibits.

Exh. No. Description

10.1 Patent and License Agreement by and between Quick-Med Technologies, Inc. and VIRIDIS BioPharma Pvt. Ltd. effective as of April 1, 2013.

10.2 Amendment No. 4 to Patent and License Agreement by and between Quick-Med Technologies, Inc. and VIRIDIS BioPharma Pvt. Ltd. dated May 9, 2013.

-----------------------------------------------
Quick-Med Engages Match Point Partners as Financial Advisor

Specialist Firm Expert in Healthcare Markets Served by QMT

GAINESVILLE, FL -- (Marketwired) -- 04/12/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company, announced that is that it has retained Match Point Partners to manage its investor and public relations programs. Match Point Partners is a New York based strategy and financial advisory firm that helps healthcare and technology companies manage and grow through inflection points and maximize long-term value.

"We are continuing the commercial expansion of our NIMBUS® and Stay Fresh® product lines with our US and international partners," said Quick-Med CFO Paul Jenssen. "We are excited to have the help of Match Point Partners to communicate our growth and increase our visibility with our partners and supporters."

"QMT is a highly innovative health care company that is bringing very exciting antimicrobial technologies to market," said J.D. Friedland, Founder and Senior Managing Director of Match Point. "Their products address the major public health concerns of drug-resistant bacteria in our communities, institutions, and even in our food industries. Match Point will be able to help communicate the value of these technologies better to the healthcare, consumer goods, and financial communities to improve public understanding of Quick-Med's value.

"Our work with Quick-Med reflects Match Point's approach to partner closely with our clients in a broad manner to help them achieve their financial and strategic objectives. We follow through on our commitment by working side by side with our clients at every step. This depth of collaboration helps to align client goals with our efforts and enhance company value."

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

About Match Point Partners LLC
Headquartered in New York City, Match Point Partners is a strategy and financial advisory firm that provides a unique blend of value-added strategic, operating and investment banking services to emerging middle market healthcare and technology firms. Our team of experienced entrepreneurs, bankers, and operators collaborate to develop and execute creative, innovative and often out-of-the-box solutions to help our clients achieve superior value. All securities are offered through Bridge Capital Associates, Inc., Member FINRA / SIPC. For more information, please visit www.mppartnersllc.com.

------------------------------------------
Quick-Med Announces New Members Appointed to Its Board of Directors

Appointment of Dale Bergman and Paul Jenssen

GAINESVILLE, FL -- (Marketwire) -- 02/28/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the Board has appointed new members Dale Berman and Paul Jenssen effective February 28, 2013. These members fill vacancies left by departures of Major General George Friel, USA (Ret.), who served from 2000 to 2012, and J. Ladd Greeno, who served from 2007 to 2013.

Mr. Bergman, 57, has practiced corporate and securities law for over 25 years, with specialty in advising emerging and mid-market public companies in their growth. Since March 2011, he has been a partner in the Ft. Lauderdale office of Roetzel & Andress, LPA. From May 2009 to March 2011, he was a partner in the Ft. Lauderdale office of Arnstein & Lehr and from January 2004 to April 2009, he was a member of Kluger, Peretz, Kaplan & Berlin, P.L., a Miami-Florida based law firm. Mr. Bergman does not currently serve as a director of any reporting companies. Mr. Bergman, who is a member of the Florida and New York bars, holds a bachelor's degree from Columbia College of Columbia University and a J.D. from Harvard Law School. Quick-Med Technologies believes that his lengthy experience in advising emerging and mid-market public companies in their growth makes him a valuable addition to the board of directors. The board of directors expects to appoint Mr. Bergman to its audit committee.

Mr. Jenssen has served as Chief Financial Officer and Corporate Secretary for Quick-Med Technologies since January 10, 2013. He has over 35 years of experience in strategic planning, process improvement, finance and accounting. He started his career at Deloitte Touche (1978-1984) before becoming Treasurer at Associated Press (1984-1998). In addition to working as a consultant since 1998, he was the CFO, COO and a Senior Managing Director at Rothschild North America investment bank (1998-2006). From 2006 until the present, Mr. Jenssen was the President of Jenssen Consulting, a business involved in providing strategic planning, process improvement, finance and accounting related services. Mr. Jenssen does not serve as a director of any other reporting company. Mr. Jenssen is a CPA, has an MBA from Columbia University in New York and has held several securities licenses. The registrant believes that Mr. Jenssen's financial and investment banking experiences makes him a valuable addition to its board of directors.

--------------------------------------------
Quick-Med Technologies Appoints Paul H. Jenssen as Its Chief Financial Officer

GAINESVILLE, FL -- (Marketwire) -- 01/15/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT) announced today that its Board of Directors (the "Board") appointed Paul H. Jenssen as the Company's Chief Financial Officer and corporate secretary, effective as of January 10, 2013. He replaces Nam H. Nguyen, whom Quick-Med wishes to thank for his contributions and years of service, and who will provide active support for the transition.

Mr. Jenssen has 35 years of experience in strategic planning, process improvement, finance and accounting. He started his career at Deloitte Touche (1978-1984) before becoming Treasurer at Associated Press (1984-1998). In addition to working as a consultant since 1998, he was the CFO, COO and a Senior Managing Director at Rothschild North America investment bank (1998-2006). He is a CPA, has an MBA with highest honors from Columbia University in New York and has held several securities licenses. He is also an engaged member of the community and has worked in several teaching positions. Additional information can be found in the Company's current report on Form 8-K filed with the Securities and Exchange Commission and available on the Company's website.

"We are very excited to have Paul join our team at Quick-Med, as he brings terrific experiences to support our operational and investment needs. This completes the centralization of our operations to our Gainesville site, and will improve and simplify our ability to communicate with our clients and investors as a team" stated Bernd Liesenfeld, President of Quick-Med.

About Quick-Med Technolgies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS® and NimbuDerm™ applications in several advanced medical device formats including wound care dressings, adhesives, medical grade thermoplastics, and skin sanitizers. NIMBUS is the FDA-cleared technology that has been commercialized in a line of wound dressings. The Company's MultiStat® compounds are commercialized in skin care products. The company is also commercializing its Stay Fresh™ technology for apparel and other textile applications. For more information, see: www.quickmedtech.com.

--------------------------------------------
Quick-Med Announces Update on Appointment of Director

GAINESVILLE, FL -- (Marketwire) -- 01/15/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today an update to a previous press release announcement. Quick-Med announced November 13, 2012 that John W. Sheets was appointed to join the board of directors of the company. Delays in receiving clearance from his employer's (Boston Scientific) corporate counsel have prevented Dr. Sheets from being able to join the company's board to date. As a result, Dr. Sheets' appointment as a board member has been rescinded by the company's board of directors at this time. Both Dr. Sheets and the company remain enthusiastic to work together and intend to do so as the situation permits.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. In addition to NIMBUS, Quick-Med's Stay Fresh® technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.

© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.

---------------------------------------------
Quick-Med Announces First Commercial Sale of Advanced Dressings With NIMBUS(R) Technology

Viridis BioPharma Launches Microfoam(TM) Advanced Wound Care Dressings in India

GAINESVILLE, FL -- (Marketwire) -- 01/08/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that Viridis BioPharma Pvt. Ltd. has begun selling and shipping Microfoam™ dressings to customers. Microfoam is the first advanced wound care dressing to utilize Quick-Med's proprietary non-leaching NIMBUS® technology. Viridis received approval by the Food and Drug Administration of India in September 2011 to manufacture and market Microfoam wound dressings incorporating NIMBUS antimicrobial technology.

NIMBUS represents a next generation in wound care. This unique technology offers surgeons, wound care clinicians, infection control experts and primary care doctors an important new weapon against the transmission of such virulent bacteria as Methicillin-resistant Staphylococcus aureus (MRSA). It is the first non-leaching antimicrobial available in a wound dressing.

"It's exciting that this unique technology is now available in an advanced wound dressing format, in an emerging market," said Bernd Liesenfeld, Quick-Med's president. "India's large population, increasing investments in health care and fast growing wound care market represents a significant opportunity for Viridis to provide patients and caregivers with great a product, and to drive sales with our unique, value-added NIMBUS antimicrobial feature."

The NIMBUS technology is designed to prevent bacteria developing resistance, and avoid releasing toxic material into the wound, so there is no impeding the wound healing process. It is a novel antimicrobial technology: non-leaching and effective even in high concentrations of body fluids. NIMBUS technology is easy for the caregiver to implement as part of prophylactic care for patients at risk for infections.

As part of its commercialization efforts, Viridis BioPharma has sponsored clinical trials to demonstrate the efficacy of Microfoam dressings. "India tops the diabetes sufferers list as per World Health Organization (WHO) figures and consequently chronic diabetic wounds and ulcers. Quick-Med's NIMBUS Technology applied through Microfoam dressing shows remarkable relief in burn and wound cases and particularly in diabetic chronic wounds, as well as in venous and pressure ulcers, in an Indian clinical trial," commented Dr. Dilip Mehta, CEO of Viridis BioPharma Pvt. Ltd.

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.

About Viridis BioPharma Pvt. Ltd.
Through strategic associations with international pharmaceutical and biopharma companies, Viridis BioPharma Pvt. Ltd. commercializes products with therapeutic efficacy and growth potential in the Indian subcontinent and delivers a range of clinically-proven products to enable people to live better and more active lives. Viridis currently manufactures and markets a number of medical devices for companies, manufactured under license for B. Braun, American BioTech Labs, and Bhabha Atomic Research Center (BARC). For more information, see: www.viridisbiopharma.com

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. In addition to NIMBUS, Quick-Med's Stay Fresh® technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.

© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc. Microfoam™ is a trademark of Viridis BioPharma Pvt. Ltd.

------------------------------------------------
USPTO Grants Quick-Med Tenth U.S. Patent for NIMBUS(R) Technology

New Patent Covers for NimbuDerm Hand Sanitizer and a Range of Other NIMBUS Antimicrobial Product Applications

GAINESVILLE, FL -- (Marketwire) -- 01/02/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded a tenth U.S. patent for its novel, non-leaching NIMBUS® antimicrobial technology.

The U.S. Patent and Trademark Office has granted Quick-Med Technologies U.S. Patent No. 8,343,523 titled, "Disinfectant with Durable Activity Based on Alcohol-Soluble Quaternary Ammonium Polymers and Copolymers." The new patent provides for a novel alcohol-soluble, water insoluble disinfectant for achieving a prolonged antimicrobial property to a variety of surfaces including skin. It covers the composition and method for several NIMBUS polyurethane quaternary applications including certain formulations of the Company's proprietary NimbuDerm™ hand sanitizer and a variety of NIMBUS applications including medical adhesives, foam wound dressings, sutures, catheters and other medical tubing.

"We are very pleased that the U.S. Patent Office has granted this tenth NIMBUS patent which further solidifies our leadership in non-leaching antimicrobial technology," said Bernd Liesenfeld, Quick-Med's president. "This new patent captures additional special characteristics of our unique NIMBUS technology and provides intellectual property protection for several key applications of our growing family of NIMBUS antimicrobial polymers."

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. In addition to NIMBUS, Quick-Med's Stay Fresh® technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.

© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.

-------------------------------------------------
Quick-Med Technologies Announces Further Expansion of Its NIMBUS(R) Technology Global Patent Portfolio

New Patents in India and China Plus Notice of Allowance in Canada Expand International NIMBUS Intellectual Property Coverage

GAINESVILLE, FL -- (Marketwire) -- 12/18/12 --

Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today advances in patent coverage in India, China, and Canada for the Company's novel, non-leaching NIMBUS® antimicrobial technology.

The State Intellectual Property of the People's Republic of China and the Patent Office of India have granted Quick-Med Technologies' pending patent entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers" in their respective jurisdictions. Additionally, the Canadian Intellectual Property Office has issued a "Notice of Allowance" for this pending patent in Canada. These new patents will significantly expand the international intellectual property coverage for NIMBUS.

The three new patents are similar to U.S. Patent No. 8,088,400, also entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers." They cover the Company's novel polyurethane-modified polycation, the newest member of the NIMBUS technology family of antimicrobials. NIMBUS technology encompasses the chemistry of antimicrobials that comprise a high charge density polycation that is built into the backbone of various polymers such as polyurethane in this case.

The new patents are key "composition-of-matter" patents that cover incorporation of a NIMBUS polycation into main chain of a urethane polymer. The physical state of the polyurethane polycation can be modified to alter the strength of the antimicrobial, the breathability of the film or coating and its flexibility or rigidity. The patents provide protection for various claims regarding the efficacy and durability of an antimicrobial polyurethane.

"This patent adds an exciting new dimension to our NIMBUS technology," says Dr. William Toreki, co-inventor and Quick-Med's vice president of Research & Development. "Our new polyurethane polycation has been licensed for medical adhesives and is well suited for a wide range of applications including films and coatings, catheters and other types of extruded tubing, and as a durable hand sanitizer."

"These NIMBUS patents are strategically important because they significantly expand the global coverage for our proprietary NIMBUS technology into exciting and emerging markets," said Dr. Bernd Liesenfeld, Quick-Med's president. "NIMBUS technology can make an important contribution to infection prevention programs in each of these markets."

NIMBUS technology provides efficacy against a broad range of both Gram-positive and Gram-negative bacteria. NIMBUS antimicrobials are not depleted in use, maintain effectiveness even in the presence of large amounts of blood or body fluids, and by design, pose no risk of bacteria developing resistance.

NIMBUS non-leaching antimicrobial technology was cleared by FDA in 2009 and is the only non-leaching antimicrobial technology available in wound dressings. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the healthcare and consumer markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters. Additionally, its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.

© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.

[ThoughtPower]

Nice pick- indeed.

[10 bagger]

VSTI.. $0.122 THIS IS MY STOCK FOR 2013.. I expect a 15 bagger (At Least fro when first listed..) ..A TRUE TABLE POUNDER.. Shares issued and
outstanding 103,992,869
--------------------------------------------------------------------------------
Western Maryland Health System Expands Use of Versus RTLS to Enhance Staff Safety
PR Newswire - Apr 09 11:58 EDT

Visibility™ Staff Assist Solution Deployed in Behavioral Health Unit

TRAVERSE CITY, Mich., April 9, 2013 /PRNewswire/ -- Western Maryland Health System (WMHS) has recently expanded use of its Real-time Locating System (RTLS) from Versus Technology, Inc. (Pink Sheets: VSTI.PK), using their existing sensory network to implement the Visibility™ Staff Assist solution. Deployed in WMHS' Behavioral Health Unit, Staff Assist provides a mobile, location-aware call button for caregivers.

According to the U.S. Department of Justice's National Crime Victimization Survey conducted 2005 to 2009, mental health occupations had one of the highest rates of workplace violence, second only to law enforcement. A 2011 survey by the Emergency Nurses Association found panic buttons to be one of the only environmental measures associated with a lower rate of workplace violence in healthcare.

Because WMHS is committed to enhancing the safety of its staff, the hospital sought to improve safety protocols for behavioral health workers. They selected Versus' Staff Assist solution because it could easily be added to their existing RTLS network, says Jeffery D. O'Neal, LCPC, the systems director for WMHS' Behavioral and Occupational Health Services department.

WMHS, located in Cumberland, Md., has been using Versus' RTLS since 2009 for asset tracking, patient tracking and egress control. By leveraging the existing RTLS sensory network in the Behavioral Health Unit, implementation of Staff Assist involved only installing software and providing Versus Clearview™ Badges, equipped with call buttons, to staff members.

"We saw an opportunity to expand the Versus system using the same sensors," explains O'Neal. "By providing badges to our staff, if they find themselves in a precarious situation with an aggressive or threatening patient, they are able to push the button on the badge and trigger what we call a 'code green,' or a crisis response team."

When a badge button is pressed, the Staff Assist software sends a pop-up alert showing both the staff member's name and location to workstations in the facility's call center, as well as to the nurse's station and Ascom phones. The person's current location is also highlighted on Versus' Enterprise View™ Floorplan, which displays a map of the unit. Call Center workers then call the code, knowing both the name and exact location of the staff member in crisis.

O'Neal says the mobile panic button provided by Staff Assist is an improvement over previous safety protocols. "Staff would have to use their portable telephone to call a code," he says, "which they may not have been able to do if they were being attacked by a client."

Staff members in WMHS' Behavioral Health Unit feel the system has not only improved safety, but also morale. "Working in the behavioral health unit can be stressful," says Vicki Svensson, RN, nurse manager. "Knowing that our hospital places priority on our safety, and gives us a way to call for help, really helps ease our minds as we care for our patients."

The success WMHS experienced in improving patient safety with Versus' RTLS led them to consider the Staff Assist solution. "The thing that has impressed me the most is how accurate the system is," O'Neal says. "We've had patients who have tried leaving the behavioral health unit, and using Versus [for egress alerts], we're always able to get the patient right in the main hall. We have not had any elopements from our unit since we started using Versus. From a safety perspective, that's huge."

By utilizing the same network for multiple applications — asset tracking, patient tracking, egress control, and now Staff Assist — WMHS significantly lowers the total cost of ownership for their RTLS.

As a bonus, Staff Assist was paid for with a patient safety grant. "Our health system had already made a commitment to support the expansion of the Versus system, but it being paid for by a grant was great," O'Neal says.

Life Safety Solutions Integrators, a Certified Versus System Integrator located in Timonium, Md., installed and provides ongoing support for the Versus sensory network.

About Western Maryland Health System
The Western Maryland Health System (WMHS) in Cumberland provides a wide range of healthcare services along the continuum of care for residents in Allegany and Garrett Counties in Maryland and surrounding counties in West Virginia and Pennsylvania. WMHS includes the Western Maryland Regional Medical Center, a 275-bed facility that opened in November 2009. Other components include a nursing home, outpatient diagnostic centers, and a network of urgent care clinics, primary care centers and physician practices. www.wmhs.com

About Life Safety Solutions Integrators
Life Safety Solutions Integrators is a solutions provider of low-voltage electronics and life safety systems for government, education, healthcare and business in the Greater Washington D.C., Northern Virginia and Maryland areas. Since 1978, LSSI has been engineering, installing and maintaining fire alarms, intercoms, security systems, nurse call systems and much more. Learn more at www.lifesafetysystems-lss.com.

About Versus Technology, Inc.
Established in 1988, Versus Technology, Inc. specializes in real-time location systems (RTLS) for healthcare. Used by more than 700 hospitals for enterprise patient tracking, bed management, asset tracking, and nurse call automation, Versus improves patient flow and documentation of caregiver and patient interactions, while enhancing communication and efficiency. Exclusively endorsed by the American Hospital Association, the Versus infrared (IR) and Active RFID solution is responsible for clinical-grade location and automation at a number of hospitals, clinics and long-term care facilities worldwide. To learn more about Versus Technology, Inc. (Pink Sheets: VSTI.PK), our technology and client successes, visit versustech.com and view our RTLS Demo.
========================================================

Aker Eye/Vision Source Improves Patient Flow, Efficiency with RTLS Technology

Optometry Clinic one of two in nation using wireless real-time locating

TRAVERSE CITY, Mich., Feb. 21, 2013 /PRNewswire/ -- Aker Eye/Vision Source, an eye clinic in Titusville, Fla., is one of the first optometry practices in the nation to improve patient flow and efficiency with a Real-time Locating System (RTLS) from Versus Technology, Inc (OTCPINK: VSTI).

The Versus Advantages™ Clinic patient flow system, an RTLS consisting of staff and patient badges that communicate with wireless V-Link™ sensors installed in each patient care area, tracks and times the stages of each patient visit (e.g. check-in, pre-testing, exam, etc.).

While the times are recorded, real-time locations of patients and staff are displayed on an electronic Glance-and-Go™ floor plan of the office (click for example). Pop-up messages also alert optometrists when patients are ready to be seen.

Greg Aker, O.D., discovered the patient flow system while searching for ways to reduce stress for his staff. Between two optometrists, his practice can see as many as 65 patients per day. "We were getting bogged down," he says, and the heavy patient load was taking a toll. "I knew there had to be a way to smooth the process out."

The eye center implemented the Advantages Clinic RTLS in January of 2013. The system immediately improved the clinic's efficiency. On the very first day, the average patient's overall visit time was reduced by 10 minutes.

According to Dr. Aker, that's because the Advantages system offers real-time visibility and alerts to help keep patients moving through the office efficiently.

Dr. Aker explains the immediate benefit that his staff receive: "At a glance, they know how many patients are waiting, and they know if an exam room is full. Before, they would literally have to get up, walk down the hall, walk in, look in the exam rooms to see which one is free, walk back up, get the patient, and bring them back. The Versus system eliminated that."

For the optometrists, the system's alerts and timers are motivators to keep patient flow moving. "It's the best part about the whole system," Dr. Aker says. "I'm seeing a timer tick by with how long the patient's been waiting for me. If the patient's been left alone for 15 minutes, this blue alert turns to red, so I know, boy, I better get in there."

What do patients think of the system? "I've invested in a lot of technologically advanced equipment throughout the whole office—it's kind of a theme around here," Dr. Aker says. But the Versus Glance-and-Go monitors are what "wows" his patients. "Oh, they marvel. They just shake their heads and say, 'You're the most advanced office I've ever seen.'"

As for staff, Dr. Aker says that out of all the technology he uses, the Advantages Clinic RTLS is the one system that has made their work day better. "Multiple employees have come to me and said, 'Hands down this is the best thing you've ever done.' That's a powerful statement."

Dr. Aker expects efficiencies gained from the system will grow as he begins to use the historical data offered through Versus' Reports Plus™ Analytics software. Ready-made reports compare wait times, overall visit times or other metrics against benchmarks to identify potential bottlenecks in patient flow.

While Versus' RTLS has been used in hospitals for more than 20 years, Aker Eye/Vision Source joins Key-Whitman Eye Center, with offices in Dallas, Plano and Arlington, Texas, as one of only two optometry practices in the nation using the technology.

Versus is the first RTLS vendor to offer affordable real-time locating to clinics of all sizes, thanks to its new V-Link sensory network. The battery-powered, wireless V-Link sensors are quickly and easily installed in a matter of days, without pulling wire. Together with the 10th-generation, AC-powered V-Direct™ sensory network, V-Link allows Versus and its Certified System Integrators to offer comprehensive options to healthcare facilities exploring the benefits of RTLS.

About Aker Eye/Vision Source

At Aker Eye/Vision Source, service to the patient is the highest priority. Through the use of advanced technology, the practice strives to offer an eyecare experience like none other. The center is led by Greg Aker, O.D., who began serving the area of Titusville, Fla., in 1984 and has since built a name for himself as a preeminent optometry provider. Dr. Aker is joined by Sarah Harbove, O.D., who is proud to provide quality eye care in her hometown. Learn more at akereyecenter.com.

==========================================================
Children's of Alabama Live with Versus RTLS Asset Tracking, Four Rivers Integration

TRAVERSE CITY, Mich., Feb. 19, 2013 /PRNewswire/ -- Children's of Alabama in Birmingham has implemented the Versus Advantages™ Asset Tracking solution. The real-time locating system (RTLS) from Versus Technology, Inc. (OTCPINK: VSTI) includes two-way HL7 integration to Four Rivers Total Maintenance System (TMS).

The Versus RTLS Asset Tracking solution was selected for its proven accuracy and the ability to expand the solution to other uses as needed.

The system has been installed throughout the new Benjamin Russell Hospital for Children which opened in August of 2012, and will be expanded across the remaining six inpatient units making up the Children's of Alabama's main campus. VT Group Healthcare, in Birmingham, Ala., a certified Versus System Integrator, is installing the system.

The hospital is currently tracking approximately 3,000 mobile assets, including IV pumps, beds and stretchers across 760,000 square feet. The first phase of the implementation will allow the hospital to:

reduce shrinkage due to lost or stolen items,
quickly locate critical equipment for patient safety,
manage utilization of key inventory,
improve response times for patient care needs, and
improve overall patient satisfaction.
The integration to Four Rivers TMS application will help Children's of Alabama better manage its equipment fleet by associating key equipment status data with the equipment's real-time location. Factors such as preventative maintenance, warranties and recall notifications are maintained and managed in the Four Rivers system, while Versus provides the equipment's current location. The integration with Versus allows staff to see which equipment is available and where it is.

Asset tracking is one of many RTLS uses. With the Versus system, hospitals can also track and automate patient flow, quickly locate nurses, physicians and other staff, as well as monitor hand hygiene compliance.

Jack Storey, CIO of Children's of Alabama explains, "We selected Versus for our expansion facility because it allows us to have multiple RTLS-driven applications on one infrastructure. Our initial focus was equipment tracking and the Integration to Four Rivers was important to us. The Versus infrastructure can also be used by our GE [Ascom Telligence™] nurse call system for nurse tracking. Additional applications within the Versus suite of products would also allow us to add patient tracking and/or hand washing monitoring if we decide that functionality is needed in the future. It is beneficial for us to have a single system and infrastructure that we can cross-utilize and leverage throughout the hospital."

Versus' RTLS is proven at more than 700 hospitals and clinics—many of which have been operating daily on the same sensory network for more than 15 years. Using infrared (IR) technology for room and bed-level locating and radio frequency identification (RFID) for status communication, the Versus RTLS guarantees No False Positives.

Unlike other real-time locating systems, Versus requires a read, or "hit," from badge or tag that is physically present in a sensed location. Versus' ability to guarantee accuracy allows physicians, nurses, clinicians and clinical engineers to quickly locate patients, staff and equipment and trust that the data is accurate. It also means that Versus can automate other systems without delay and without the risk of providing false data.

To learn more about Asset Tracking and other uses for RTLS in the clinical environment, visit Versus' website at visit versustech.com or register for our RTLS sessions at the HIMSS13 Annual Conference & Exhibition in New Orleans, La., March 3-7, 2013 by visiting versustech.com/himss13.

About Children's of Alabama

Children's of Alabama has provided specialized medical care for ill and injured children across the state and throughout the southeastern U.S. since 1911. For the past three years, Children's has been ranked among the best children's hospital programs in the nation by US News & World Report. Last year, patients made more than 634,000 outpatient and nearly 14,000 inpatient visits to Children's from every county in Alabama and from 47 other states. With more than 2 million square feet, it is the third largest pediatric medical facility in the U.S. Children's offers inpatient and outpatient services across its Russell Campus on Birmingham's historic Southside with additional outpatient services provided at Children's South and Children's on 3rd. Primary care is provided at more than a dozen medical offices in communities across central Alabama. Children's of Alabama is the only medical center in Alabama dedicated solely to the care and treatment of children. It is a private, not-for-profit medical center that serves as the primary site of the University of Alabama at Birmingham (UAB) pediatric medicine, surgery, research and residency programs. Children's recently moved much of its inpatient services into a new building named The Benjamin Russell Hospital for Children. More information is available at www.childrensal.org.

About VT Group Healthcare

VT Group provides customer-critical technical services to government agencies and commercial entities. Through its Integrated Solutions, Technical Services and Unmanned Services business units, VT Group delivers critical solutions in C4IT design, integration and installation; healthcare technology; asset management; equipment life cycle support; facility operations and maintenance; logistics services and support; utility management; and unmanned systems support. Whether it is improving communications or quick response to patients' needs, VT Group's Healthcare Division is a leading agent for Ascom Patient Systems Telligence™ Nurse Call, installing and maintaining the advanced Voice over Internet Protocol (VoIP) healthcare communication platform, integrated with Versus RTLS. By keeping staff connected or aiding in the expedition of critical patient information through Healthcare Media Retrieval Systems, VT Group Healthcare is a reliable, responsive supporter for both the healthcare professional and the patients they serve. For more information on VT Group, visit www.vt-group.com.


====================================================
Four Rivers TMS Asset Management Software Integrates to Versus RTLS

TRAVERSE CITY, Mich., Feb. 14, 2013 /PRNewswire/ -- Hospitals wishing to track the real-time locations of mobile medical equipment while using Four Rivers® Total Maintenance System (TMS®) will experience improved workflows, thanks to a recent integration with the Versus Technology, Inc. (OTCPINK: VSTI) Real-time Locating System (RTLS).

The integration, already in use at Children's of Alabama in Birmingham, features a single-source procurement process, where a Versus asset tag ID is entered once into the TMS software. Through a bi-directional interface, the asset is automatically registered within the Versus system so its location can be immediately tracked. Versus then provides real-time location updates to TMS, permitting enterprise-wide location visibility.

An average hospital can lose $4,000 per day in lost wages due to time spent searching for mobile assets such as IV pumps. Additionally, many hospitals purchase 20% more equipment than necessary just to ensure availability in case inventory can't be found. By monitoring the real-time locations of these mobile assets and tracking how often they're used in patient care, hospitals can dramatically decrease operational costs and capital investments while increasing staff and patient satisfaction.

Biomedical and other staff can quickly locate assets through the RTLS location field in TMS, where they also track maintenance and other asset details. Clinical staff in patient care units can view equipment locations on Versus Glance-and-Go™ boards, displayed as either a floorplan of the unit, or as a list view of available equipment. Inventory control staff may also use Versus' full-featured par-level asset management software to automate replenishment functions.

Children's of Alabama uses Four Rivers TMS integrated with Versus to track approximately 3,000 mobile assets, including IV pumps, beds and stretchers. Biomedical staff keep track of preventative maintenance, warranties and recall notifications in TMS, where they now know an asset's real-time location thanks to the RTLS integration.

"By combining Versus' real-time location data with our TMS, we are enabling our customers to work smarter," says Larry Shields, Product Coordinator with Four Rivers. "Our joint customers will now be able to use the best features of both systems, making operations more efficient."

After the RTLS asset tag ID is added to TMS, the hospitals also have immediate access to equipment and location information in Versus software. For example, hospitals can use Versus' par-level feature to ensure optimal inventory of IV and other pumps in patient care areas. Clinicians can also access lists of available equipment and their locations via Versus Glance-and-Go boards on overhead screens or workstation web browsers.

"The integration with Four Rivers TMS expands the benefits of RTLS for biomedical engineering without placing additional process burdens on the department," explains Kevin Jackson, Chief Technology Officer for Versus. "Versus seamlessly integrates real-time asset tracking with the TMS features, making it easy for inventory control staff to better serve the facility, physicians, and nurses. This interoperability, a cornerstone of Versus solutions, ultimately improves the efficiency of patient care."

To learn more about Asset Management and other uses for RTLS in the clinical environment, visit Versus' website at versustech.com or register for our RTLS sessions at the HIMSS13 Annual Conference & Exhibition in New Orleans, La., March 3-7, 2013 by visiting versustech.com/himss13.

About Four Rivers Software Systems
Four Rivers Software Systems, Inc. is focused on delivering comprehensive maintenance management software (EAM/CMMS) and computer-aided facilities management (CAFM) solutions to the healthcare industry. Serving more 1,800 healthcare organizations, Four Rivers provides powerful tools to increase productivity and profitability. The Four Rivers product family includes TMS OnSite & TMS OnLine, TMS CAFM, a full suite of Mobile Solutions and a number of optional solutions to help healthcare organizations.
==========================================================
Versus Technology Announces Fiscal Year Results

TRAVERSE CITY, MI -- (Marketwire) -- 12/21/12 -- Versus Technology, Inc. ("Versus" or the "Company") (PINKSHEETS: VSTI) announced revenues of $11,424,000 for the year ended October 31, 2012, a 73.4% increase, compared to revenues of $6,589,000 for fiscal year 2011. Revenues for the quarter ended October 31, 2012, totaled $4,606,000 compared to revenues of $2,605,000 for the same period in fiscal 2011. Versus' revenue can vary significantly depending on the timing and delivery of major customer projects. Accordingly, revenues reported in any one quarter are not necessarily indicative of what full year results will be.

Fiscal 2012 gross profit as a percentage of revenue was 75.9% compared to 71.0% in fiscal 2011. The higher margins are the result of increased software revenues as a percentage of total revenues, 36.1% in fiscal 2012 compared to 16.3% in fiscal 2011. Similarly, gross profit for the current year's fourth quarter as a percentage of revenue was 85.4% compared to 72.7% for the same quarter of the prior year.

Operating expenses other than cost of revenues for the full year increased from $4,964,000, or 75.3% of revenues in 2011 to $6,132,000, or 53.7% of revenues, in 2012. The increase is the direct result of continued investment in growth strategies directed at building the sales organization and System Integrator channel. Fourth quarter operating expenses other than cost of revenue totaled $1,800,000, or 39.1% of revenues, compared to $1,190,000, or 45.7% of revenues, in 2011.

The Company reported net income of $3,529,000 which includes a deferred income tax benefit of $988,000. This is compared to a net loss of $278,000 for fiscal 2011. Net income for the quarter ended October 31, 2012, was $3,121,000 compared to net income of $704,000 for the same period in fiscal 2011.

Effective with the new fiscal year, the Company will discontinue issuing press releases publishing financial results. Shareholders should visit the Company's website or contact Joe Winowiecki at [e-mail] for information regarding access to future financial results.

For additional information, please refer to the attached unaudited consolidated financial statements.

About Versus Technology, Inc.
Established in 1988, Versus Technology, Inc. specializes in real-time location systems (RTLS) for healthcare. Used for enterprise patient tracking, bed management, asset tracking, and nurse call automation, Versus Advantages™ improves patient flow and documentation of caregiver and patient interactions, while enhancing communication and efficiency. Exclusively endorsed by the American Hospital Association, the Versus Advantages infrared (IR) and Active RFID solution is responsible for clinical-grade location and automation at a number of hospitals, clinics and long-term care facilities throughout North America. To learn more about Versus Technology, Inc. (PINKSHEETS: VSTI), our technology and client successes, visit www.versustech.com and take the Advantages Tour.

Safe Harbor Provision

This document may contain forward-looking statements relating to future events, such as the development of new products, the commencement of production, or the future financial performance of the Company. These statements fall within the meaning of forward-looking information as defined in the Private Securities Litigation Reform Act of 1995. These statements are subject to a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, economic, competitive, governmental, and technological factors affecting the Company's markets and market growth rates, products and their rate of commercialization, services, prices and adequacy of financing, and other factors. The Company undertakes no obligation to update, amend, or clarify forward-looking statements, whether because of new information, future events, or otherwise.

REPORT OF MANAGEMENT

The accompanying consolidated balance sheets of Versus Technology, Inc. and Subsidiary as of October 31, 2011, and October 31, 2010, and the related consolidated statements of operations and cash flows for the fiscal year ended October 31, 2011, and 2010, have been prepared by management.

Management has elected to omit the statement of shareholders' equity and substantially all of the footnote disclosures required by accounting principles generally accepted in the United States. If the omitted statement and disclosures were included in the financial statements, they might influence the user's conclusions about the Company's financial position, results of operations, and cash flows. Accordingly, these financial statements are not designed for those who are not informed about such matters.

The reader should refer to the Versus Technology, Inc. 2011 Annual Report which is available upon request for further details regarding the Company's financial position at October 31, 2011.

Joseph E. Winowiecki
Chief Financial Officer

December 21, 2012



VERSUS TECHNOLOGY, INC. AND SUBSIDIARY
Consolidated Balance Sheets

October 31,
-----------------------
2012 2011
----------- -----------
Assets

Current assets
Cash and cash equivalents $ 2,189,000 $ 1,380,000
Accounts receivable 4,174,000 1,965,000
Inventories, net 893,000 741,000
Prepaid expenses and other current assets 145,000 211,000
Deferred income taxes 1,108,000 -
----------- -----------

Total current assets 8,509,000 4,297,000
----------- -----------

Property and equipment
Machinery and equipment 727,000 631,000
Furniture and fixtures 102,000 99,000
Leasehold improvements 457,000 429,000
----------- -----------

1,286,000 1,159,000
Less accumulated depreciation 795,000 696,000
----------- -----------

Net property and equipment 491,000 463,000

Goodwill 1,533,000 1,533,000
Other intangible assets, net 224,000 128,000

Other noncurrent assets 46,000 10,000
----------- -----------

Total assets $10,803,000 $ 6,431,000
=========== ===========



See accompanying report of management.

The full annual report is available upon request.



VERSUS TECHNOLOGY, INC. AND SUBSIDIARY
Consolidated Balance Sheets

October 31,
--------------------------
2012 2011
------------ ------------
Liabilities and shareholders' equity

Current liabilities
Accounts payable $ 680,000 $ 599,000
Accrued expenses 829,000 499,000
Income taxes payable 120,000 -
Deferred revenue from customer advance
payments 386,000 306,000
------------ ------------

Total liabilities (all current) 2,015,000 1,404,000
------------ ------------

Shareholders' equity
Common stock $0.01 par value; 150,000,000
shares authorized; 103,992,869 issued and
outstanding 1,040,000 1,016,000
Additional paid-in capital 43,453,000 43,245,000
Accumulated deficit (35,705,000) (39,235,000)
------------ ------------

Total shareholders' equity 8,788,000 5,027,000
------------ ------------

Total liabilities and shareholders' equity $ 10,803,000 $ 6,431,000
============ ============



See accompanying report of management.

The full annual report is available upon request.



VERSUS TECHNOLOGY, INC. AND SUBSIDIARY
Consolidated Statements of Operations

Three months ended
October 31, Year-ended October 31,
----------------------- -----------------------
2012 2011 2012 2011
----------- ----------- ----------- -----------
Revenues $ 4,606,000 $ 2,605,000 $11,424,000 $ 6,589,000

Operating Expenses
Cost of revenues 674,000 712,000 2,757,000 1,908,000
Research and development 287,000 170,000 925,000 770,000
Sales and marketing 1,128,000 828,000 3,952,000 3,329,000
General and
administrative 385,000 192,000 1,255,000 865,000
----------- ----------- ----------- -----------

Total Operating Expenses 2,474,000 1,902,000 8,889,000 6,872,000
----------- ----------- ----------- -----------
Income (Loss) From
Operations 2,132,000 703,000 2,535,000 (283,000)
----------- ----------- ----------- -----------

Interest income 1,000 1,000 6,000 5,000
----------- ----------- ----------- -----------

Income (Loss) From
Operations Before Taxes 2,133,000 704,000 2,541,000 (278,000)
----------- ----------- ----------- -----------

Income tax benefit
(expense) 988,000 - 988,000 -
----------- ----------- ----------- -----------

Net Income (Loss) $ 3,121,000 $ 704,000 $ 3,529,000 $ (278,000)
=========== =========== =========== ===========

Basic and Diluted Net
Income (Loss) Per Share $ 0.03 $ 0.01 $ 0.03 $ -
=========== =========== =========== ===========



See accompanying report of management.

The full annual report is available upon request.



VERSUS TECHNOLOGY, INC. AND SUBSIDIARY
Consolidated Statements of Cash Flows

Year ended October 31,
-----------------------
2012 2011
----------- -----------
Cash flows from operating activities
Net income (loss) $ 3,529,000 $ (278,000)
Adjustments to reconcile net (loss) income to net
cash provided by (used in) operating activities:
Depreciation and amortization 138,000 106,000
Share-based compensation 90,000 117,000
Deferred tax asset (1,108,000) -
Changes in operating assets and liabilities which
provided (used) cash:
Accounts receivable (2,210,000) (498,000)
Inventories (152,000) 95,000
Prepaid expenses and other current assets 67,000 (50,000)
Accounts payable 81,000 56,000
Accrued expenses 330,000 92,000
Income taxes payable 120,000 -
Deferred revenue from customer advance payments 80,000 (65,000)
----------- -----------

Net cash provided by (used in) operating activities 965,000 (425,000)
----------- -----------

Cash used in investing activities
Additions to property and equipment (155,000) (278,000)
Increase in other noncurrent assets (143,000) -
----------- -----------

Net cash used in investing activities (298,000) (278,000)
----------- -----------

Cash flows from financing activities
Issuance of common stock upon exercise of stock
options 127,000 -
Issuance of Common Stock 15,000 -
----------- -----------

Net cash provided by financing activities 142,000 -
----------- -----------
Net increase (decrease) in cash and cash equivalents 809,000 (703,000)

Cash and cash equivalents, at the beginning of the
year 1,380,000 2,083,000
----------- -----------

Cash and cash equivalents, at the end of the year $ 2,189,000 $ 1,380,000
=========== ===========


See accompanying report of management.

The full annual report is available upon request.

Investors/Analysts contact:
Joseph E. Winowiecki
Chief Financial Officer

Media please contact:
Stephanie Bertschy
Director of Marketing
Versus Technology, Inc.
[phone]


Source: Versus Technology, Inc.





=========================================
Four Rivers TMS Asset Management Software Integrates to Versus RTLS

TRAVERSE CITY, Mich., Feb. 14, 2013 /PRNewswire/ -- Hospitals wishing to track the real-time locations of mobile medical equipment while using Four Rivers® Total Maintenance System (TMS®) will experience improved workflows, thanks to a recent integration with the Versus Technology, Inc. (OTCPINK: VSTI) Real-time Locating System (RTLS).

The integration, already in use at Children's of Alabama in Birmingham, features a single-source procurement process, where a Versus asset tag ID is entered once into the TMS software. Through a bi-directional interface, the asset is automatically registered within the Versus system so its location can be immediately tracked. Versus then provides real-time location updates to TMS, permitting enterprise-wide location visibility.

An average hospital can lose $4,000 per day in lost wages due to time spent searching for mobile assets such as IV pumps. Additionally, many hospitals purchase 20% more equipment than necessary just to ensure availability in case inventory can't be found. By monitoring the real-time locations of these mobile assets and tracking how often they're used in patient care, hospitals can dramatically decrease operational costs and capital investments while increasing staff and patient satisfaction.

Biomedical and other staff can quickly locate assets through the RTLS location field in TMS, where they also track maintenance and other asset details. Clinical staff in patient care units can view equipment locations on Versus Glance-and-Go™ boards, displayed as either a floorplan of the unit, or as a list view of available equipment. Inventory control staff may also use Versus' full-featured par-level asset management software to automate replenishment functions.

Children's of Alabama uses Four Rivers TMS integrated with Versus to track approximately 3,000 mobile assets, including IV pumps, beds and stretchers. Biomedical staff keep track of preventative maintenance, warranties and recall notifications in TMS, where they now know an asset's real-time location thanks to the RTLS integration.

"By combining Versus' real-time location data with our TMS, we are enabling our customers to work smarter," says Larry Shields, Product Coordinator with Four Rivers. "Our joint customers will now be able to use the best features of both systems, making operations more efficient."

After the RTLS asset tag ID is added to TMS, the hospitals also have immediate access to equipment and location information in Versus software. For example, hospitals can use Versus' par-level feature to ensure optimal inventory of IV and other pumps in patient care areas. Clinicians can also access lists of available equipment and their locations via Versus Glance-and-Go boards on overhead screens or workstation web browsers.

"The integration with Four Rivers TMS expands the benefits of RTLS for biomedical engineering without placing additional process burdens on the department," explains Kevin Jackson, Chief Technology Officer for Versus. "Versus seamlessly integrates real-time asset tracking with the TMS features, making it easy for inventory control staff to better serve the facility, physicians, and nurses. This interoperability, a cornerstone of Versus solutions, ultimately improves the efficiency of patient care."

To learn more about Asset Management and other uses for RTLS in the clinical environment, visit Versus' website at versustech.com or register for our RTLS sessions at the HIMSS13 Annual Conference & Exhibition in New Orleans, La., March 3-7, 2013 by visiting versustech.com/himss13.

About Four Rivers Software Systems
Four Rivers Software Systems, Inc. is focused on delivering comprehensive maintenance management software (EAM/CMMS) and computer-aided facilities management (CAFM) solutions to the healthcare industry. Serving more 1,800 healthcare organizations, Four Rivers provides powerful tools to increase productivity and profitability. The Four Rivers product family includes TMS OnSite & TMS OnLine, TMS CAFM, a full suite of Mobile Solutions and a number of optional solutions to help healthcare organizations.

About Versus Technology, Inc.
Established in 1988, Versus Technology, Inc. specializes in real-time location systems (RTLS) for healthcare. Used by more than 700 hospitals for enterprise patient tracking, bed management, asset tracking, and nurse call automation, Versus Advantages™ improves patient flow and documentation of caregiver and patient interactions, while enhancing communication and efficiency. Exclusively endorsed by the American Hospital Association, the Versus Advantages infrared (IR) and Active RFID solution is responsible for clinical-grade location and automation at a number of hospitals, clinics and long-term care facilities worldwide. To learn more about Versus Technology, Inc., our technology and client successes, visit versustech.com and take the Advantages Tour.

Safe Harbor Provision
This release may include forward-looking statements which "bespeak caution," and which are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. The statements are made only as of the date of this release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

Media Contact:
Investor/Analyst Contact:

Versus Technology, Inc.
Versus Technology, Inc.

Stephanie Bertschy, Director of Marketing
Joseph Winowiecki, Chief Financial Officer

877.983.7787
231.946.5868

[e-mail]
[e-mail]

SOURCE Versus Technology, Inc.

[10 bagger]

SPND.. $3.75..Liquidity and Capital Resources

The Company's operating capital needs, as well as its capital spending program are generally funded from cash flow generated by operations. Because future cash flow is subject to a number of variables, such as the level of production and the sales price of oil and natural gas, the Company can provide no assurance that its operations will provide cash sufficient to maintain current levels of capital spending. Accordingly, the Company may be required to seek additional financing from third parties in order to fund its exploration and development programs.

Results of Operations


2012 Compared to 2011
Oil revenue for 2012 was approximately $7,116,000 compared to $4,084,000 for 2011, an increase of approximately $3,032,000 or 74%. Oil prices increased to an average of $89.49 per barrel in 2012 from an average of $83.85 per bbl in 2011, an increase of $5.63 per bbl or 7%. In addition to the increase in prices, oil sales increased to 79,514 bbls from approximately 48,708 bbls in 2011, an increase of 30,814 bbls or 63%. The increase in oil revenue and sales is predominantly due to participation in new wells during the last half 2012.

Gas revenue for 2012 was approximately $2,882,000 compared to $3,916,000 for 2011, a decrease of approximately $1,034,000 or 26%. Gas sales increased to approximately 792,000 mcf in 2012 from approximately 734,000 mcf in 2011, an increase of 58,000 mcf or 8%. The net increase in natural gas sales was due to the participation in, and the acquisition of new wells. Gas prices, however, decreased to an average of $3.64 per mcf in 2012, a decrease of $1.70 or 32% from an average of $5.34 per mcf in 2011.

Revenue from lease operations was $359,000 for 2012, an increase of $70,000 or 24% from $289,000 in 2011. This was due primarily to an increase in field supervision charges on operated wells of approximately $44,000 as a result of workover activity during 2012. In addition there was an increase in administrative overhead billed to working interest owners of approximately $26,000 due primarily to an increase in COPAS overhead rates billed

Revenue from gas gathering for 2012 was $145,000, a decrease of $27,000 or 16% from $172,000 in 2011. This was due primarily to a decrease in natural gas volume sold through Prairie Pipeline.

Real estate income for 2012 was $242,000, down 44% or $194,000 from $436,000 in 2011. This was due primarily to the expiration of a large lease contract in late 2011 which was not renewed and some lease renewal incentives.

Interest income for 2012 was approximately $78,000, a decrease of approximately $5,000 from approximately $83,000 in 2011 or 6%. Overall interest rates on deposit accounts at most of the banks in which the Company is a depositor, have decreased over prior years.

Other income for 2012 was $1,284,000, as compared to $360,000 in 2011, an increase of $924,000 or 257%. This change is due to the increase in cash received for farm-out agreements in 2012 over that received during 2011. From time to time, the Company farms out some of its leasehold acreage to non-affiliated third parties for exploration and development drilling. Generally, the Company receives a one-time payment for the agreement. The revenues from these farm-out agreements vary in size and frequency and should not be considered as regularly recurring revenues that the Company receives.

Lease operations expense for 2012 was $2,631,000 as compared to $2,444,000 in 2011, a net increase of approximately $187,000, or 8%. Of this net increase, approximately $112,000 is due to increased workover activity, approximately $78,000 is due to new properties added since 2011, and a reduction of approximately $31,000 is due to a decrease in expenses from non-operated properties. The remaining $28,000 represents net increases and decreases on various properties due to general price increases and changes in levels of workover activity. These increases were offset by a one-time payment covering expenses from 2002 to 2011 associated with the acquisition of the working interest in the Davis Heirs #1 well during the first quarter of 2011.

Production taxes, gathering, transportation and marketing expenses for 2012 were approximately $891,000 compared to $809,000 in 2011, a net increase of $82,000. This 10% net increase is the result of an increase in severance taxes based on the increase in oil revenues. This increase was offset by an overall decrease in severance taxes based on decreased gas revenues and severance tax exemptions on certain of the Company's gas wells. Gathering and transportation charges increased due to a net increase in gas volumes sold during the period, which was offset by an overall decrease in marketing and other deductions.

Pipeline and rental operation expenses were approximately $26,000 in 2012 compared to approximately $25,000 in 2011, an increase of approximately $1,000 or 4%. This was due mainly to an increase in the costs associated with compressor and pipeline repairs.

Real estate operations expenses for 2012 were $185,000, down from $225,000 in 2011. This 18% decrease of $40,000 was primarily due to operating efficiencies, from the reduced usage of the building as the result of the expiration of the lease noted above.

Depreciation and amortization expense for 2012 was $1,647,000 compared to $1,152,000 for 2011, an increase of $495,000, or 43%. The Company re-evaluated its proved oil and gas reserves as of December 31, 2012, and decreased its estimated total proved reserves by approximately 203,000 BOE to 1,588,000 BOE at the end of 2012 compared to 1,791,000 BOE at the end of 2011, a decrease of approximately 11%. Sales of oil and gas products during 2012 increased by approximately 40,000 BOE from approximately 171,000 BOE in 2011 to approximately 211,000 BOE in 2012, an increase of approximately 23%. (See Footnote 18 to the Financial Statements). This resulted in an increase in the depletion rate factor from 8.718% in 2011 on an unamortized full cost pool base of $11,843,000 to a depletion rate factor of 11.754% on an unamortized full cost pool base of $13,464,000 in 2012. The net increase in the unamortized full cost pool base of $1,621,000 was due primarily to an increase in the amounts capitalized in the full cost pool of approximately $2,654,000 less the increase in accumulated depletion of $1,032,479.

Asset Retirement Obligation ("ARO") accretion expense for 2012 was $40,000 up from $34,000 in 2011; an increase of $6,000 or 17%. The ARO calculation is based on the Company's annual reserve report and takes into consideration the changes between years of the Company's estimated obligation to plug its interest in existing wells. This estimated future cost is discounted using a 10% discount factor based on the estimated life of each property. Changes are incorporated as applicable into the full cost pool and the carrying value of the liability. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.

General and administrative expenses for 2012 were $3,719,000 compared to $3,275,000 for 2011, an increase of approximately $444,000 between years or 14%. This increase is due mainly to payroll and associated employee benefit costs during 2012.

Interest expense for 2012 was $29,000, down from $55,000 in 2011; a decrease of $26,000 or 47%. The reason for the reduction is the decreasing loan balance on which interest is paid, and that the interest rate on the loan was adjusted from 6.11% in December, 2011 to 3.61% for future years.


2011 Compared to 2010

Oil revenue for 2011 was approximately $4,084,000 compared to $2,368,000 for 2010, an increase of approximately $1,716,000 or 72%. Oil prices increased to an average of $83.85 per barrel in 2011 from an average of $74.35 per bbl in 2010, an increase of $9.50 per bbl or 13%. In addition to the increase in prices, oil sales increased to 48,708 bbls from approximately 31,526 bbls in 2010, an increase of 17,182 bbls or 55%. The increase in oil revenue and sales is predominantly due to properties acquired or drilled in 2011.

Gas revenue for 2011 was approximately $3,916,000 compared to $3,934,000 for 2010, a decrease of approximately $18,000 or 0.5%. Gas sales decreased to approximately 734,000 mcf in 2011 from approximately 824,000 mcf in 2010, a reduction of 90,000 mcf or 11%. Gas prices, however, increased to an average of $5.34 per mcf in 2011, an increase of $0.45 or 9% from an average of $4.89 per mcf in 2010.

Revenue from lease operations was $289,000 for 2011, a decrease of $30,000 or 9% from $319,000 in 2010. This decrease was a result of lower pumper fees and field supervision costs charged to operated properties between the two years.

Revenue from gas gathering for 2011 was $172,000, a decrease of $7,000 or 4% from $179,000 in 2010. This was due primarily to the decrease in gas volume sold.

Real estate income for 2011 was $436,000, down 3% or $12,000 from $448,000 in 2010. This was due primarily to the expiration of a rental contract in late 2011 which was not renewed and some lease renewal incentives.

Interest income for 2011 was $83,000, a decrease of $75,000 from $158,000 in 2010 or 47%. Overall interest rates on deposit accounts at most of the banks in which the Company is a depositor, have decreased significantly over prior years.

Other income for 2011 was $360,000, as compared to $250,000 in 2010, an increase of $110,000 or 44%. The increase is due primarily to increases in farmouts and assignment of certain leases between years. In addition, amounts were brought into income from reconciliation efforts on accounts payable for non-operated properties. Amounts carried as payables were determined not to be liabilities and were taken to income.

Lease operating expenses increased to $2,444,000 in 2011 from $1,901,000 in 2010 an increase of $543,000 or 29%. Approximately $525,000 of this net increase comes from operated wells drilled or acquired in 2011 or late 2010. Another $185,000 comes from an increase in non-operated wells, the majority of which is due to the acquisition of a non-operated working interest in the Davis Heirs #1 which included expenses from a time period of 2002 to 2011. Expenses to plug non-economical wells decreased by $157,000 from 2010 and the remaining difference was the result of a net difference in workover costs between the two years.

Production taxes, gathering, transportation and marketing expenses for 2011 were approximately $809,000 compared to $712,000 in 2010, a net increase of $97,000. This 14% net increase is due an increase of approximately $116,000 in Severance Taxes paid on properties acquired in 2011 or late 2010. This amount is offset by a reduction in other revenue deductions of approximately $20,000.

Pipeline and rental operation expenses were $25,000 in 2011 from $33,000 in 2010 a decrease of $8,000 or 24%. This was due mainly to a decrease in the costs associated with compressor and pipeline repairs.

Real estate operations expenses for 2011 were $225,000, down from $246,000 in 2010. This 9% decrease of $21,000 was mainly due to the reduction of electricity costs after the Company changed electric carriers.

Depreciation and amortization expense for 2011 was $1,152,000 compared to $1,042,000 for 2010, an increase of $110,000, or 11%. The Company re-evaluated its proved oil and gas reserves as of December 31, 2011, and decreased its estimated total proved reserves by approximately 342,000 BOE to 1,791,000 BOE at the end of 2011 compared to 2,133,000 BOE at the end of 2010, a decrease of approximately 16.0%. Sales of oil and gas products during 2011 increased by approximately 2,000 BOE from approximately 169,000 BOE in 2010 to approximately 171,000 BOE in 2011, an increase of approximately 1.2%. (See Footnote 18 to the Financial Statements). This resulted in an increase in the depletion rate factor from 7.336% in 2010 on an unamortized full cost pot base of $12,496,000 to a depletion rate factor of 8.718% on an unamortized full cost pot base of $11,843,000 in 2011. The decrease in the unamortized full cost pot base of $653,000 was due primarily to a reduction of future development costs as calculated in the Company's reserve report between 2010 and 2011 of approximately $2,079,000.

Asset Retirement Obligation ("ARO") accretion expense for 2011 was $34,000 down from $48,000 in 2010; a decrease of $14,000 or 29%. The ARO calculation is based on the Company's annual reserve report and takes into consideration the changes between years of the Company's estimated obligation to plug its interest in existing wells. This estimated future cost is discounted using a 10% discount factor based on the estimated life of each property. Changes are incorporated as applicable into the full cost pot and the carrying value of the liability. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.

General and administrative expenses for 2011 were $3,275,000 compared to $3,467,000 for 2010, a decrease of approximately $192,000 between years or 6%. This decrease is due mainly to the reduction in payroll and associated employee benefit costs during 2011.

Interest expense for 2011 was $55,000, down from $84,000 in 2010; a decrease of $29,000 or 35%. The majority of this change is due to a Revenue Agent's Report assessed in late 2010 that was not incurred in 2011.

Certain Factors That Could Affect Future Operations

Certain information contained in this report, as well as written and oral statements made or incorporated by reference from time to time by the Company and its representatives in other reports, filings with the Securities and Exchange Commission, press releases, conferences, teleconferences or otherwise, may be deemed to be 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934 and are subject to the 'Safe Harbor' provisions of that section.

[10 bagger]

GAMR.. $0.415 Complete DD Package.. add on..

Great American Group Announces Improved Fourth Quarter and Full Year 2012 Financial Results

WOODLAND HILLS, CA -- (Marketwire) -- 03/28/13 -- Great American Group, Inc.® (OTCBB: GAMR) ("Great American Group" or the "Company"), a leading provider of asset disposition, valuation and appraisal services, today announced financial results for its fourth quarter and full year ended December 31, 2012.

Fiscal 2012 total revenues of $83.9 million, a 32.1% increase from $63.5 million a year ago
Fiscal 2012 net income of $3.5 million, versus net income of $0.6 million from a year ago
Fiscal 2012 diluted earnings per share of $0.12, versus diluted earnings per share of $0.02 from a year ago "During fiscal 2012 we experienced significant year-over-year improvements in our financial results with a strong increase in revenues and profitability, as business activity across a number of our divisions improved from prior year levels," said Andrew Gumaer, Chief Executive Officer of Great American Group. Mr. Gumaer added, "GA Europe, GA Appraisals, and GA Keen Realty are three of our divisions that experienced significant increases in business activity in 2012 and helped to drive our overall financial performance. The positive contributions from all three divisions helped to diversify Great American's revenues and offset a decline in activity in our US Retail business. We are pleased with the growth that each of these three divisions have experienced over the last several years and hope to continue our investment in their future development."

Fourth Quarter Results

For the fourth quarter, the Company reported total revenues of $30.7 million, a significant increase from revenues of $11.4 million in the fourth quarter of 2011. Revenues from services and fees were $24.5 million, compared to $10.5 million in the same period the prior year. Revenues from sale of goods were $6.3 million, compared to $0.9 million in the fourth quarter of 2011. The increase in total revenues during the quarter was primarily due to increases in the UK Retail Stores segment, as well as the retail liquidation segment that participated in the liquidation of Comet, a 236 store electronics chain in the United Kingdom. The Company's results include the consolidation of Shoon, the UK shoe retailer in which the Company invested last May. Shoon contributed $10.2 million of revenue and net income of $0.5 million to our Company's consolidated results in 2012.

Direct cost of services was $7.8 million, compared to $3.8 million a year ago. The increase in direct cost of services was primarily the result of an increase in costs incurred as result of services performed in connection with the Comet liquidation engagement during the fourth quarter of 2012. Cost of goods sold was $4.3 million in the fourth quarter of 2012, compared to $1.1 million in the fourth quarter of the prior year.

Selling, general and administrative expenses increased to $13.7 million, compared to $6.1 million in the fourth quarter of 2011. The increase in selling, general and administrative expenses was primarily attributed to increases in payroll and operating expenses from the ongoing expansion of the Company's UK operations and the operating expenses of Shoon.

Operating income for the fourth quarter of 2012 was $4.9 million, compared to $0.3 million during the fourth quarter of 2011.

Interest expense during the fourth quarter of 2012 declined to $0.7 million from $1.0 million in the same period a year ago. The decline in interest expense was primarily the result of a decrease in US retail liquidation activity that required borrowings from our line of credit in 2011.

Pretax income was $4.1 million compared to pretax loss of $0.5 million in the fourth quarter of 2011. Net income was $2.4 million, or $0.08 per diluted share, compared to net loss of $0.7 million, or $0.02 per diluted share in the fourth quarter of 2011.

Twelve Months Ended December 31, 2012

For the twelve months of 2012, the Company reported improved total revenues of $83.9 million, compared to $63.5 million in the twelve months of 2011. Revenues from services and fees were $65.6 million, compared to $60.6 million a year ago. Sales of goods were $18.3 million compared to $2.9 million in the same period of 2011.

Total operating expenses were $76.5 million, compared to $56.1 million in 2011. Operating income was $7.4 million, flat compared to the prior year. Pretax income was $6.3 million, compared to $2.7 million during the twelve months of 2011. The Company recorded a provision for income taxes of $1.9 million compared to $2.1 million in the same period of 2011. Net income during the twelve months of 2012 was $3.5 million, or $0.12 per diluted share, compared with $0.6 million, or $0.02 in the same period of 2011.

Adjusted EBITDA for the twelve months of 2012 was $8.7 million compared to $8.5 million in 2011.

Financial Position

At December 31, 2012, the Company had $18.7 million in cash and cash equivalents and $7.9 million of restricted cash, an increase compared to $15.0 million of cash and cash equivalents at December 31, 2011.

Conference Call

The Company will host a conference call today at 4:30 p.m. ET, to discuss results for the fourth quarter ended December 31, 2012. To participate in the event by telephone, please dial [phone], 10 minutes prior to the start time (to allow time for registration) and use conference ID # 408841. International callers should dial [phone]. A digital replay will be available beginning March 28, 2013, at 7:30 p.m. ET, through April 4, 2013, at 11:59 p.m. ET. To access the replay, dial [phone] (U.S.), and use passcode 408841. International callers should dial [phone] and enter the same passcode.

The call will also be broadcast over the Internet and can be accessed on the Investor Relations section of the Company's website at www.greatamerican.com. A replay of the call will also be available for 90 days on the website.

About Great American Group, Inc. (OTCBB: GAMR)

Great American Group is a leading provider of asset disposition and auction solutions, advisory and valuation services, capital investment, and real estate advisory services for an extensive array of companies. A trusted strategic partner at every stage of the business lifecycle, Great American Group efficiently deploys resources with sector expertise to assist companies, lenders, capital providers, private equity investors and professional service firms in maximizing the value of their assets. The company has in-depth experience within the retail, industrial, real estate, healthcare, energy and technology industries. The corporate headquarters is located in Woodland Hills, Calif. with additional offices in Atlanta, Boston, Charlotte, N.C., Chicago, Dallas, New York, San Francisco and London. For more information, call [phone] or visit www.greatamerican.com.

Forward-Looking Statements

This press release may contain forward-looking statements by Great American Group that are not based on historical fact, including, without limitation, statements containing the words "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions and statements. Because these forward-looking statements involve known and unknown risks and uncertainties, there are important factors that could cause actual results, events or developments to differ materially from those expressed or implied by these forward-looking statements. Such factors include those risks described from time to time in Great American Group's filings with the SEC, including, without limitation, the risks described in Great American Group's proxy statement/prospectus filed with the SEC on July 19, 2012, and its Annual Report on Form 10-K for the year ended December 31, 2011. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. All information is current as of the date this press release is issued, and Great American Group undertakes no duty to update this information.

Note Regarding Use of Non-GAAP Financial Measures

Certain of the information set forth herein, including Adjusted EBITDA, may be considered non-GAAP financial measures. Great American Group believes this information is useful to investors because it provides a basis for measuring Great American Group's performance against the contingent share earnout provisions in the AAMAC transaction. In addition, Great American Group's management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measures in evaluating Great American Group's operating performance, capital resources and cash flow. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-financial measures as reported by Great American Group may not be comparable to similarly titled amounts reported by other companies.



GREAT AMERICAN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except par value)

December 31, December 31,
2012 2011
------------- -------------

Assets
Current assets:
Cash and cash equivalents $ 18,721 $ 15,034
Restricted cash 7,923 -
Accounts receivable, net 16,591 7,482
Advances against customer contracts 2,441 5,276
Inventory 2,216 -
Goods held for sale or auction 10,196 12,934
Loan receivable - 8,306
Note receivable - related parties 611 3,844
Deferred income taxes 4,114 4,460
Prepaid expenses and other current assets 1,145 1,110
------------- -------------
Total current assets 63,958 58,446
Property and equipment, net 970 916
Goodwill 5,688 5,688
Other intangible assets, net 140 140
Deferred income taxes 9,484 10,504
Other assets 343 664
------------- -------------
Total assets $ 80,583 $ 76,358
============= =============

Liabilities and Equity (Deficit)
Current liabilities:
Accounts payable and accrued liabilities $ 16,886 $ 13,718
Auction and liquidation proceeds payable 864 18
Mandatorily redeemable noncontrolling
interests 2,856 3,408
Revolving credit facility 2,304 1,942
Current portion of long-term debt 1,724 1,724
Notes payable 9,628 11,555
Current portion of capital lease obligation 13 29
------------- -------------
Total current liabilities 34,275 32,394
Capital lease obligation, net of current
portion - 13
Long-term debt, net of current portion 50,483 52,207
------------- -------------
Total liabilities 84,758 84,614
------------- -------------
Commitments and contingencies
Great American Group, Inc. stockholders'
equity (deficit):
Preferred stock, $0.0001 par value;
10,000,000 shares authorized; none issued - -
Common stock, $0.0001 par value; 135,000,000
shares authorized; 30,002,975 and
31,001,609 issued and outstanding as of
December 31, 2012 and 2011, respectively 4 4
Additional paid-in capital 3,082 3,177
Retained earnings (deficit) (7,669) (11,190)
Accumulated other comprehensive income
(loss) (520) (247)
------------- -------------
Total Great American Group, Inc.
stockholders' equity (deficit) (5,103) (8,256)
Noncontrolling interests 928 -
------------- -------------
Total equity (deficit) (4,175) (8,256)
------------- -------------
Total liabilities and equity (deficit) $ 80,583 $ 76,358
============= =============


GREAT AMERICAN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except share data)

Three Months Ended
December 31, Year Ended December 31,
------------------------ ------------------------
2012 2011 2012 2011
----------- ----------- ----------- -----------
Revenues:
Services and fees $ 24,470 $ 10,480 $ 65,624 $ 60,627
Sale of goods 6,260 887 18,312 2,899
----------- ----------- ----------- -----------
Total revenues 30,730 11,367 83,936 63,526
----------- ----------- ----------- -----------
Operating expenses:
Direct cost of
services 7,814 3,845 23,911 19,749
Cost of goods sold 4,301 1,104 12,750 3,391
Selling, general and
administrative 13,679 6,098 39,834 32,946
----------- ----------- ----------- -----------
Total operating
expenses 25,794 11,047 76,495 56,086
----------- ----------- ----------- -----------
Operating income
(loss) 4,936 320 7,441 7,440
Other income (expense):
Other income (expense) - 13 - -
Interest income 15 67 201 476
Loss from equity
investment in Great
American Real Estate,
LLC (165) 153 (120) (369)
Gain from bargain
purchase - - 1,366 -
Interest expense (661) (1,011) (2,612) (4,885)
----------- ----------- ----------- -----------
Income (loss) before
benefit (provision)
for income taxes 4,125 (458) 6,276 2,662
Benefit (provision) for
income taxes (1,549) (196) (1,936) (2,060)
----------- ----------- ----------- -----------
Net income (loss) 2,576 (654) 4,340 602
Net income attributable
to noncontrolling
interests 194 - 819 -
----------- ----------- ----------- -----------
Net income (loss)
attributable to
Great American
Group, Inc. $ 2,382 $ (654) $ 3,521 $ 602
=========== =========== =========== ===========

Basic earnings (loss)
per share $ 0.08 $ (0.02) $ 0.12 $ 0.02
Diluted earnings (loss)
per share $ 0.08 $ (0.02) $ 0.12 $ 0.02

Weighted average basic
shares outstanding 28,682,975 28,681,609 28,682,975 28,539,651
Weighted average diluted
shares outstanding 29,614,252 28,681,609 29,614,252 29,408,466


GREAT AMERICAN GROUP, LLC AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
(Dollars in thousands)

Year ended December 31,
------------------------
2012 2011
----------- -----------
Cash flows from operating activities:
Net income (loss) $ 4,340 $ 602
Adjustments to reconcile net income (loss) to
net cash provided by (used in) operating
activities:
Depreciation and amortization 835 981
Provision for doubtful accounts 108 424
Impairment of goods held for sale or auction 194 159
Share-based payments - 431
Effect of foreign currency on operations (98) (14)
Noncash interest expense - 1,083
Amortization of discount on note payable - 609
Loss on equity investment in Great American
Real Estate, LLC 120 369
Gain from bargain purchase (1,366) -
Loss on disposal of assets 3 4
Deferred income taxes 1,366 1,871
Change in fair value of mandatorily redeemable
noncontrolling interests - (83)
Income allocated to mandatorily redeemable
noncontrolling interests 1,928 3,934
Change in operating assets and liabilities:
Accounts receivable and advances against
customer contracts (6,172) (7,032)
Inventory 1,618 -
Goods held for sale or auction 2,361 224
Loan receivable 8,519 (8,306)
Prepaid expenses and other assets (33) 1,093
Accounts payable and accrued expenses 1,641 3,300
Auction and liquidation proceeds payable 846 (1,694)
----------- -----------
Net cash (used in) provided by operating
activities 16,210 (2,045)
----------- -----------
Cash flows from investing activities:
Acquisition of business (1,246) -
Purchase of noncontrolling interest in
subsidiary (95) -
Purchases of property and equipment (634) (264)
Proceeds from sale of property and equipment 21 -
Decrease (increase) in notes receivable -
related party 3,233 2,706
Equity investment in Great American Real Estate,
LLC (120) (1,202)
Decrease (increase) in restricted cash (7,923) -
----------- -----------
Net cash provided by (used in) investing
activities (6,764) 1,240
----------- -----------
Cash flows from financing activities:
Proceeds from revolving line of credit 362 1,942
Proceeds from note payable - 7,000
Repayment of notes payable and capital lease
obligations (2,138) (7,786)
Repayments of long-term debt (1,724) (1,724)
Payment of employment taxes on vesting of
restricted stock - (132)
Proceeds from formation of noncontrolling
interests 78 -
Distributions to noncontrolling interests (2,466) (3,301)
----------- -----------
Net cash (used in) provided by financing
activities (5,888) (4,001)
Effect of foreign currency on cash 129 (240)
----------- -----------
Net (decrease) increase in cash and cash
equivalents 3,687 (5,046)
Cash and cash equivalents, beginning of year 15,034 -
----------- -----------
Cash and cash equivalents, end of year $ 18,721 $ (5,046)
=========== ===========


GREAT AMERICAN GROUP, INC. AND SUBSIDIARIES
ADJUSTED EBITDA RECONCILIATION
(Dollars in thousands)

Three Months Ended
December 31,
------------------------
2012 2011
----------- -----------
Adjusted EBITDA Reconciliation:

Net income (loss) as reported $ 2,382 $ (654)

Adjustments:
Provision (benefit) for income taxes 1,549 196
Interest expense 661 1,011
Interest income (15) (67)
Depreciation and amortization 224 356
Share based compensation - -
----------- -----------

Total EBITDA adjustments 2,419 1,496
----------- -----------

Adjusted EBITDA $ 4,801 $ 842
=========== ===========


Year Ended December 31,
------------------------
2012 2011
----------- -----------
Adjusted EBITDA Reconciliation:

Net income (loss) as reported $ 3,521 $ 602

Adjustments:
Provision (benefit) for income taxes 1,936 2,060
Interest expense 2,612 4,885
Interest income (201) (476)
Depreciation and amortization 835 981
Share based compensation - 431
----------- -----------

Total EBITDA adjustments 5,182 7,881
----------- -----------

Adjusted EBITDA $ 8,703 $ 8,483
=========== ===========



Investor Contacts:

Great American Group
Phil Ahn
SVP, Strategy & Corporate Development
818-884-3737

Addo Communications
Patricia Nir
310-829-5400



===========================================================
Great American Group Subsidiary Provides Funding for UK Footwear Chain....

-GA Europe investment allows Shoon to take over 39 Jane Shilton outlets-

WOODLAND HILLS, Calif.--(BUSINESS WIRE)-- GA Europe, a subsidiary of Great American Group, Inc. (OTCBB: GAMR), will further invest in the UK-based Shoon footwear chain in which it acquired an interest last year.

With funding provided by GA Europe, Shoon plans to take over 39 Jane Shilton outlets which operate in a range of department stores including Beales and Browns. Shoon will also acquire the associated Jane Shilton footwear stock upon completion, as well as the Jane Shilton footwear license. The arrangement is subject to the agreement of the individual host stores and will take effect beginning August 1st, once current notice periods have expired.

“We are very pleased to be making this investment in Jane Shilton’s footwear brand,” stated Stephen Sanders, Managing Director of Shoon. “It has a clear market position supported by Jane Shilton’s heritage in handbags and developed through its partnerships with independent department stores. With a similar customer profile to Shoon, we believe we have an excellent opportunity to develop both businesses. Also, with GA Europe’s support, we have been able to revive Shoon and this deal represents an exciting stage in our development.”

Shoon operates a chain of footwear stores, selling mainly women’s branded shoes in the market between high street multiple chains and upmarket boutiques and designer labels, appealing to customers who are fashion aware with a clear sense of their own style while looking for comfort and fit at a reasonable price. The Jane Shilton outlets will complement Shoon’s existing market position and provide opportunities for significant operational synergies and cost savings in sourcing.

“We are very excited to be making this additional investment in Shoon,” added Gavin George, Chief Executive of GA Europe. “This deal demonstrates our creative approach to backing and developing retail businesses where we can successfully apply our capital while leveraging our specialized restructuring skills and extensive retail networks.”

About Great American Group, Inc. (OTCBB: GAMR)


========================================================
GA Keen Realty Advisors Hired by Federal Receiver to Sell Former Headquarters of Peregrine Financial Group

– State-of-the-Art LEED Certified 48,250 Sq. Ft. Building in Cedar Falls, Iowa –

Bid Deadline: May 24, 2013

Auction: May 31, 2013

NEW YORK--(BUSINESS WIRE)-- GA Keen Realty Advisors, a division of Great American Group, Inc. (OTCBB: GAMR), is marketing a 48,250-square-foot office building in Cedar Falls, Iowa that has been built to Leadership in Energy and Environmental Design (LEED) Gold standards for its environmentally-friendly construction.

The property and facilities are being sold as part of a Federal Receiver’s sale, with GA Keen Realty Advisors working with the court appointed receiver, Chicago-based attorney Michael M. Eidelman, in marketing the building and property. The bid deadline is Friday, May 24, 2013, with an auction scheduled for Friday, May 31, 2013. Bid procedures are available and offers can be accepted by the Receiver prior to the auction.

“This is an extraordinary, world-class building that is an outstanding location for a corporate headquarters or a tremendous opportunity for an investor,” said GA Keen Realty Advisors Co-President Matthew Bordwin. “The building’s sustainable design and highly desirable amenities make it an attractive purchase for a variety of users. Additionally, it’s nestled in a beautiful suburban area that’s only a few minutes from the interstate.”

Built in 2008, the building design features minimize emissions, water use, waste, and indoor pollutants. Located on a 22-acre site at 1 Peregrine Way, it is designated as a Class A professional office building and includes 108 exterior parking stalls and 43 underground parking spaces. The exterior is all glass and features finishes of bamboo, cork, carpet and natural stone. Amenities also include a two-story atrium, kitchen and cafeteria, an exercise facility with locker rooms, a day-care center, and flexible office configurations with movable systems.

The building is the former headquarters of Peregrine Financial Group (PFG), owned by Russell Wasendorf, Sr., which filed for bankruptcy in July 2012.

GA Keen Realty Advisors was retained by Order of the United States District Court, Northern Division of Illinois on February 26, 2013. For more information about the office building, contact Matthew Bordwin at [e-mail], Chris Mahoney at [e-mail] or Heather Milazzo at [e-mail] or call 646-381-9222. Additional information can be found at www.greatamerican.com/keen.

About GA Keen Realty Advisors, LLC

GA Keen Realty Advisors, located in New York, provides real estate analysis, valuation and strategic planning services, brokerage, M&A, auction services, lease restructuring services and real estate capital market services. For more information about GA Keen Realty Advisors, call 646-381-9222 or visit http://www.greatamerican.com/keen.


========================================================

Great American Group Handles Liquidation of Bakers Footwear Group

- Major Discounts Offered to Customers at Remaining Stores and Online -

WOODLAND HILLS, Calif.--(BUSINESS WIRE)-- Great American Group, Inc. (OTCBB:GAMR) has been selected to handle the liquidation of Bakers Footwear Group, Inc., offering discounts for products in 56 of Bakers Footwear Groups’ remaining stores, as well as online at www.bakersshoes.com.

“We are offering significant discounts online and on all store items, so consumers will have the opportunity to purchase quality, name-brand women’s shoes at steep discounts,” said Scott Carpenter, President of Great American Group’s Retail Division.

With merchandise being sold for at least 40 percent off, Carpenter urges shoppers to head to their local stores or visit the website soon for the best selection.

Bakers locations in Alabama, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Michigan, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Texas, and Virginia are part of the sale event, which is also being conducted online at www.bakersshoes.com

On Jan. 15, 2013 a bankruptcy judge for the U.S. Bankruptcy Court in St. Louis signed a Chapter 7 order allowing Bakers Footwear Group to conduct going-out-of-business sales at its remaining stores.

Bakers Footwear Group is the third shoe retailer that has selected Great American Group to liquidate stores over the past 18 months. Great American Group assisted Payless ShoeSource and Sterling Shoes with store restructuring projects, consolidating store locations for both companies in 2011 and 2012.

Bakers Footwear Group, once a leading national mall-based retailer of shoes for young women, operated 236 Bakers and Wild Pair shoe stores in 37 states before filing for Chapter 11 bankruptcy last October due to declining sales. At that time, the company hired GA Keen Realty Advisors, LLC of New York, a division of Great American Group, to market leases for 150 Bakers and Wild Pair shoe store locations in 31 states.

Founded in 1929 under a different name, Bakers Footwear Group stores target women between 12 and 29 years old, selling merchandise including private label and national brand dress, casual and sport shoes, boots, sandals and accessories.

About Great American Group, Inc. (OTCBB:GAMR

====================================================
GA Keen Realty Advisors Marketing Long Island National Golf Club in Riverhead, Long Island, New York

Business Wire - Jan 24 09:30 EDT

Alert hits:/ga /ga
Company Symbols: NASDAQ-OTCBB:GAMR


- Buyers sought for Robert Trent Jones, Jr. designed course and clubhouse property with residential development potential -

NEW YORK--(BUSINESS WIRE)-- GA Keen Realty Advisors, a division of Great American Group, Inc. (OTCBB:GAMR), is selling the Long Island National Golf Club in Riverhead, New York through a bankruptcy sale process.

Located at 1793 Northville Turnpike, in the heart of Long Island’s east end wine country and minutes from the world-famous ”Hamptons”, the public golf club is best known for its links-style design created by renowned golf course architect Robert Trent Jones, Jr. The 150 acre site is also suitable for residential development pursuant to its current zoning designation.

“While many golf courses have seen revenues decline over the past few years, Long Island National Golf Club has maintained its profitability,” said GA Keen Realty Advisors Co-President Matthew Bordwin. “The course’s success, masterpiece design and location among scenic farmlands and vineyards make it a highly desirable purchase for buyers and investors. Further, the beauty of the Long Island’s East End, specifically the North Fork’s wine region, makes this a terrific residential development opportunity as well.”

The 6,838-yard course was created to take advantage of rolling hills, dramatic elevation changes and a spectacular mix of traditional design elements. The sale includes the 18-hole links-style course developed on a 150-acre landscaped site, along with a pro shop, grill and clubhouse with a full-service restaurant.

The property and facilities are being marketed as part of a bankruptcy sale and offers are now being considered.

For more information about Long Island National Golf Club, contact Craig Fox, Stacy Ferrone or Matthew Bordwin at 646-381-9222 or at [e-mail], [e-mail] or [e-mail].

About GA Keen Realty Advisors, LLC

GA Keen Realty Advisors, located in New York, provides real estate analysis, valuation and strategic planning services, brokerage, M&A, auction services, lease restructuring services and real estate capital market services. For more information about GA Keen Realty Advisors, call 646-381-9222 or visit http://www.greatamerican.com/keen.

About Great American Group, Inc. (OTCBB:GAMR)

==========================================================
GA Capital Provides $15 Million Secured Term Loan for Hancock Fabrics

Business Wire - Dec 06 09:00 EDT

Alert hits:/ga /ga
Company Symbols: NASDAQ-OTCBB:GAMR, OTC-PINK:HKFI


WOODLAND HILLS, Calif.--(BUSINESS WIRE)-- GA Capital, a division of Great American Group, Inc. (OTCBB: GAMR) that provides senior and junior secured loan facilities to help middle market businesses meet their financing needs, has closed on a $15 million term loan facility for Hancock Fabrics.

GA Capital will act as the administrative agent for the term loan.

“We’ve been impressed with the financial expertise shown by our new partner, GA Capital, throughout this process,” said Hancock Fabrics Executive Vice President and Chief Financial Officer Robert Driskell. “With their assistance, along with other recent financing efforts, we’ve been able to enhance our cash and liquidity position and now have more flexibility to execute our operational improvement plans.”

The loan for Hancock Fabrics was completed under the leadership of Stuart Armstrong, who was named president of GA Capital in May. Previously, Armstrong was one of the founders and served as Executive Vice President of Tygris Commercial Finance and as President of Tygris Corporate Finance.

“As an integral component of a larger refinancing effort by Hancock Fabrics, we are excited to provide the company additional working capital so it may continue to execute a successful business strategy,” Armstrong said.

GA Capital Managing Director Robert Louzan and Assistant Vice President Krista Mello were part of the team that put the financing facility in place.

Hancock Fabrics, Inc. (OTC: HKFI), headquartered in Baldwyn, Miss., is a specialty retailer of clothing/home fabrics and sewing accessories that operates 262 retail stores in 37 states along with an internet store at www.hancockfabrics.com.

GA Capital, a division of Great American Group, provides senior and junior secured corporate loans that range from $15 million to $250 million assisting companies in refinancing existing debt, fueling new growth strategies and enhancing their liquidity profiles. For more information, contact [phone] or visit http://www.greatamerican.com/services/ga_capital/ga_capital.html.

About Great American Group, Inc. (OTCBB: GAMR)

[10 bagger]

GAMR.. $0.31 Complete DD Package..

Great American Group, Inc.
21860 Burbank Boulevard
Suite 300 South
Woodland Hills, CA 91367
Phone: [phone]
Fax: [phone]
Website: http://www.greatamerican.com
==========================================

Great American Group is a leading provider of asset disposition and auction solutions, advisory and valuation services, capital investment, and real estate advisory services for an extensive array of companies. A trusted strategic partner at every stage of the business lifecycle, Great American Group efficiently deploys resources with sector expertise to assist companies, lenders, capital providers, private equity investors and professional service firms in maximizing the value of their assets. The company has in-depth experience within the retail, industrial, real estate, healthcare, energy and technology industries. The corporate headquarters is located in Woodland Hills, Calif. with additional offices in Atlanta, Boston, Charlotte, N.C., Chicago, Dallas, New York, San Francisco and London. For more information, call [phone] or visit www.greatamerican.com.

21860 Burbank Boulevard, Suite 300 South Woodland Hills, CA
==========================================


==========================================

Investor Contacts:

Great American Group
Phil Ahn
SVP, Strategy & Corporate Development
818-884-3737

Addo Communications
Patricia Dolmatsky-Nir
310-829-5400

21860 Burbank Boulevard, Suite 300 South Woodland Hills, CA
==============================================

Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued..
Common stock, $0.0001 par value; 135,000,000 shares authorized; 30,002,975 and 31,001,609 issued and outstanding as of September 30, 2012 and December 31, 2011, respectively
================================================

10K's and other filings..
http://finance.yahoo.com/q/sec?s=GAMR+SEC+Filings
=================================================
Insider Transactions..
Date Insider Shares Type Transaction Value*
Nov 19, 2012 MILLER LLOYD I III
Beneficial Owner (10% or more) 250,000 Indirect Purchase at $0.26 per share. 65,000
Nov 15, 2012 MILLER LLOYD I III
Beneficial Owner (10% or more) 8,156 Indirect Purchase at $0.30 per share. 2,446
Nov 14, 2012 MILLER LLOYD I III
Beneficial Owner (10% or more) 1,276,844 Indirect Statement of Ownership N/A
Aug 18, 2011 ERICKSON PAUL
Officer 50,000 Direct Purchase at $0.12 per share. 6,000
Aug 2, 2011 ELLIOTT INTERNATIONAL, L.P.
Beneficial Owner (10% or more) 507,120 Direct Purchase at $0.08 per share. 40,569
Aug 2, 2011 ELLIOTT ASSOCIATES, L.P.
Beneficial Owner (10% or more) 338,080 Direct Purchase at $0.08 per share. 27,046
Aug 1, 2011 ELLIOTT ASSOCIATES, L.P.
Beneficial Owner (10% or more) 300,000 Direct Purchase at $0.07 per share. 21,000
Jul 31, 2011 ELLIOTT ASSOCIATES, L.P.
Beneficial Owner (10% or more) 400,000 Direct Purchase at $0.06 per share. 24,000
Jul 14, 2011 RILEY BRYANT R
Director 17,820 Direct Disposition (Non Open Market) at $0.30 per share. 5,346
Jul 14, 2011 HART MATTHEW J
Director 17,820 Direct Disposition (Non Open Market) at $0.30 per share. 5,346
Jul 14, 2011 LEVITT MICHAEL J
Director 14,000 Direct Disposition (Non Open Market) at $0.30 per share. 4,200
Jul 14, 2011 KLEIN MARK D
Director 14,000 Direct Disposition (Non Open Market) at $0.30 per share. 4,200
Jul 14, 2011 HILTON HUGH G
Director 17,820 Direct Disposition (Non Open Market) at $0.30 per share. 5,346
=================================================

Press releases for the past year..

=================================================

Great American Group Announces Third Quarter 2012 Financial Results

WOODLAND HILLS, CA -- (Marketwire) -- 11/14/12 -- Great American Group, Inc.® (OTCBB: GAMR) ("Great American Group" or the "Company"), a leading provider of asset disposition, valuation and appraisal services, today announced financial results for its third quarter ended September 30, 2012.

Total revenues of $14.2 million, a decrease from $28.5 million a year ago Net loss of $0.5 million, versus net income of $4.0 million from a year ago.. Diluted loss per share of $0.02, versus a diluted earnings per share of $0.14 from a year ago ..

Third Quarter Results

For the third quarter ended September 30, 2012, the Company reported total revenues of $14.2 million, a decrease from revenues of $28.5 million in the third quarter of 2011. Revenues from services and fees were $11.0 million, compared to $27.6 million in the same period the prior year. Revenues from sale of goods were $3.3 million, compared to $0.9 million in the third quarter of 2011. The decrease in total revenues during the quarter was primarily due to decreases in the auction and liquidation segment of $17.3 million, and a decrease in revenues in the valuation and appraisal services segment of $0.1 million, offset by an increase in revenues of $3.1 million from the UK Retail Stores segment.

"During the third quarter we experienced a slowdown in business activity in our auction and liquidation segment. In the prior year quarter, we generated revenues of $14.7 million from the TJ Hughes retail liquidation engagement in the United Kingdom and the Borders retail liquidation engagement in the United States and there were no similar large retail liquidation engagements in the third quarter of this year," said Andrew Gumaer, Chief Executive Officer of Great American Group. "Revenues from our auction and liquidation segment typically comprise a significant amount of our total revenues and thus can impact our operating results from quarter to quarter. I am happy to report that we are currently participating in the joint venture that is conducting the sale of all inventory for Fashion Bug, a 568 store women's apparel and accessories chain. The 568 Fashion Bug stores are located in 39 states and is part of Ascena's planned divestiture of the Fashion Bug brand and orderly wind down of the Fashion Bug operations. In addition, we were recently engaged to provide consulting services on the store closure for Comet, a 236 store electronics chain in the United Kingdom. We expect our engagement on Comet to be mostly completed by the end of 2012. We continue to be highly focused on the execution of our business initiatives and expanding our business outside the United States."

Direct cost of services was $4.8 million, compared to $7.6 million a year ago. The decrease in direct cost of services was primarily the result of a decrease in the number of fee and commission engagements in the third quarter of 2012, where the Company contractually bills fees, commissions and reimbursable expenses as compared to the third quarter of the prior year. Cost of goods sold was $2.2 million in the third quarter of 2012, compared to $1.0 million in the third quarter of the prior year.

Selling, general and administrative expenses decreased to $7.9 million, compared to $10.9 million in the third quarter of 2011. The decrease in selling, general and administrative expenses was primarily the result of a decrease of $2.0 million in the auction and liquidation segment, a decrease of $0.1 million in the valuation and appraisal segment, and a decrease of $2.6 million in corporate and other, offset by an increase of $1.6 million in the UK Retail Stores segment as a result of the consolidation of Shoon in May 2012.

Loss before the benefit of income taxes was $1.1 million during the third quarter of 2012, compared to income before the provision of income taxes of $6.0 million in the third quarter of 2011. During the third quarter of 2012, the Company recorded a benefit for income taxes of $0.4 million, compared with a provision for income taxes of $2.0 million in the third quarter of 2011. Net loss attributable to the Company was $0.6 million, or $0.02 per diluted share, compared to net income of $4.0 million, or $0.14 per diluted share in the third quarter of 2011.

Nine Month Results

For the first nine months of 2012, the Company reported total revenues of $53.2 million, compared to $52.2 million in the first nine months of 2011. Revenues from services and fees were $41.1 million, compared to $50.1 million a year ago. Sales of goods were $12.1 million compared to $2.0 million in the same period of 2011.

Total operating expenses were $50.7 million, compared to $45.0 million in 2011. Operating income was $2.5 million, compared to $7.1 million in the prior year. Income before provision for income taxes for the first nine months of 2012 was $2.2 million, compared to $3.1 million during the first nine months of 2011. The Company recorded a provision for income taxes of $0.4 million compared to $1.9 million in the same period of 2011. Net income attributable to the Company during the first nine months of 2012 was $1.1 million, or $0.04 per diluted share, compared with $1.3 million, or $0.04 in the same period of 2011.

Financial Position

At September 30, 2012, the Company had $19.0 million in cash and cash equivalents, an increase compared to $15.0 million at December 31, 2011. Working capital was $26.5 million at September 30, 2012.

=========================================================

GA Keen Realty Advisors Successfully Closes on Sale of Four Brooklyn, NY Apartment Buildings....

-Buildings were formerly owned by Brookdale Hospital-

NEW YORK--(BUSINESS WIRE)-- GA Keen Realty Advisors, LLC, a division of Great American Group, Inc. (OTCBB: GAMR), recently advised Brookdale Hospital and Medical Center on a complex, $22 million sale of a real estate portfolio consisting of four apartment buildings previously owned by the hospital.

GA Keen Realty Advisors brought together a group of Brooklyn multi-family investors, led by apartment owners David Spira and Robert Wolf, who closed on the purchase Nov. 2. According to GA Keen Realty Advisors Co-President Matthew Bordwin, a 12-month “rent hold” needed to be addressed as part of the sale, making the deal more challenging. In addition, the New York State Attorney General’s office needed to approve the transaction, as is policy when selling a property owned by a not-for-profit entity.

“The rents being paid by the tenants are below market, and we expect they’ll stay that way due to rent regulations,” Bordwin said. “Given these constraints, the sales price generated represented an outstanding price for the seller based on the current net operating income being generated by the properties.”

“We were extremely pleased with the expertise provided by GA Keen Realty Advisors and the end result we achieved,” said Steve Korf, a partner with the consulting firm of Grant Thornton and the interim chief operating officer at Brookdale Hospital. “Our firm was hired earlier this year to stabilize the hospital’s financial position and this transaction represents a positive step in that process.”

The properties included a 20-story, 172-unit building at 7 Hegeman Ave.; a 12-story, 113-unit building at 660 E. 98th St.; a six-story, 54-unit property at 505 Rockaway Parkway; and a four-story, 42-unit building at 525 Rockaway Parkway.

GA Keen Realty Advisors representatives involved in the transaction included Bordwin, co-president Harold Bordwin and brokers Christopher Mahoney and Heather Milazzo. Other members of the negotiating team were attorneys Brian Cohen, Chris Rabil and Jeff Thrope with the law firm of Foley & Lardner LLP, and Eric Altman, Jay Gerzog and Daniel Lewis with the law firm of Epstein Becker Green. Other members of the Grant Thornton team working with Korf included Mark Toney, the Chief Executive Officer, James Porter and Chris Jadro.

About GA Keen Realty Advisors, LLC

GA Keen Realty Advisors, located in New York, provides real estate analysis, valuation and strategic planning services, brokerage, M&A, auction services, lease restructuring services and real estate capital market services. For more information, contact GA Keen Realty Advisors at [phone] or visit http://www.greatamerican.com/keen
===================================================

GA Capital Provides $15 Million Secured Term Loan for Hancock Fabrics

WOODLAND HILLS, Calif.--(BUSINESS WIRE)-- GA Capital, a division of Great American Group, Inc. (OTCBB: GAMR) that provides senior and junior secured loan facilities to help middle market businesses meet their financing needs, has closed on a $15 million term loan facility for Hancock Fabrics.

GA Capital will act as the administrative agent for the term loan.

“We’ve been impressed with the financial expertise shown by our new partner, GA Capital, throughout this process,” said Hancock Fabrics Executive Vice President and Chief Financial Officer Robert Driskell. “With their assistance, along with other recent financing efforts, we’ve been able to enhance our cash and liquidity position and now have more flexibility to execute our operational improvement plans.”

The loan for Hancock Fabrics was completed under the leadership of Stuart Armstrong, who was named president of GA Capital in May. Previously, Armstrong was one of the founders and served as Executive Vice President of Tygris Commercial Finance and as President of Tygris Corporate Finance.

“As an integral component of a larger refinancing effort by Hancock Fabrics, we are excited to provide the company additional working capital so it may continue to execute a successful business strategy,” Armstrong said.

GA Capital Managing Director Robert Louzan and Assistant Vice President Krista Mello were part of the team that put the financing facility in place.

Hancock Fabrics, Inc. (OTC: HKFI), headquartered in Baldwyn, Miss., is a specialty retailer of clothing/home fabrics and sewing accessories that operates 262 retail stores in 37 states along with an internet store at www.hancockfabrics.com.

GA Capital, a division of Great American Group, provides senior and junior secured corporate loans that range from $15 million to $250 million assisting companies in refinancing existing debt, fueling new growth strategies and enhancing their liquidity profiles. For more information, contact [phone] or visit http://www.greatamerican.com/services/ga_capital/ga_capital.html.
======================================================

Great American Group Subsidiary Engaged to Manage 236-Store UK Electronics Chain

-GA Europe responsible for store management, stock liquidation at Comet as a new buyer is sought-

WOODLAND HILLS, Calif.--(BUSINESS WIRE)-- GA Europe™, a subsidiary of Great American Group, Inc. (OTCBB: GAMR), has been appointed by Administrator Deloitte to manage the Comet chain of electronics stores, which went into Administration on Nov. 2.

In addition to managing the store operations and implementing a stock liquidation program, GA Europe is conducting ROT (retention of title) negotiations with suppliers as well as buying in new stock for the business.

“With 236 stores and in the region of GBP135million ($216 million US) of stock, Comet is the highest profile retail administration in the UK since Woolworths in 2008,” said Gavin George, chief executive officer of GA Europe, “GA Europe’s appointment to manage the business in administration underlines our growing reputation as the UK’s leading retail restructuring firm.”

To date, a total of 40 stores have had to close, with further closures expected over the coming weeks unless a buyer is found for the business. According to representatives from Deloitte, discussions are underway with companies who have expressed interest in parts of the business.

Comet filed for Administration almost a year after private investment firm OpCapita bought the business. It is the latest casualty in a highly active UK retail restructuring market.

“On-going structural changes in the sector, fragile consumer confidence and a very tough lending climate are likely to sustain these levels in 2013,” George said. “We believe UK retail is probably two years into a five-year period of rebalancing which will result in a 15 to 20 percent decline in non-food physical space.”

For more information about asset disposition, valuation and appraisal services available through Great American Group or GA Europe, visit the company’s website at www.greatamerican.com.

About Great American Group, Inc. (OTCBB: GAMR)

Great American Group is a leading provider of asset disposition and auction solutions, advisory and valuation services, capital investment, and real estate advisory services for an extensive array of companies. A trusted strategic partner at every stage of the business lifecycle, Great American Group efficiently deploys resources with sector expertise to assist companies, lenders, capital providers, private equity investors and professional service firms in maximizing the value of their assets. The company has in-depth experience within the retail, industrial, real estate, healthcare, energy and technology industries. The corporate headquarters is located in Woodland Hills, Calif. with additional offices in Atlanta, Boston, Charlotte, N.C., Chicago, Dallas, New York, San Francisco and London. For more information, call [phone] or visit www.greatamerican.com.

About GA Europe

GA Europe is a wholly owned subsidiary of the publicly listed Great American Group Inc. New to the European market in 2010, it is fast developing a compelling track record in solving challenging retail situations, operating in partnership with retailers, private equity sponsors, financial stakeholders, corporate lenders and their professional advisors. GA Europe’s services focus on valuing retail assets, lending to retailers and ‘working out’ complex distressed situations, often by taking senior investment positions.

Since 2010, GA Europe has completed approximately 15 transactions including:

July 2012: Acquired the debt in value retailer Ashloch (trading as Ethel Austin), subsequently restructuring the business before a large part of the business was sold to trade player Liric.
May 2012: Supported a management buyout of footwear retailer Shoon from Administration by providing funding for working capital and delivering operational support to the business. GA Europe also took a minority equity stake
July 2011: Acquired the debt of TJ Hughes, a 56-strong value department store chain. The business was restructured with a significant part of the chain being sold to trade player Benross Group.
Other recent engagements include advisory deals on Game Group, Fenn Wright Manson, Bonmarché, and Jane Norman, and deals in Germany and Italy with Wehmeyer Lifestyle and Blockbuster Italia, respectively.
================================================

150 Retail Store Leases of Bakers and Wild Pair Shoes are Included in Bankruptcy Sale Process

GA Keen Realty Advisors Running Nationwide Bankruptcy Sales Process

NEW YORK--(BUSINESS WIRE)-- GA Keen Realty Advisors, LLC of New York, a division of Great American Group, Inc. (OTCBB: GAMR), has begun marketing leases for 150 Bakers and Wild Pair shoe store locations across the country.

According to GA Keen Realty Advisors Co-President Harold Bordwin, “For retailers looking to expand, our bankruptcy sales process is the fastest and easiest way to open new stores and new markets. While December 4 is the deadline for submitting bids for the December 11 auction, we expect to have the ability to name a stalking horse prior to the auction. Thus, we are encouraging retailers to talk with us as soon as possible.”

The stores, ranging from 1,254 to more than 4,000 square feet in size, are located in 31 states including Arkansas, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Louisiana, Maine, Maryland, Michigan, Missouri, North Carolina, New Hampshire, New Jersey, New Mexico, Nevada, New York, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, and Wisconsin.

All transactions are subject to bankruptcy court approval.

For more information about the properties, contact Harold Bordwin or Heather Milazzo at 646-381-9222 or email [e-mail].

About GA Keen Realty Advisors, LLC

GA Keen Realty Advisors, located in New York, provides real estate analysis, valuation and strategic planning services, brokerage, M&A, auction services, lease restructuring services and real estate capital market services. For more information, contact GA Keen Realty Advisors at [phone] or visit http://www.greatamerican.com/services/real_estate/real_estate.html.
================================================

Bankruptcy Lease Auction* - GA Keen Realty Advisors Markets DAFFY’S Retail Sites in New York, New Jersey

-Former Daffy’s retail locations offer strategic locations, flagship potential-

NEW YORK--(BUSINESS WIRE)-- GA Keen Realty Advisors, a division of Great American Group, Inc. (OTCBB: GAMR), is marketing several world-class lease opportunities that offer strategic retail locations in New York City and surrounding areas and boroughs, along with three sites in northeastern New Jersey.

GA Keen Realty Advisors has been retained by Jericho Acquisitions I, LLC and Aurora Capital Associates to market the remaining 11 former Daffy’s high-fashion discount stores as part of a bankruptcy lease auction, according to GA Keen Realty Advisors Co-President Harold Bordwin.

“All sites are available at below-market lease rates and are in strategic locations with flagship potential, which make these properties desirable for retailers who want to make inroads into New York City and its adjacent markets,” Bordwin said.

The retail spaces range from 17,000 to 54,000 square feet in size and are at the following locations:

Route 1 and Route 9 North, Elizabeth, New Jersey
165 Route 4 West, Paramus, New Jersey (Paramus Place)
215 Route 46 West, Totowa, New Jersey (Totowa Shopping Center)
2146 Bartow Ave., Bronx, New York (Bay Plaza)
88-01 Queens Blvd., Elmhurst, New York (Queens Place)
1900 Northern Blvd., Manhasset, New York
335 Madison Ave. at 44th St., New York City
135 East 57th St., New York City
1775 Broadway at 57th St., New York City
229 West 43rd St., New York City
3 East 18th St., New York City
The bid deadline is Friday, Dec. 7 and an auction date is currently set for Wednesday, Dec. 12. All transactions are subject to bankruptcy court approval. “We have the ability to transact prior to the bid deadline so we encourage all interested parties to reach out to us immediately.” For more information about the properties, contact Harold Bordwin at 646-381-9222 or email [e-mail].

Daffy’s Inc., founded in 1961 and based in Secaucus, New Jersey, was known for selling national fashion brands at up to 80 percent off list prices. A victim of a fiercely competitive landscape that had already claimed rivals Syms and Filene’s Basement, the company announced it was going out of business in July.

GA Keen Realty Advisors provides real estate analysis, valuation and strategic planning services, brokerage, M&A, auction services, lease restructuring services and real estate capital market services. For more information, contact GA Keen Realty Advisors at [phone] or visit http://www.greatamerican.com/services/real_estate/real_estate.html.
====================================

Great American Group Selected to Liquidate Assets Owned by Russell Wasendorf, Sr., Former CEO of Now-Defunct Peregrine Financial Group, Inc.

- Funds collected will be used to help repay company investors -

WOODLAND HILLS, Calif.--(BUSINESS WIRE)-- A 1957 Ford Thunderbird, all-terrain vehicles, a 3,400-bottle wine collection and an extensive collection of sports memorabilia are just some of the more eclectic assets formerly owned by Russell Wasendorf, Sr. that are being prepared for liquidation by Great American Group, Inc. (OTCBB: GAMR).

Great American Group was selected by court-appointed receiver, Chicago-based attorney Michael Eidelman, to sell Wasendorf’s personal assets. Wasendorf, who served as CEO of Peregrine Financial Group (PFG), recently pleaded guilty to embezzling $200 million from investors. PFG filed for Chapter 7 bankruptcy liquidation in July.

According to Peter Wyke, senior vice president for Great American Group’s wholesale and industrial division, proceeds from the liquidation will be used to repay investors for part of their losses.

“Basically, any tangible personal property assets, product inventories or fixed assets either owned by Wasendorf or any Wasendorf entity will be sold as part of the liquidation,” he said. “We’re already receiving interest in many of the assets, including those at the myVerona restaurant, which was owned by Wasendorf, and within the CEO’s former residence.”

Some of Wasendorf's personal possessions for sale include autographed football jerseys from former St. Louis Rams and Arizona Cardinals quarterback Kurt Warner, ex-San Francisco 49ers quarterback Joe Montana and a signed Super Bowl XX jersey from the Chicago Bears' William "Refrigerator" Perry. These and many other items will be sold during a live webcast auction scheduled to begin at 10 a.m. Wednesday, Dec. 5 at the former PFG headquarters building at 1 Peregrine Way.

Auction items may be inspected from 10 a.m. – 4 p.m. (CST) at the following three locations in Cedar Falls, Iowa:

myVerona Restaurant, 419 Main St.
Corporate Offices, 8100 Beaver Hills Dr.
Warehouse, 5729 Westminster Dr.
For more detailed information, visit the Great American Group auction webpage at http://www.greatamerican.com/auctions/AuctionEventDetails.aspx?EventID=680 or contact Peter Wyke at [phone] or by email at [e-mail].
===============================================

Great American Group Hosts Solar Equipment Auction on Sept. 18

-Items from three Abound Solar plant locations for sale-

WOODLAND HILLS, Calif.--(BUSINESS WIRE)-- Great American Group, Inc. (OTCBB: GAMR) will conduct the first of two auctions for state-of-the-art solar manufacturing equipment located at four Colorado plants formerly operated by Abound Solar.

The first online auction begins at 8 a.m. (MDT) Tuesday, Sept. 18 and ends at 11 a.m. (MDT) on Wednesday, Sept. 19.

“We have a superb offering of module manufacturing and related facilities equipment along with test chambers, microscopes, machine shop equipment, plant equipment and many other items,” said Paul Brown, Great American Group Vice President of Wholesale & Industrial Services. “This will be a multi-million dollar offering. So far, we’ve received significant global interest from potential bidders from the solar industry, along with the semiconductor industry and related sectors.”

Brown also said there are a large number of completed solar panels, ready to ship on pallets, which may be available through private negotiation.

“The interest in the completed panels has been very high because it presents a unique opportunity for buyers to acquire them at a fraction of their new cost,” he said.

The online auction will involve the sale of assets at former Abound Solar test facilities located in Loveland, Fort Collins and Longmont, Colorado. All items can be inspected between 9 a.m. and 4 p.m. (MDT) on Monday, Sept. 17 and Tuesday, Sept. 18.

Other manufacturing equipment at Abound Solar’s main production facility in Longmont will be auctioned live on site during a two-day webcast auction, Oct. 2-3. For more information, visit http://www.greatamerican.com/auctions/AuctionEventDetails.aspx?EventID=664.

All auctions are managed in conjunction with the Branford Group, which specializes in surplus industrial machinery and equipment auctions and valuations.

About Great American Group, Inc. (OTCBB: GAMR)

Great American Group is a leading provider of asset disposition and auction solutions, advisory and valuation services, capital investment, and real estate advisory services for an extensive array of companies. A trusted strategic partner at every stage of the business lifecycle, Great American Group efficiently deploys resources with sector expertise to assist companies, lenders, capital providers, private equity investors and professional service firms in maximizing the value of their assets. The company has in-depth experience within the retail, industrial, real estate, healthcare, energy and technology industries. The corporate headquarters is located in Woodland Hills, Calif. with additional offices in Atlanta, Boston, Charlotte, N.C., Chicago, Dallas, New York, San Francisco and London. For more information, call [phone] or visit www.greatamerican.com.
====================================

Casual Male Selects Great American Group to Help with DXL Store Expansion

-National apparel retailer outsources store set-up through store opening program-

WOODLAND HILLS, Calif.--(BUSINESS WIRE)-- When the Casual Male Retail Group (Casual Male) embarked on the nationwide roll-out of its new DestinationXL (DXL) store format, which consolidated its value, mid-range and luxury men’s apparel all within a single location, the company decided to take a new approach with merchandising and store set-ups as well.

Casual Male COO/CFO Dennis Hernreich decided to outsource the store set-up function, and chose the store opening program offered by Great American Group, Inc. (OTCBB: GAMR).

“We opened four stores using our own visual team and district managers, flying large groups of associates in to help set-up the DXL store layout each time,” said Brian Doherty, director of field support with Casual Male. “Although there’s a cost associated with paying for flights and hotels for a four-to-five night stay, we realized that the real cost was pulling these people away from their day-to-day responsibilities and the effect it had on each district’s overall sales performance.”

Casual Male conducted a pilot project pitting Great American Group against another firm, with both companies setting up two DXL stores each, and then assessed the results.

“We were impressed with the level of expertise and precision Great American Group demonstrated in executing the DXL store opening plan, which led us to use their team for all DXL openings,” Doherty said. “Great American Group sent a team to our DXL store in Las Vegas and spent a week there learning our business and meeting with our management and visual team. We quickly realized Great American Group was best equipped to help us with the DXL expansion.”

Great American Group has experienced tremendous success with the program – and is on track to help Casual Male set up the majority of the 50 DXL stores scheduled to open throughout the U.S. by the end of the year.

“We have hundreds of associates around the country with years of retail experience,” said Scott Carpenter, president, GA Retail. “This service gives us an opportunity to put that expertise to work for retailers who are opening new stores, remodeling or are in the process of consolidating store locations.”

Doherty notes that in addition to store layout and merchandising support services, Great American Group also has experience through its liquidation work with Casual Male. Great American Group helped Casual Male “fold in” existing inventory from the smaller, former Casual Male locations into the larger DXL stores which range in size from 7,000 to 10,000 square feet.

“Our Store Opening Program provides clients with a one-stop shop for their global expansion needs,” said Mike Wyse, Great American Group vice president. “Our goal is to simplify the store opening process. Reassigning corporate staff, experienced managers and sales people from existing stores for store openings is disruptive and can have a negative effect on sales and customer service. With our program, retailers avoid those issues.”

Doherty says Casual Male plans to continue using Great American Group’s Store Opening Program during the “rapid expansion” of its new DXL store format.

“I think any retailer who is expanding, introducing a new store concept or consolidating retail operations should look into this service from Great American Group,” Doherty said.

For more information about the Store Opening Program, contact Mike Wyse at 646-381-9217, or via e-mail at [e-mail].
==============================================

Wind-Down Sale Starts Immediately In 568 Fashion Bug Locations

PR Newswire - Sep 04 10:20 EDT

Alert hits:(/G
Company Symbols: NASDAQ-OTCBB:GAMR, ACORN:A.3221249036

Entire $500,000,000 Inventory Will Be Sold

BENSALEM. Pa., Sept. 4, 2012 /PRNewswire/ -- SB Capital Group, LLC, Tiger Capital Group, LLC, and Great American Group, LLC, announced today the formation of a joint venture to conduct a sale of all inventory in the 568 stores of women's retailer Fashion Bug, a unit of Charming Shoppes, Inc., a recently acquired subsidiary of Ascena Retail Group, Inc. The "Total Inventory Blowout Sale" will be conducted in the 568 Fashion Bug stores located in communities across 39 states, and is part of Ascena's planned divestiture of the brand and the orderly wind down of the Fashion Bug operation.

In what will be an epic sale, shoppers will be able to take advantage of the tremendous savings offered at one of the most widely recognized women's stores in the country. Fashion Bug stores are stocked full of fresh new arrivals with the best in fall fashion, and shoppers will find compelling discounts of as much as 50% on everything in Fashion Bug's entire $500,000,000 retail inventory. The "Total Inventory Blowout Sale" will reinforce Fashion Bug's strong, high-value message of "Look Great, Spend Less" and will give women everywhere an unmatched opportunity to build their wardrobes at meaningful discounts off Fashion Bug's already low original prices.

Fashion Bug offers women's apparel in plus, misses and juniors sizes, and includes offerings of intimate apparel, accessories, and footwear. Founded as part of Charming Shoppes, Inc., the first Fashion Bug store was opened in the 1960's in Audubon, New Jersey. The company grew with rapid expansion in the late 1970's, and reached a peak of more than 1,400 stores in the 1990's.

As part of the process, Fashion Bug has retained more than 5,900 store and district personnel to assist the joint venture in operating the stores through the completion of the sale process.

About SB Capital Group, LLC

SB Capital Group, a Schottenstein affiliate, is a leader in the field of asset recovery, rescue finance, restructuring and strategic store closing events. As equity stakeholders in businesses comprising sectors as diversified as retail enterprises, consumer products, franchising, licensing and real property, SB Capital Group leverages resources and depth of experience to provide services with applicability across a wide spectrum of industries. Recognized worldwide as a trusted partner for businesses and professionals, SB Capital Group adds value to high level strategic planning as well as day-to-day operations. Our participation in transactions that span the globe has solidified our reputation as one of the most creative and innovative financial service and asset realization firms in existence today. Discover more at www.sbcapitalgroup.com

About Tiger Capital Group, LLC

Tiger Group provides advisory, restructuring, valuation, disposition and auction services within a broad range of retail, wholesale, and industrial sectors. With over 40 years of experience and substantial financial backing, Tiger offers a uniquely nimble combination of expertise, innovation and financial resources to drive results. Tiger's seasoned professionals help clients identify the underlying value of assets, monitor asset risk factors and, when needed, convert assets to capital in a variety of ways quickly and decisively. Tiger's collaborative and no-nonsense approach is the foundation for its many long-term 'partner' relationships and decades of uninterrupted success. Tiger maintains offices in Boston, Los Angeles, New York and Atlanta. To learn more about Tiger, please visit, www.TigerGroupLLC.com.
====================================================

Great American Group(R)* Announces Improved Second Quarter 2012 Financial Results

WOODLAND HILLS, CA -- (Marketwire) -- 08/14/12 -- Great American Group, Inc. (OTCBB: GAMR)

Total revenues of $19.7 million, an increase of 100% from a year ago
Operating income of $0.8 million, versus an operating loss of $2.2 million a year ago
Net income of $0.6 million, versus a net loss of $2.2 million a year ago
Diluted earnings per share of $0.02, versus a diluted loss per share of $0.08 a year ago
Great American Group, Inc. (OTCBB: GAMR) ("Great American Group" or the "Company"), a leading provider of asset disposition, valuation and appraisal services, today announced financial results for its second quarter ended June 30, 2012.

Second Quarter Results
For the second quarter ended June 30, 2012, the Company reported total revenues of $19.7 million, an increase of 100% from revenues of $9.8 million in the second quarter of 2011. Revenues from services and fees were $13.3 million, compared to $9.6 million in the same period the prior year. Revenues from sale of goods were $6.4 million, compared to $0.3 million in the second quarter of 2011. The increase in total revenues during the quarter was primarily due to increases in the auction and liquidation segment of $6.7 million, an increase in revenues in the valuation and appraisal services segment of $0.3 million, and revenues of $2.8 million from the UK retail stores segment, as a result of the Company's investment in Shoon Trading Limited ("Shoon"), a shoe retailer with operations in the United Kingdom. This represents a new reportable segment in our financial statements.

"During the quarter we experienced improvements in our financial results from the previous year," said Andrew Gumaer, Chief Executive Officer of Great American Group. "Our enhanced performance reflects increased activity in our auction and liquidation segment from operations in the United Kingdom and contributions from our GA Keen Realty Advisors division. The new UK retail stores segment operates eleven Shoon retail stores in the United Kingdom and is complementary to our continued expansion in the UK. As we head into the second half of 2012, we remain highly focused on the execution of our business initiatives and achieving our financial objectives to position the business for continued growth and profitability."

Direct cost of services was $5.0 million, compared to $3.5 million a year ago. The increase in direct cost of services was primarily the result of an increase in the number of fee and commission engagements in the second quarter of 2012, where the Company contractually bills fees, commissions and reimbursable expenses, in the auction and liquidation segment as well as an increase in headcount which resulted in an increase in salaries, wages and benefits in the valuation and appraisal segment compared to the same period in 2011. Cost of goods sold was $4.1 million in the second quarter of 2012, compared to $0.4 million in the second quarter of the prior year. The increase in cost of goods sold in the second quarter of 2012 included costs of goods sold of $1.5 million related to retail sales from the Shoon stores located in the United Kingdom.

Selling, general and administrative expenses were $9.8 million, compared to $8.2 million in the second quarter of 2011. The increase in selling, general and administrative expenses was primarily the result of an increase of $0.5 million in the auction and liquidation segment and $1.1 million in the UK retail stores segment which is new in the second quarter as a result of the consolidation of Shoon on May 4, 2012. The increase in selling, general and administrative expenses of $0.1 million related to corporate overhead was offset by the decrease in selling, general and administrative expenses $0.1 million in the valuation and appraisal segment.

On May 4, 2012, the Company invested $0.1 million for a 40% interest in the common stock of Shoon. Shoon purchased the rights to operate the former Shoon internet business and retail stores that were in administration in the United Kingdom. As part of the investment, the Company has also loaned Shoon approximately $1.3 million that is collateralized by retail inventory. The Company, together with its 40% investment in the common stock of Shoon and its control of the majority of the board or directors, is deemed to be the primary beneficiary of Shoon. As such, for generally accepted accounting principles in the United States, the Company is required to consolidate the operations of Shoon. The results of operations of Shoon from May 4, 2012, the date of investment, through June 30, 2012, have been included in the Company's condensed consolidated statements of operations.

In addition, during the second quarter, the Company recorded a gain on bargain purchase of $1.4 million since the fair value of assets acquired in the Shoon transaction exceeded consideration paid. The gain on bargain purchase is record net of tax and is included as a separate component of other income (expense) in the condensed consolidated statements of operations.

Income from operations before provision for income taxes was $1.5 million during the second quarter of 2012, compared to loss from operations before benefit for income taxes of $3.1 million in the second quarter of 2011. Excluding the gain from bargain purchase of $1.4 million included in other income related to the investment and consolidation of Shoon, income from operation before provision for income taxes was $0.2 million during the second quarter of 2012. During the second quarter of 2012, the Company recorded a provision for income taxes of $0.1 million, compared with a benefit for income taxes of $0.9 million in the second quarter of 2011. Overall, in the second quarter of 2012, the Company generated net income of $0.6 million, or $0.02 per diluted share, compared with net loss of $2.2 million, or $0.08 per diluted share, in the second quarter of 2011.

Six Month Results
For the first six months of 2012, the Company reported total revenues of $39.0 million, compared to $23.6 million in the first six months of 2011. Revenues from services and fees were $30.2 million, compared to $22.6 million a year ago. Sales of goods were $8.8 million compared to $1.1 million in the same period of 2011.

Total operating expenses were $35.8 million, compared to $25.6 million in 2011. Operating income was $3.2 million, compared to an operating loss of $1.9 million in the prior year. Earnings from operations before income taxes were $3.3 million, compared to a loss from operations before income taxes of $2.9 million during the first six months of 2011. The Company recorded a provision for income taxes of $0.8 million during the first six months of 2012, compared to a benefit for income taxes of $0.2 million in the same period of 2011. Net income during the first six months of 2012 was $1.7 million, or $0.06 per diluted share, compared with a net loss of $2.8 million, or $(0.10) in the same period of 2011.

Financial Position
At June 30, 2012, the Company had $23.4 million in cash and cash equivalents, an increase of $8.4 million, from $15.0 million at December 31, 2011. Working capital was $29.0 million at June 30, 2012.

Conference Call
The Company will host a conference call at 4:30 p.m. EDT on Tuesday, August 14, 2012, to discuss results for the second quarter ended June 30, 2012. To participate in the event by telephone, please dial [phone], 10 minutes prior to the start time (to allow time for registration) and use conference ID #4550214. International callers should dial [phone]. A digital replay will be available beginning August 14, 2012, at 7:30 p.m. EDT, through August 21, 2012, at 11:59 p.m. EDT. To access the replay, dial [phone] (U.S.), and use passcode 4550214. International callers should dial [phone] and enter the same passcode. The call will also be broadcast over the Internet and can be accessed on the Investor Relations section of the Company's Web site at www.greatamerican.com. To listen to the webcast, please visit the site at least 15 minutes prior to the start of the call in order to register, download and install any necessary audio software. A replay of the call will also be available for 90 days on the Web site.

About Great American Group, Inc.

Great American Group, Inc. is a leading provider of asset disposition solutions and valuation and appraisal services to a wide range of retail, wholesale and industrial clients, as well as lenders, capital providers, private equity investors and professional service firms. Great American Group has offices in Atlanta, Boston, Charlotte, Chicago, Dallas, London, Los Angeles, New York and San Francisco. For more information, please visit www.greatamerican.com.

*Great American Group and the Eagle Design are trademarks registered in the US Patent and Trademark Office and are exclusive property of Great American Group, Inc.

Forward-Looking Statements
This press release may contain forward-looking statements by Great American Group that are not based on historical fact, including, without limitation, statements containing the words "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions and statements. Because these forward-looking statements involve known and unknown risks and uncertainties, there are important factors that could cause actual results, events or developments to differ materially from those expressed or implied by these forward-looking statements. Such factors include those risks described from time to time in Great American Group's filings with the SEC, including, without limitation, the risks described in Great American Group's proxy statement/prospectus filed with the SEC on July 19, 2012, and its Annual Report on Form 10-K for the year ended December 31, 2011. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. All information is current as of the date this press release is issued, and Great American Group undertakes no duty to update this information.

Note Regarding Use of Non-GAAP Financial Measures
Certain of the information set forth herein, including Adjusted EBITDA, may be considered non-GAAP financial measures. Great American Group believes this information is useful to investors because it provides a basis for measuring Great American Group's performance against the contingent share earnout provisions in the AAMAC transaction. In addition, Great American Group's management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measures in evaluating Great American Group's operating performance, capital resources and cash flow. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-financial measures as reported by Great American Group may not be comparable to similarly titled amounts reported by other companies. NEED Investment Ideas...?? GO TO:

[10 bagger]

Top 12 picks.. ASNB,, CIBH,, CPHMF,, VSTI,, ENSV,, GAMR,, KLYG,, TPNL,, LVWD,, SPND,, TEXC,, HIIT...

[10 bagger]

03/28/2013 Top 21 Trading positions and March results.....

March 28, 2013 Position.. Market Value: $1,420,960.90 Up $63,209.00 or 4.65% since February 28, 2013..
Adjusted for trading losses of $17,287.00
April Starting position.. $1,420,960.90 Up 36.22% since YE..

CASH 400,719 $1.00 1.00 28.20% $400,719.00

CPHMF 37,164 3.65 9.55% $135,648.60 CPHMF $3.65 + 37,164

SPND 53,840 $2.50 9.47% $134,600.00 SPND $2.50 -1,976

LVWD 212,119 0.43 6.42% $91,211.17 LVWD $0.43 +169,403

ENSV 64,776 1.27 5.83% $82,265.52 ENSV..$1.27 +13666

GAMR 202,904 $0.39 5.57% $79,132.56 GAMR..$0.39 +8000

VSTI 394,312 $0.1728 4.80% $68,137.11 VSTI.. $0.1728 -768888

CIBH 91,625 0.65 4.19% $59,556.25 CIBH.. $0.65 +91625

TPNL 163,650 0.282 3.25% $46,149.30 TPNL.. $0.282 +30888

GLMB 403,791 $0.111 3.15% $44,820.80 GLMB..$0.111 +46816

BNLB 475,931 $0.0937 3.14% $44,594.73 BNLB.. $0.0937 +333976

TEXC 287,797 $0.145 2.94% $41,730.56 No Change..

ADTY 134,072 $0.29 2.74% $38,880.88 ADTY.. $0.29 +10151

BOLL 25,258 $1.50 2.67% $37,887.00 BOLL.. 1.50 +500

PYDS 178,857 $0.16 2.01% $28,617.12 PYDS.. $$0.16 -6102

ASNB 463,363 $0.052 1.70% $24,094.88 ASNB.. $0.052 +161751

PHOS 17,776 0.951 1.19% $16,904.98 PHOS.. $0.952 +17776

ETCIA 86,300 $0.183 1.11% $15,792.90 ETCIA,, $0.183 +27300

DTRK 18,259 0.53 0.68% $9,041.86 DTRK.. $0.53 +18259

PBSV 9,111 1.02 0.65% $9,293.22 PBSV.. 1.03 -25676

PAOS 23,136 $0.25 0.25 0.41% $5,784.00 PAOS.. $0.25 -8054

KLYG 68,288 $0.08 0.38% $5,463.04 KLYG,, $0.08 +20500

CDOC.. (00) $0.112 -82566
PXFG.. (00) $0.17 -197061
ITSI.. (00) $1.09 -48167

Top 20 Positions Trades for the month of March..

03/28/13 Transfer 750,000 VTSI.. to Investment Account @ $0.1728..

03/28/13 3:49 PM EDT Sell 1000 ENSV Executed @ $1.27 Details | Edit
03/28/13 3:33 PM EDT Sell 2382 ENSV Executed @ $1.27 Details | Edit
03/28/13 3:32 PM EDT Sell 5000 ENSV Executed @ $1.27 Details | Edit
03/28/13 3:04 PM EDT Buy 4900 ESPI Executed @ $0.0655 Details | Edit
03/28/13 2:23 PM EDT Sell 4500 ASNB Executed @ $0.0628 Details | Edit
03/28/13 2:09 PM EDT Buy 888 VSTI Executed @ $0.1728 Details | Edit
03/28/13 2:05 PM EDT Buy 18000 VSTI Executed @ $0.1728 Details | Edit
03/28/13 2:05 PM EDT Buy 20000 VSTI Executed @ $0.1728 Details | Edit
03/28/13 1:42 PM EDT Buy 8088 BNLB Executed @ $0.0938 Details | Edit
03/28/13 1:41 PM EDT Buy 4800 BNLB Executed @ $0.0938 Details | Edit
03/28/13 12:10 PM EDT Sell 40000 ASNB Executed @ $0.0638 Details | Edit
03/28/13 11:51 AM EDT Sell 5812 ASNB Executed @ $0.0638 Details | Edit
03/28/13 11:50 AM EDT Sell 288 ASNB Executed @ $0.065 Details | Edit
03/28/13 11:44 AM EDT Sell 510 ENSV Executed @ $1.25 Details | Edit
03/28/13 11:44 AM EDT Sell 15000 ASNB Executed @ $0.0578 Details | Edit
03/28/13 10:51 AM EDT Sell 20000 ASNB Executed @ $0.055 Details | Edit
03/28/13 10:49 AM EDT Sell 10000 ASNB Executed @ $0.055 Details | Edit
03/28/13 10:14 AM EDT Sell 1336 ENSV Executed @ $1.24 Details | Edit
03/28/13 10:08 AM EDT Buy 327 CIBH Executed @ $0.62 Details | Edit
03/28/13 10:06 AM EDT Sell 1000 ENSV Executed @ $1.24 Details | Edit
03/28/13 10:00 AM EDT Sell 2000 ENSV Executed @ $1.24 Details | Edit
03/28/13 9:45 AM EDT Buy 2000 CIBH Executed @ $0.62 Details | Edit
03/28/13 9:39 AM EDT Buy 2000 CIBH Executed @ $0.65 Details | Edit
03/28/13 9:36 AM EDT Buy 1000 DTRK Executed @ $0.53 Details | Edit
03/27/13 3:59 PM EDT Buy 12488 TPNL Executed @ $0.25 Details | Edit
03/27/13 3:59 PM EDT Buy 6400 TPNL Executed @ $0.25 Details | Edit
03/27/13 3:59 PM EDT Buy 3600 TPNL Executed @ $0.25 Details | Edit
03/27/13 3:58 PM EDT Buy 2400 TPNL Executed @ $0.245 Details | Edit
03/27/13 3:58 PM EDT Buy 6000 TPNL Executed @ $0.25 Details | Edit
03/27/13 3:29 PM EDT Buy 2000 DTRK Executed @ $0.5328 Details | Edit
03/27/13 12:27 PM EDT Sell 5800 ENSV Executed @ $1.2 Details | Edit
03/27/13 12:25 PM EDT Buy 8400 CIBH Executed @ $0.63 Details | Edit
03/27/13 11:43 AM EDT Buy 13909 MOBS Executed @ $0.1628 Details | Edit
03/27/13 11:40 AM EDT Buy 4979 MOBS Executed @ $0.1628 Details | Edit
03/27/13 11:09 AM EDT Sell 888 SPND Executed @ $2.48 Details | Edit
03/27/13 9:59 AM EDT Sell 4000 ENSV Executed @ $1.21 Details | Edit
03/27/13 9:41 AM EDT Sell 1388 SPND Executed @ $2.46 Details | Edit
03/26/13 3:56 PM EDT Buy 1300 DTRK Executed @ $0.5328 Details | Edit
03/26/13 3:45 PM EDT Buy 500 CPHMF Executed @ $3.661 Details | Edit
03/26/13 3:27 PM EDT Buy 310 CIBH Executed @ $0.65 Details | Edit
03/26/13 3:27 PM EDT Buy 2500 CIBH Executed @ $0.65 Details | Edit
03/26/13 3:19 PM EDT Sell 4790 ENSV Executed @ $1.22 Details | Edit
03/26/13 3:16 PM EDT Sell 4888 ENSV Executed @ $1.21 Details | Edit
03/26/13 10:10 AM EDT Buy 888 CPHMF Executed @ $3.5498 Details | Edit
03/26/13 9:30 AM EDT Buy 500 CONX Executed @ $0.1808 Details | Edit
03/26/13 9:30 AM EDT Buy 159 DTRK Executed @ $0.48 Details | Edit
03/25/13 3:59 PM EDT Buy 2000 CIBH Executed @ $0.6028 Details | Edit
03/25/13 3:56 PM EDT Buy 10000 CIBH Executed @ $0.6028 Details | Edit
03/25/13 3:55 PM EDT Buy 4200 CIBH Executed @ $0.6028 Details | Edit
03/25/13 3:42 PM EDT Buy 3000 CIBH Executed @ $0.67 Details | Edit
03/25/13 3:39 PM EDT Buy 1000 CIBH Executed @ $0.65 Details | Edit
03/25/13 3:39 PM EDT Buy 5000 CIBH Executed @ $0.65 Details | Edit
03/25/13 3:16 PM EDT Buy 5100 KLYG Executed @ $0.08 Details | Edit
03/25/13 3:04 PM EDT Buy 2340 CIBH Executed @ $0.6 Details | Edit
03/25/13 12:40 PM EDT Sell 10000 CONX Executed @ $0.1988 Details | Edit
03/25/13 12:30 PM EDT Buy 1000 CIBH Executed @ $0.57 Details | Edit
03/25/13 11:18 AM EDT Buy 2548 CIBH Executed @ $0.5328 Details | Edit
03/25/13 11:13 AM EDT Buy 5952 CIBH Executed @ $0.57 Details | Edit
03/25/13 10:42 AM EDT Buy 10000 CIBH Executed @ $0.525 Details | Edit
03/25/13 10:09 AM EDT Buy 48 CIBH Executed @ $0.5 Details | Edit
03/25/13 10:09 AM EDT Buy 6000 CIBH Executed @ $0.5 Details | Edit
03/25/13 10:06 AM EDT Buy 1452 CIBH Executed @ $0.51 Details | Edit
03/25/13 10:04 AM EDT Buy 548 CIBH Executed @ $0.51 Details | Edit
03/25/13 10:04 AM EDT Buy 1000 CIBH Executed @ $0.51 Details | Edit
03/25/13 10:04 AM EDT Buy 1000 CIBH Executed @ $0.51 Details | Edit
03/25/13 10:04 AM EDT Buy 5000 CIBH Executed @ $0.5 Details | Edit
03/25/13 9:59 AM EDT Sell 3000 CHCR Executed @ $0.1088 Details | Edit
03/25/13 9:56 AM EDT Buy 12452 CIBH Executed @ $0.5 Details | Edit
03/25/13 9:55 AM EDT Buy 2548 CIBH Executed @ $0.5 Details | Edit
03/22/13 2:48 PM EDT Buy 3574 LVWD Executed @ $0.43 Details | Edit
03/22/13 2:48 PM EDT Buy 2103 LVWD Executed @ $0.43 Details | Edit
03/22/13 2:14 PM EDT Buy 5000 LVWD Executed @ $0.41 Details | Edit
03/22/13 2:05 PM EDT Buy 8000 BNLB Executed @ $0.095 Details | Edit
03/22/13 1:57 PM EDT Buy 3000 LVWD Executed @ $0.41 Details | Edit
03/22/13 1:56 PM EDT Buy 412 LVWD Executed @ $0.41 Details | Edit
03/22/13 1:44 PM EDT Buy 1000 CPHMF Executed @ $3.18 Details | Edit
03/22/13 1:43 PM EDT Buy 2000 CPHMF Executed @ $3.18 Details | Edit
03/22/13 1:24 PM EDT Sold 11971 BIOYF Executed @ $1.3065 Details | Edit
03/22/13 11:35 AM EDT Buy 388 LVWD Executed @ $0.4028 Details | Edit
03/22/13 11:35 AM EDT Buy 5000 LVWD Executed @ $0.4028 Details | Edit
03/22/13 11:34 AM EDT Buy 4612 LVWD Executed @ $0.4028 Details | Edit
03/22/13 11:34 AM EDT Buy 388 LVWD Executed @ $0.4028 Details | Edit
03/22/13 11:34 AM EDT Buy 8500 LVWD Executed @ $0.4028 Details | Edit
03/22/13 11:09 AM EDT Buy 3488 LVWD Executed @ $0.39 Details | Edit
03/22/13 11:09 AM EDT Buy 500 LVWD Executed @ $0.39 Details | Edit
03/22/13 11:08 AM EDT Buy 14900 LVWD Executed @ $0.39 Details | Edit
03/22/13 11:05 AM EDT Buy 2500 LVWD Executed @ $0.385 Details | Edit
03/22/13 11:05 AM EDT Buy 5900 LVWD Executed @ $0.385 Details | Edit
03/22/13 9:54 AM EDT Buy 1600 LVWD Executed @ $0.3808 Details | Edit
03/22/13 9:54 AM EDT Buy 50 LVWD Executed @ $0.3808 Details | Edit
03/22/13 9:54 AM EDT Buy 5600 LVWD Executed @ $0.377 Details | Edit
03/21/13 2:04 PM EDT Buy 5888 LVWD Executed @ $0.33 Details | Edit
03/21/13 2:04 PM EDT Buy 9000 LVWD Executed @ $0.33 Details | Edit
03/21/13 2:03 PM EDT Buy 4000 LVWD Executed @ $0.33 Details | Edit
03/21/13 1:30 PM EDT Buy 3475 LVWD Executed @ $0.35 Details | Edit
03/21/13 1:01 PM EDT Buy 9000 LVWD Executed @ $0.35 Details | Edit
03/21/13 12:44 PM EDT Buy 8000 LVWD Executed @ $0.376 Details | Edit
03/21/13 12:29 PM EDT Buy 3025 LVWD Executed @ $0.35 Details | Edit
03/21/13 11:47 AM EDT Buy 15000 LVWD Executed @ $0.35 Details | Edit
03/21/13 11:47 AM EDT Buy 5000 LVWD Executed @ $0.35 Details | Edit
03/21/13 11:45 AM EDT Buy 20373 LVWD Executed @ $0.35 Details | Edit
03/21/13 11:38 AM EDT Buy 10000 LVWD Executed @ $0.349 Details | Edit
03/21/13 9:37 AM EDT Buy 14500 LVWD Executed @ $0.33 Details | Edit
03/20/13 3:00 PM EDT Buy 6050 PYDS Executed @ $0.1538 Details | Edit
03/20/13 12:32 PM EDT Buy 2500 ASNB Executed @ $0.0468 Details | Edit
03/20/13 12:18 PM EDT Buy 10251 ADTY Executed @ $0.24 Details | Edit
03/20/13 9:52 AM EDT Buy 1700 GAMR Executed @ $0.34 Details | Edit
03/20/13 9:52 AM EDT Buy 6300 GAMR Executed @ $0.34 Details | Edit
03/19/13 12:29 PM EDT Sell 30000 ASNB Executed @ $0.057 Details | Edit
03/19/13 11:07 AM EDT Sell 834 ASNB Executed @ $0.0588 Details | Edit
03/19/13 10:27 AM EDT Buy 11388 CONX Executed @ $0.19 Details | Edit
03/19/13 10:07 AM EDT Buy 1000 CONX Executed @ $0.19 Details | Edit
03/19/13 9:38 AM EDT Sell 3738 PBSV Executed @ $1.05 Details | Edit
03/19/13 9:35 AM EDT Sell 6097 PBSV Executed @ $1.06 Details | Edit
03/19/13 9:30 AM EDT Sell 11479 PBSV Executed @ $1.06 Details | Edit
03/19/13 9:30 AM EDT Sell 2600 PBSV Executed @ $1.1 Details | Edit
03/19/13 9:30 AM EDT Sell 1800 PBSV Executed @ $1.1 Details | Edit
03/18/13 3:57 PM EDT Sell 3000 ASNB Executed @ $0.0588 Details | Edit
03/18/13 1:35 PM EDT Buy 255 BNLB Executed @ $0.0958 Details | Edit
03/18/13 1:10 PM EDT Sell 9000 PXFG Executed @ $0.17 Details | Edit
03/18/13 11:50 AM EDT Buy 13295 BNLB Executed @ $0.0958 Details | Edit
03/18/13 11:43 AM EDT Buy 5750 BNLB Executed @ $0.0958 Details | Edit
03/18/13 11:35 AM EDT Buy 6500 BNLB Executed @ $0.0978 Details | Edit
03/18/13 11:01 AM EDT Buy 11000 BNLB Executed @ $0.0978 Details | Edit
03/18/13 11:01 AM EDT Buy 17400 BNLB Executed @ $0.095 Details | Edit
03/18/13 9:49 AM EDT Buy 7000 PYDS Executed @ $0.16 Details | Edit

03/15/13 Transfer 138,554 PXFG.. to Investment Account @ $0.17..

03/15/13 3:50 PM EDT Buy 300 PYDS Executed @ $0.16 Details | Edit
03/15/13 3:46 PM EDT Sell 5000 PXFG Executed @ $0.18 Details | Edit
03/15/13 3:46 PM EDT Sell 4500 PXFG Executed @ $0.18 Details | Edit
03/15/13 3:46 PM EDT Sell 2000 PXFG Executed @ $0.18 Details | Edit
03/15/13 3:46 PM EDT Sell 5000 PXFG Executed @ $0.18 Details | Edit
03/15/13 3:46 PM EDT Sell 14000 PXFG Executed @ $0.18 Details | Edit
03/15/13 3:46 PM EDT Sell 5000 PXFG Executed @ $0.18 Details | Edit
03/15/13 3:46 PM EDT Sell 10000 PXFG Executed @ $0.19 Details | Edit
03/15/13 3:46 PM EDT Sell 1480 PXFG Executed @ $0.191 Details | Edit
03/15/13 3:20 PM EDT Buy 500 CONX Executed @ $0.19 Details | Edit
03/15/13 11:51 AM EDT Buy 5000 BNLB Executed @ $0.1012 Details | Edit
03/15/13 11:47 AM EDT Buy 2800 PYDS Executed @ $0.16 Details | Edit
03/15/13 11:45 AM EDT Buy 15000 BNLB Executed @ $0.1012 Details | Edit

03/14/13 Transfer 23,203 ITSI to Investment Account @ $1.18..

03/14/13 3:59 PM EDT Buy 7900 PYDS Executed @ $0.16 Details | Edit
03/14/13 3:46 PM EDT Buy 5000 CONX Executed @ $0.19 Details | Edit
03/14/13 2:12 PM EDT Buy 6800 PYDS Executed @ $0.16 Details | Edit
03/14/13 12:25 PM EDT Sell 401 ITSI Executed @ $1.04 Details | Edit
03/14/13 12:18 PM EDT Sell 200 ITSI Executed @ $1.04 Details | Edit
03/14/13 11:25 AM EDT Sell 1000 ITSI Executed @ $1.04 Details | Edit
03/14/13 11:15 AM EDT Sell 1150 ITSI Executed @ $1.04 Details | Edit
03/14/13 11:13 AM EDT Sell 2000 ITSI Executed @ $1.04 Details | Edit
03/14/13 11:10 AM EDT Sell 980 ITSI Executed @ $1.04 Details | Edit
03/14/13 11:08 AM EDT Sell 780 ITSI Executed @ $1.04 Details | Edit
03/14/13 10:52 AM EDT Buy 7900 KLYG Executed @ $0.1028 Details | Edit
03/14/13 10:32 AM EDT Sell 1000 ITSI Executed @ $1.06 Details | Edit
03/14/13 10:31 AM EDT Buy 3000 ENSV Executed @ $1.12 Details | Edit
03/14/13 10:31 AM EDT Sell 5000 ITSI Executed @ $1.06 Details | Edit
03/14/13 10:04 AM EDT Sell 3138 ITSI Executed @ $1 Details | Edit
03/14/13 10:03 AM EDT Sell 1988 ITSI Executed @ $1.01 Details | Edit
03/14/13 10:03 AM EDT Sell 400 ITSI Executed @ $1.01 Details | Edit
03/14/13 10:03 AM EDT Sell 1000 ITSI Executed @ $1.01 Details | Edit
03/14/13 10:03 AM EDT Sell 650 ITSI Executed @ $1.01 Details | Edit
03/14/13 9:31 AM EDT Buy 5000 CONX Executed @ $0.19 Details | Edit

03/13/13.. Transfer 82,566 CDOC to Investment account,, @ $0.15..

03/13/13 3:59 PM EDT Buy 5000 KLYG Executed @ $0.1028 Details | Edit
03/13/13 3:58 PM EDT Buy 2500 KLYG Executed @ $0.1028 Details | Edit
03/13/13 3:57 PM EDT Buy 1700 PBSV Executed @ $1.17 Details | Edit
03/13/13 3:44 PM EDT Sell 100 ITSI Executed @ $1.18 Details | Edit
03/13/13 3:43 PM EDT Buy 45800 BNLB Executed @ $0.101 Details | Edit
03/13/13 2:54 PM EDT Buy 500 ENSV Executed @ $1.12 Details | Edit
03/13/13 2:54 PM EDT Buy 2000 ENSV Executed @ $1.12 Details | Edit
03/13/13 2:53 PM EDT Buy 1500 ENSV Executed @ $1.12 Details | Edit
03/13/13 2:53 PM EDT Buy 1000 ENSV Executed @ $1.12 Details | Edit
03/13/13 2:50 PM EDT Buy 5000 ENSV Executed @ $1.12 Details | Edit
03/13/13 1:55 PM EDT Buy 4000 CPHMF Executed @ $3.1661 Details | Edit
03/13/13 1:24 PM EDT Sell 5357 CCNI Executed @ $0.2168 Details | Edit
03/13/13 1:24 PM EDT Sell 10000 CCNI Executed @ $0.2168 Details | Edit
03/13/13 1:24 PM EDT Sell 1843 ITSI Executed @ $1.08 Details | Edit
03/13/13 1:19 PM EDT Sell 104 CDOC Executed @ $0.123 Details | Edit
03/13/13 1:02 PM EDT Buy 7900 DTRK Executed @ $0.5195 Details | Edit
03/13/13 1:02 PM EDT Buy 1000 DTRK Executed @ $0.515 Details | Edit
03/13/13 1:00 PM EDT Buy 8000 CPHMF Executed @ $3.17 Details | Edit
03/13/13 12:34 PM EDT Sell 284 GLMB Executed @ $0.1288 Details | Edit
03/13/13 11:30 AM EDT Sell 250 ITSI Executed @ $1.08 Details | Edit
03/13/13 11:29 AM EDT Sell 1800 ITSI Executed @ $1.08 Details | Edit
03/13/13 11:29 AM EDT Sell 700 ITSI Executed @ $1.09 Details | Edit
03/13/13 11:29 AM EDT Sell 1000 ITSI Executed @ $1.1 Details | Edit
03/13/13 11:29 AM EDT Sell 350 ITSI Executed @ $1.11 Details | Edit
03/13/13 11:26 AM EDT Buy 4900 DTRK Executed @ $0.42 Details | Edit
03/13/13 10:37 AM EDT Sell 2000 ITSI Executed @ $1.12 Details | Edit
03/13/13 10:29 AM EDT Sell 400 ITSI Executed @ $1.12 Details | Edit
03/13/13 10:28 AM EDT Sell 1000 ITSI Executed @ $1.12 Details | Edit
03/13/13 10:26 AM EDT Sell 1000 ITSI Executed @ $1.12 Details | Edit
03/13/13 10:18 AM EDT Sell 191 ITSI Executed @ $1.15 Details | Edit
03/13/13 10:18 AM EDT Sell 1000 ITSI Executed @ $1.15 Details | Edit
03/13/13 10:16 AM EDT Sell 9 ITSI Executed @ $1.15 Details | Edit
03/13/13 10:15 AM EDT Sell 200 ITSI Executed @ $1.15 Details | Edit
03/13/13 10:15 AM EDT Sell 1500 ITSI Executed @ $1.16 Details | Edit
03/13/13 10:15 AM EDT Sell 100 ITSI Executed @ $1.15 Details | Edit
03/13/13 10:15 AM EDT Sell 1000 ITSI Executed @ $1.23 Details | Edit
03/13/13 9:58 AM EDT Buy 1000 PBSV Executed @ $1.2 Details | Edit
03/13/13 9:51 AM EDT Buy 23888 GLMB Executed @ $0.1158 Details | Edit
03/13/13 9:50 AM EDT Buy 500 PBSV Executed @ $1.2 Details | Edit
03/08/13 3:01 PM EST Buy 9800 ASNB Executed @ $0.0508 Details | Edit
03/08/13 3:01 PM EST Buy 48000 ASNB Executed @ $0.0508 Details | Edit
03/08/13 2:55 PM EST Buy 348 PYDS Executed @ $0.1578 Details | Edit
03/08/13 1:42 PM EST Buy 2888 CPHMF Executed @ $3.0215 Details | Edit
03/08/13 1:36 PM EST Buy 1888 CPHMF Executed @ $3.0176 Details | Edit
03/07/13 3:34 PM EST Sell 5554 PAOS Executed @ $0.27 Details | Edit
03/07/13 3:32 PM EST Sell 2500 PAOS Executed @ $0.2683 Details | Edit
03/07/13 3:23 PM EST Buy 56000 ASNB Executed @ $0.0528 Details | Edit
03/07/13 3:18 PM EST Buy 33270 ASNB Executed @ $0.0568 Details | Edit
03/07/13 3:18 PM EST Buy 103606 ASNB Executed @ $0.0568 Details | Edit
03/07/13 1:35 PM EST Buy 383 PHOS Executed @ $0.9 Details | Edit
03/07/13 1:11 PM EST Buy 13688 GLMB Executed @ $0.1118 Details | Edit
03/07/13 1:11 PM EST Buy 15200 GLMB Executed @ $0.1118 Details | Edit
03/07/13 11:52 AM EST Sell 28 CONX Executed @ $0.1968 Details | Edit
03/07/13 11:52 AM EST Sell 28700 CONX Executed @ $0.1968 Details | Edit
03/07/13 11:27 AM EST Buy 12000 BNLB Executed @ $0.1042 Details | Edit
03/07/13 11:27 AM EST Buy 2700 BNLB Executed @ $0.1042 Details | Edit
03/07/13 11:16 AM EST Buy 500 BOLL Executed @ $1.52 Details | Edit
03/07/13 10:34 AM EST Buy 1000 PHOS Executed @ $1.12 Details | Edit
03/07/13 10:19 AM EST Buy 7000 PHOS Executed @ $1.12 Details | Edit
03/07/13 10:17 AM EST Buy 505 PHOS Executed @ $1.12 Details | Edit
03/07/13 9:53 AM EST Buy 7000 BNLB Executed @ $0.105 Details | Edit
03/07/13 9:51 AM EST Buy 5000 BNLB Executed @ $0.105 Details | Edit
03/07/13 9:49 AM EST Buy 8888 PHOS Executed @ $1.11 Details | Edit
03/07/13 9:49 AM EST Buy 12500 BNLB Executed @ $0.105 Details | Edit
03/07/13 9:48 AM EST Buy 7800 BNLB Executed @ $0.105 Details | Edit
03/07/13 9:45 AM EST Buy 9388 PBSV Executed @ $1.26 Details | Edit
03/07/13 9:34 AM EST Buy 3500 PBSV Executed @ $1.26 Details | Edit
03/06/13 3:57 PM EST Sell 160 CONX Executed @ $0.1988 Details | Edit
03/06/13 3:10 PM EST Buy 88 GLMB Executed @ $0.1208 Details | Edit
03/06/13 3:09 PM EST Buy 12800 GLMB Executed @ $0.1208 Details | Edit
03/06/13 2:52 PM EST Buy 6800 ENSV Executed @ $0.9328 Details | Edit
03/06/13 1:04 PM EST Sell 30000 GLMB Executed @ $0.13 Details | Edit
03/06/13 1:02 PM EST Sell 4342 GLMB Executed @ $0.13 Details | Edit
03/06/13 1:01 PM EST Sell 88 GLMB Executed @ $0.1288 Details | Edit
03/06/13 1:01 PM EST Sell 14458 GLMB Executed @ $0.1288 Details | Edit
03/06/13 12:16 PM EST Buy 2000 ITSI Executed @ $1.03 Details | Edit
03/06/13 11:50 AM EST Buy 10000 BNLB Executed @ $0.0975 Details | Edit
03/06/13 10:24 AM EST Buy 28888 GLMB Executed @ $0.1108 Details | Edit
03/06/13 11:28 AM EST Sell 10000 PYDS Executed @ $0.171 Details | Edit
03/06/13 11:21 AM EST Sell 20000 PYDS Executed @ $0.17 Details | Edit
03/06/13 10:24 AM EST Buy 28888 GLMB Executed @ $0.1108 Details | Edit
03/06/13 10:16 AM EST Buy 1500 ENSV Executed @ $1 Details | Edit
03/06/13 10:15 AM EST Buy 1200 BNLB Executed @ $0.0962 Details | Edit
03/06/13 10:14 AM EST Buy 500 ENSV Executed @ $1 Details | Edit
03/06/13 10:14 AM EST Buy 1000 ENSV Executed @ $1 Details | Edit
03/06/13 10:12 AM EST Buy 2500 ENSV Executed @ $1 Details | Edit
03/06/13 9:44 AM EST Buy 300 SPND Executed @ $2.37 Details | Edit
03/05/13 10:49 AM EST Buy 233 ITSI Executed @ $0.96 Details | Edit
03/05/13 10:45 AM EST Buy 14300 ETCIA Executed @ $0.21 Details | Edit
03/05/13 10:43 AM EST Buy 13000 ETCIA Executed @ $0.21 Details | Edit
03/05/13 10:41 AM EST Buy 38 ENSV Executed @ $1 Details | Edit
03/05/13 10:40 AM EST Buy 4100 ENSV Executed @ $1 Details | Edit
03/05/13 10:37 AM EST Buy 3538 BNLB Executed @ $0.098 Details | Edit
03/05/13 10:37 AM EST Buy 35350 BNLB Executed @ $0.098 Details | Edit
03/05/13 10:23 AM EST Buy 9400 BNLB Executed @ $0.1 Details | Edit
03/05/13 10:17 AM EST Sell 5000 GLMB Executed @ $0.1301 Details | Edit
03/05/13 10:16 AM EST Sell 3000 GLMB Executed @ $0.1301 Details | Edit
03/05/13 10:05 AM EST Sell 36 GLMB Executed @ $0.128 Details | Edit
03/05/13 10:05 AM EST Sell 13700 GLMB Executed @ $0.128 Details | Edit
03/05/13 10:00 AM EST Sell 6000 GLMB Executed @ $0.128 Details | Edit
03/05/13 9:43 AM EST Buy 12 ASNB Executed @ $0.0538 Details | Edit
03/05/13 9:38 AM EST Buy 14100 BNLB Executed @ $0.1 Details | Edit
03/04/13 3:07 PM EST Buy 15000 BNLB Executed @ $0.1 Details | Edit
03/04/13 2:52 PM EST Buy 2000 ASNB Executed @ $0.0538 Details | Edit
03/04/13 2:35 PM EST Buy 1000 PYDS Executed @ $0.1658 Details | Edit
03/04/13 2:09 PM EST Buy 9000 BNLB Executed @ $0.096 Details | Edit
03/04/13 2:09 PM EST Buy 18000 BNLB Executed @ $0.1 Details | Edit
03/04/13 2:06 PM EST Sell 7888 VSTI Executed @ $0.1988 Details | Edit
03/04/13 2:06 PM EST Sell 6000 VSTI Executed @ $0.1988 Details | Edit
03/04/13 1:34 PM EST Buy 8000 BNLB Executed @ $0.1 Details | Edit
03/04/13 1:02 PM EST Buy 3900 ENSV Executed @ $1.04 Details | Edit
03/04/13 1:01 PM EST Buy 850 ENSV Executed @ $1.03 Details | Edit
03/04/13 12:49 PM EST Sell 5000 VSTI Executed @ $0.1988 Details | Edit
03/04/13 12:35 PM EST Sell 100 ADTY Executed @ $0.3288 Details | Edit
03/04/13 12:27 PM EST Sell 14788 VSTI Executed @ $0.1688 Details | Edit
03/04/13 12:23 PM EST Sell 9000 VSTI Executed @ $0.1688 Details | Edit
03/04/13 12:18 PM EST Sell 10000 VSTI Executed @ $0.1688 Details | Edit
03/04/13 11:18 AM EST Sell 2800 PBSV Executed @ $1.33 Details | Edit
03/04/13 11:16 AM EST Buy 18000 BNLB Executed @ $0.1 Details | Edit
03/04/13 11:15 AM EST Buy 4000 BNLB Executed @ $0.099 Details | Edit
03/04/13 11:14 AM EST Sell 1200 PBSV Executed @ $1.32 Details | Edit
03/04/13 11:00 AM EST Buy 507 LVWD Executed @ $0.273 Details | Edit
03/04/13 10:56 AM EST Sell 1050 PBSV Executed @ $1.25 Details | Edit
03/04/13 10:52 AM EST Buy 3100 ITSI Executed @ $1.03 Details | Edit
03/04/13 10:39 AM EST Sell 450 PBSV Executed @ $1.24 Details | Edit
03/04/13 10:35 AM EST Buy 10500 BNLB Executed @ $0.0958 Details | Edit
03/04/13 10:35 AM EST Buy 320 LVWD Executed @ $0.273 Details | Edit
03/04/13 10:18 AM EST Sell 5100 VSTI Executed @ $0.1688 Details | Edit
03/04/13 10:14 AM EST Sell 2000 PBSV Executed @ $1.24 Details | Edit
03/04/13 10:07 AM EST Sell 550 PBSV Executed @ $1.24 Details | Edit
03/01/13 3:37 PM EST Sell 2000 PBSV Executed @ $1.2 Details | Edit
03/01/13 3:32 PM EST Sell 1000 PBSV Executed @ $1.2 Details | Edit
03/01/13 3:25 PM EST Sell 5000 PBSV Executed @ $1.2 Details | Edit
03/01/13 3:22 PM EST Sell 6888 BIOYF Executed @ $1.2122 Details | Edit
03/01/13 3:22 PM EST Sell 8888 BIOYF Executed @ $1.2162 Details | Edit
03/01/13 3:11 PM EST Buy 3200 ENSV Executed @ $0.96 Details | Edit
03/01/13 3:11 PM EST Buy 25 ENSV Executed @ $0.96 Details | Edit
03/01/13 2:57 PM EST Buy 1260 ENSV Executed @ $0.96 Details | Edit
03/01/13 2:54 PM EST Buy 3403 ENSV Executed @ $0.95 Details | Edit
03/01/13 2:43 PM EST Sell 1000 PBSV Executed @ $1.26 Details | Edit
03/01/13 2:08 PM EST Buy 500 LVWD Executed @ $0.273 Details | Edit
03/01/13 11:23 AM EST Sell 17900 CONX Executed @ $0.19 Details | Edit
03/01/13 10:41 AM EST Buy 2300 LVWD Executed @ $0.273 Details | Edit

All trades of My Top 20 Positions posted at: http://investorshub.advfn.com/Hanks-Trading-account-10347/
My favorite board is:http://investorshub.advfn.com/Value-Microcaps-Motherboard-3251/

[10 bagger]

ENSV $1.25..

ENSERVCO Reports Record Financial Results for Fourth Quarter and Full Fiscal Year*; Revenue Growth Accelerates Sharply in 2013 First Quarter

Marketwire - Mar 28 09:00 EDT

Alert hits:/en
Company Symbols: NASDAQ-OTCBB:ENSV


DENVER, CO -- (Marketwire) -- 03/28/13 -- ENSERVCO Corporation (OTCQB: ENSV)

Selected Highlights:

Q4 revenue a record $11.3 million, up 79% from Q4 2011
Q4 income from continuing operations increases by $1.5 million to $742,000 from Q4 2011
Q4 adjusted EBITDA** increases to $2.8 million from $494,000 in Q4 2011
First full fiscal year of profitability as public company
Q1 2013 revenue projected at $18 million to $20 million versus $9.5 million in Q1 2012

ENSERVCO Corporation (OTCQB: ENSV), a provider of well-site services to the domestic onshore conventional and unconventional oil and gas industries, today reported record earnings and revenue for the fourth quarter and full fiscal year ended December 30, 2012. Fourth quarter revenue increased 79% to a record $11.3 million from $6.3 million in last year's fourth quarter. The increase was attributable to a strong improvement in revenue from well enhancement services (frac heating, hot oiling, acidizing and pressure testing), which advanced 132% to $8.7 million from $3.8 million in last year's fourth quarter. Revenue from fluid management services (water hauling/disposal and frac tank rentals) for the quarter was flat versus last year's fourth quarter at $2.4 million.

Fourth quarter gross profit increased to 33% from 23% in the 2011 fourth quarter. Operating income was $2.2 million dollars, a $3.0 million positive swing when compared with a loss from operations of $805,000 in the fourth quarter of 2011. Income from continuing operations was $742,000, or $0.03 per diluted share, an improvement of $1.5 million versus a loss of $745,000, or $0.03 per diluted share, in the comparable prior-year quarter. Adjusted EBITDA** was $2.8 million, up from $494,000 in the 2011 fourth quarter.

"The results of our expansion strategy are clearly evident in our fourth quarter financial performance," said Rick Kasch, president and CFO. "Our new service territories, broader customer base and expanded equipment fleet, combined with normal winter weather, drove a strong improvement in our revenue and earnings performance.

"Thus far in 2013, we have seen our growth accelerate, as a normal winter pattern continues and we add new equipment to begin servicing the Utica Shale region. These developments, coupled with strong demand from existing customers, are expected to result in first quarter revenue in a range of $18 million to $20 million, up from the $9.5 million reported in the 2012 first quarter."

"Our focus during 2013 will be on continued geographic expansion, particularly within oil-focused regions. We also will work to expand the range of services we are providing to several large new customers that have come to us for frac water heating. Ongoing well maintenance services generate approximately 60% of our revenue, and are vital to the optimal performance of a producing well. As customers bring new wells online, we believe they will be ideal candidates for our well maintenance services such as acidizing, hot oiling, pressure testing and water hauling.

"Customer demand during the first quarter continues to outpace our service capacity, so we plan to invest in additional equipment during the balance of the year. We will provide more detail on our CapEx budget and expansion plans sometime during the second quarter. Given current demand and a range of new business opportunities, we are very optimistic that 2013 will be another year of strong financial growth."

Full-Year Results
For the full fiscal year, which included a restrained first quarter due to exceptionally warm weather, revenue was a record $31.5 million, up 32% from $23.9 million in 2011. Gross profit, which was negatively impacted by warm weather and idled service crews during portions of the first quarter, improved to 26% from 25% in the prior year. Operating income was $1.7 million versus a loss from operations of $1.6 million in 2011. In what was the Company's first full year of profitability since becoming public, income from continuing operations was $401,000, or $0.02 per diluted share, versus a loss in 2011 of $1.6 million, or $0.07 per diluted share. Adjusted EBITDA** was $4.9 million, up 55% from $3.2 million in 2011.

*All revenue and earnings results discussed herein exclude discontinued operations, which were relatively insignificant.

Conference Call
Management will hold a conference call to discuss these results today at 1 p.m. Eastern (11 a.m. Mountain). The call will be accessible by dialing 877-407-8033 (201-689-8033 for international callers). No passcode is necessary. A telephonic replay will be available through April 29, 2013, by calling 877-660-6853 (201-612-7415 for international callers) and entering the Conference ID #411506.

Investors also can listen to the call via the Internet by accessing the ENSERVCO website, located at www.enservco.com, and linking to the "Investors" page. Participants should access the site at least 15 minutes early to register and download any necessary audio software. A replay of the webcast will be available for 90 days.

About ENSERVCO
Through its various operating subsidiaries, ENSERVCO has emerged as one of the energy service industry's leading providers of hot oiling, acidizing, frac heating and fluid management services. The Company owns and operates a fleet of more than 230 specialized trucks, trailers, frac tanks and related well-site equipment. ENSERVCO serves customers in six major domestic oil and gas fields, and operates in Colorado, Kansas, Montana, New Mexico, North Dakota, Oklahoma, Pennsylvania, Ohio, Texas, Wyoming and West Virginia. Additional information is available at www.enservco.com.

**Note on non-GAAP Financial Measures
This press release and the accompanying tables include a discussion of EBITDA and Adjusted EBITDA, which are non-GAAP financial measures provided as a complement to the results provided in accordance with generally accepted accounting principles ("GAAP"). The term "EBITDA" refers to a financial measure that we define as earnings plus or minus net interest plus taxes, depreciation and amortization. Adjusted EBITDA excludes from EBITDA stock-based compensation and, when appropriate, other items that management does not utilize in assessing ENSERVCO's operating performance (as further described in the attached financial schedules). None of these non-GAAP financial measures are recognized terms under GAAP and do not purport to be an alternative to net income as an indicator of operating performance or any other GAAP measure. We have reconciled Adjusted EBITDA to GAAP net income in the Consolidated Statements of Operations table at the end of this release.

We intend to continue to provide these non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of these non-GAAP financial measures will provide consistency in our financial reporting.

Cautionary Note Regarding Forward-Looking Statements
This news release contains information that is "forward-looking" in that it describes events and conditions ENSERVCO reasonably expects to occur in the future. Expectations for the future performance of ENSERVCO are dependent upon a number of factors, and there can be no assurance that ENSERVCO will achieve the results as contemplated herein. Certain statements contained in this release using the terms "may," "expects to," and other terms denoting future possibilities, are forward-looking statements. The accuracy of these statements cannot be guaranteed as they are subject to a variety of risks, which are beyond ENSERVCO's ability to predict, or control and which may cause actual results to differ materially from the projections or estimates contained herein. Among these risks are those set forth in a Form 10-K filed on March 28, 2013. It is important that each person reviewing this release understand the significant risks attendant to the operations of ENSERVCO. ENSERVCO disclaims any obligation to update any forward-looking statement made herein.




ENSERVCO Corporation
Consolidated Statements of Operations
For the Three Months Ended December 31,
2012 2011
------------------ ------------------
Statement of Operations
Revenues $ 11,254,266 $ 6,302,063

Cost of Revenue 7,548,905 4,865,243
------------------ ------------------

Gross Profit 3,705,361 1,436,820
------------------ ------------------
33% 23%
Operating Expenses
General and administrative
expenses 975,443 1,065,060
Depreciation and amortization 544,273 1,176,344
------------------ ------------------
Total operating expenses 1,519,716 2,241,404
------------------ ------------------

Income (Loss) from Operations 2,185,645 (804,584)
------------------ ------------------

Other Income (Expense)
Interest expense (264,039) (191,991)
Loss on disposals of equipment (259,150) (74,737)
Gain on sale of investments - -
Other (29,552) (11,329)
------------------ ------------------
Total other expense (552,741) (278,057)
------------------ ------------------

Income (Loss) From Continuing
Operations Before Tax (Expense)
Benefit 1,632,904 (1,082,641)
Income Tax (Expense) Benefit (890,632) 337,776
------------------ ------------------
Income (Loss) From Continuing
Operations $ 742,272 $ (744,865)
------------------ ------------------

Discontinued Operations
Loss from discontinued operations (316,921) (207,789)
Income tax benefit 123,599 81,038
------------------ ------------------
Loss on discontinued operations,
net of tax (193,322) (126,751)
------------------ ------------------

Net Income (Loss) 548,950 (871,616)
================== ==================


Earnings (Loss) per Common Share -
Basic
Income from continuing operations $ 0.03 $ (0.03)
Discontinued operations $ (0.01) $ (0.01)
------------------ ------------------
Net Income (Loss) $ 0.02 $ (0.04)

Earnings (Loss) per Common Share -
Diluted
Income from continuing operations $ 0.03 $ (0.03)
Discontinued operations $ (0.01) $ (0.01)
------------------ ------------------
Net Income (Loss) $ 0.02 $ (0.04)


Basic weighted average number of
common shares outstanding 28,184,999 21,778,866
Add: Dilutive shares assuming
exercise of options and warrants 194,991 -
------------------ ------------------
Diluted weighted average number of
common shares outstanding 24,316,869 21,778,866

EBITDA From Continuing Operations:
Income (Loss) From Continuing
Operations 742,272 (744,865)
Add (Deduct):
Interest expense 264,039 191,991
Income tax expense (benefit) 890,632 (337,776)
Depreciation and amortization 544,273 1,176,344
------------------ ------------------
EBITDA From Continuing Operations 2,441,216 285,694
Add (Deduct):
Stock-based compensation 30,903 122,414
Warrants issued - -
Loss on disposal of equipment 259,150 74,737
Gain on sale of investments - -
Other (income) expense 29,552 11,329
------------------ ------------------
Adjusted EBITDA From Continuing
Operations 2,760,821 494,174
================== ==================

EBITDA* From Discontinued
Operations:
Loss From Discontinued Operations (193,322) (126,751)
Add (Deduct):
Interest expense 171 1,035
Income tax benefit (123,599) (81,038)
Depreciation and amortization 17,714 113,233
------------------ ------------------
EBITDA* From Discontinued Operations (299,036) (93,521)
Add (Deduct):
Stock-based compensation - -
Warrants issued - -
Loss on disposal of equipment - -
Gain on sale of investments - -
Other (income) expense - -
------------------ ------------------
Adjusted EBITDA* From Discontinued
Operations (299,036) (93,521)
================== ==================



ENSERVCO Corporation
Consolidated Statements of Operations
and Comprehensive Loss
For the Years Ended December 31,
2012 2011
----------------- -----------------
Revenues $ 31,497,787 $ 23,904,384

Cost of Revenue 23,286,561 17,828,834
----------------- -----------------

Gross Profit 8,211,226 6,075,550
----------------- -----------------

Operating Expenses
General and administrative expenses 3,550,438 3,515,213
Depreciation and amortization 2,960,153 4,188,052
----------------- -----------------
Total operating expenses 6,510,591 7,703,265
----------------- -----------------

Income (Loss) from Operations 1,700,635 (1,627,715)
----------------- -----------------

Other Income (Expense)
Interest expense (902,152) (699,230)
Loss on disposals of equipment (5,739) (119,023)
Gain on sale of investments 24,653 -
Other 10,870 (49,765)
----------------- -----------------
Total other expense (872,368) (868,018)
----------------- -----------------

Income (Loss) From Continuing
Operations Before Tax (Expense)
Benefit 828,267 (2,495,733)
Income Tax (Expense) Benefit (426,779) 897,923
----------------- -----------------
Income (Loss) From Continuing
Operations $ 401,488 $ (1,597,810)
----------------- -----------------

Discontinued Operations
Loss from discontinued operations (797,636) (605,650)
Income tax benefit 311,078 236,204
----------------- -----------------
Loss on discontinued operations, net
of tax (486,558) (369,446)
----------------- -----------------

Net Loss $ (85,070) $ (1,967,256)
================= =================

Other Comprehensive (Loss) Gain
Unrealized (gain on available-for-
sale securities, net of tax 17,506 (133,665)
Unrealized loss on interest rate
swap, net of tax (4,805) -
Reclassification into earnings, net
of tax (40,579) -
----------------- -----------------
Total other comprehensive loss (27,878) (133,665)

Comprehensive Loss $ (112,948) $ (2,100,921)
================= =================



Earnings (Loss) per Common Share -
Basic
Income from continuing operations $ 0.02 $ (0.07)
Discontinued operations $ (0.02) $ (0.02)
----------------- -----------------
Net Loss $ - $ (0.09)

Earnings (Loss) per Common Share -
Diluted
Income from continuing operations $ 0.02 $ (0.07)
Discontinued operations $ (0.02) $ (0.02)
----------------- -----------------
Net Loss $ - $ (0.09)


Basic weighted average number of
common shares outstanding 23,389,151 21,778,866
Add: Dilutive shares assuming
exercise of options and warrants 927,718 -
----------------- -----------------
Diluted weighted average number of
common shares outstanding 24,316,869 21,778,866

EBITDA From Continuing Operations:
Income (Loss) From Continuing
Operations $ 401,488 $ (1,597,810)
Add (Deduct):
Interest expense 902,152 699,230
Income tax expense (benefit) 426,779 (897,923)
Depreciation and amortization 2,960,153 4,188,052
----------------- -----------------
EBITDA From Continuing Operations $ 4,690,572 $ 2,391,549
Add (Deduct):
Stock-based compensation 279,362 576,498
Warrants issued - 46,353
Loss on disposal of equipment 5,739 119,023
Gain on sale of investments (24,653) -
Other (income) expense (10,870) 49,765
----------------- -----------------
Adjusted EBITDA From Continuing
Operations $ 4,940,150 $ 3,183,188
================= =================

EBITDA* From Discontinued Operations:
Loss From Discontinued Operations $ (486,558) $ (369,446)
Add (Deduct):
Interest expense 1,770 7,714
Income tax benefit (311,078) (236,204)
Depreciation and amortization 128,935 511,588
----------------- -----------------
EBITDA* From Discontinued Operations $ (666,931) $ (86,348)
Add (Deduct):
Stock-based compensation - -
Warrants issued - -
Loss on disposal of equipment - -
Gain on sale of investments - -
Other (income) expense - -
----------------- -----------------
Adjusted EBITDA* From Discontinued
Operations $ (666,931) $ (86,348)
================= =================



ENSERVCO Corporation Consolidated Balance Sheets
December 31, December 31,
-------------- --------------
2012 2011
-------------- --------------

ASSETS
Current Assets
Cash and cash equivalents $ 533,627 $ 417,005
Accounts receivable, net 7,791,342 4,505,254
Marketable securities - 150,793
Prepaid expenses and other current assets 802,020 593,291
Inventories 273,103 549,432
Deferred tax asset 153,466 187,170
-------------- --------------
Total current assets 9,553,558 6,402,945

Property and Equipment, net 15,020,890 14,759,039
Fixed Assets Held for Sale, net 304,429 412,831
Non-Competition Agreements, net 30,000 180,000
Goodwill 301,087 301,087
Long-term portion of interest rate swap 16,171 -
Other Assets 630,891 64,770
-------------- --------------

TOTAL ASSETS $ 25,857,026 $ 22,120,672
============== ==============

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued liabilities $ 3,585,785 $ 2,954,687
Line of credit borrowings 2,151,052 2,263,227
Current portion of long-term debt 2,236,343 3,867,658
Current portion of interest rate swap 24,048 -
-------------- --------------
Total current liabilities 7,997,228 9,085,572
-------------- --------------

Long-Term Liabilities
Deferred rent payable 20,860 22,044
Subordinated debt - related party - 1,477,760
Long-term debt, less current portion 10,570,928 8,020,435
Deferred income taxes, net 451,662 387,487
-------------- --------------
Total long-term liabilities 11,043,450 9,907,726
-------------- --------------
Total liabilities 19,040,678 18,993,298
-------------- --------------

Commitments and Contingencies

Stockholders' Equity
Common and preferred stock. $.005 par
value
Authorized: 100,000,000 common shares
and 10,000,000 preferred shares
Issued: 31,928,894 common shares and -0-
preferred shares
Treasury Stock: 103,600 common shares
Issued and outstanding: 31,825,294 and
21,778,866 common shares, and -0-
preferredshares each, at December 31,
2012 and December 31, 2011,
respectively
159,127 108,894
Additional paid-in-capital 9,864,363 6,112,674
Accumulated deficit (3,202,337) (3,117,267)
Accumulated other comprehensive income (4,805) 23,073
-------------- --------------
Total stockholders' equity 6,816,348 3,127,374
-------------- --------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 25,857,026 $ 22,120,672
============== ==============


Contacts:
Pfeiffer High Investor Relations, Inc.
Geoff High
Phone [phone]
Email: Email Contact
Web: www.pfeifferhigh.com

[10 bagger]

CIBH $0.53.. Bank Consent Order Released

WAUKESHA, WI -- (Marketwire) -- 03/21/13 -- Bank holding company CIB Marine Bancshares, Inc. (OTCQB: CIBH) announced today that its wholly-owned banking subsidiary, CIBM Bank, received notification from the Federal Deposit Insurance Corporation and Illinois Department of Financial and Professional Regulation that the Consent Order that CIBM Bank has been operating under since April 2010 was terminated, effective March 20, 2013.

"The removal of the Order is an important milestone for CIBM Bank, which reflects our improved performance over the last several quarters and our team's dedication to improving its capital position, asset quality and profitability. I am thankful for the hard work of our staff and continued support of our clients," said Charles Ponicki, President and CEO.

Although the Consent Order has been terminated, CIBM Bank entered into revised regulatory requirements with the FDIC and IDFPR, effective February 14, 2013. Under the revised regulatory requirements, CIBM Bank remains subject to certain restrictions, including but not limited to maintaining a Tier 1 capital leverage ratio of 8% and Total risk-based capital ratio of 12%, as well as certain restrictions on its ability to pay dividends.

CIB Marine Bancshares, Inc. is the holding company for CIBM Bank, which operates 11 banking offices in Central Illinois, Wisconsin and Indiana. More information on the company is available at www.cibmarine.com, including recent shareholder letters, regulatory financial reports (vis-à-vis a web link) and audited financial statements.

FORWARD-LOOKING STATEMENTS
CIB Marine has made statements in this earnings release that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. CIB Marine intends these forward-looking statements to be subject to the safe harbor created thereby and is including this statement to avail itself of the safe harbor. Forward-looking statements are identified generally by statements containing words and phrases such as "may," "project," "are confident," "should be," "intend," "predict," "believe," "plan," "expect," "estimate," "anticipate" and similar expressions. These forward-looking statements reflect CIB Marine's current views with respect to future events and financial performance that are subject to many uncertainties and factors relating to CIB Marine's operations and the business environment, which could change at any time.

There are inherent difficulties in predicting factors that may affect the accuracy of forward-looking statements.

Stockholders should note that many factors, some of which are discussed elsewhere in this Earnings Release and in the documents that are incorporated by reference, could affect the future financial results of CIB Marine and could cause those results to differ materially from those expressed in forward-looking statements contained or incorporated by reference in this document. These factors, many of which are beyond CIB Marine's control, include but are not limited to:

operating, legal, and regulatory risks;
economic, political, and competitive forces affecting CIB Marine's banking business;
the impact on net interest income and securities values from changes in monetary policy and general economic and political conditions; and
the risk that CIB Marine's analyses of these risks and forces could be incorrect and/or that the strategies developed to address them could be unsuccessful.


These factors should be considered in evaluating the forward-looking statements, and undue reliance should not be placed on such statements. Forward-looking statements speak only as of the date they are made. CIB Marine undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are subject to significant risks and uncertainties and CIB Marine's actual results may differ materially from the results discussed in forward-looking statements.

Source: CIB Marine Bancshares, Inc.
===================================================
CIBH.. $0.53.. CIB Marine Bancshares Announces 2012 Financial Results..

Company Reports Earnings of $1.4 Million for the Year 2012

WAUKESHA, WI -- (Marketwire) -- 03/07/13 -- CIB Marine Bancshares, Inc. (OTCQB: CIBH) is pleased to report earnings of $1.4 million for the year ended December 31, 2012. Financial highlights for 2012 include:

Earnings from operations for the year 2012 were $1.4 million compared to a net loss of $5.4 million for the year 2011. Improvements were primarily the result of a reversal of provisions for loan losses.
Earnings per share of common stock was $0.08 for the year ending December 31, 2012, compared to losses per share of $0.30 for the year ending December 31, 2011.
Provisions for loan losses for the year 2012 were a reversal of $3.2 million compared to provisions of $6.4 million for the year 2011. The 2012 reversal of provisions was primarily the result of recoveries of prior charged-off loans.
Net interest income declined by $2.0 million from $20.2 million during the year 2011 to $18.2 million during the year 2012. The decline was primarily the result of a decline in earning assets.
Noninterest expense for the year 2012 was $20.7 million compared to $21.7 million during the same period of 2011. Declines were the result of reduced write downs and losses on assets and ongoing efforts to reduce expenses.
The book value per share of common stock was $0.42 at December 31, 2012, compared to $0.23 at December 31, 2011.
The Tier 1 leverage ratio for CIB Marine improved to 14.39% at December 31, 2012, from 13.15% at December 31, 2011.
The Nonperforming asset ratio, or the sum of nonperforming assets, restructured loans and loans 90 days or more past due and still accruing as a ratio of total assets, declined from 7.42% at December 31, 2011, to 5.93% at December 31, 2012.
CIB Marine Bancshares, Inc. is the holding company for CIBM Bank, which operates 12 banking offices in Central Illinois, Wisconsin and Indiana. More information on the company is available at www.cibmarine.com, including, but not limited to, recent shareholder letters and regulatory financial reports (vis-à-vis a web link).

FORWARD-LOOKING STATEMENTS
CIB Marine has made statements in this earnings release that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. CIB Marine intends these forward-looking statements to be subject to the safe harbor created thereby and is including this statement to avail itself of the safe harbor. Forward-looking statements are identified generally by statements containing words and phrases such as "may," "project," "are confident," "should be," "intend," "predict," "believe," "plan," "expect," "estimate," "anticipate" and similar expressions. These forward-looking statements reflect CIB Marine's current views with respect to future events and financial performance that are subject to many uncertainties and factors relating to CIB Marine's operations and the business environment, which could change at any time.

There are inherent difficulties in predicting factors that may affect the accuracy of forward-looking statements.

Stockholders should note that many factors, some of which are discussed elsewhere in this Earnings Release and in the documents that are incorporated by reference, could affect the future financial results of CIB Marine and could cause those results to differ materially from those expressed in forward-looking statements contained or incorporated by reference in this document. These factors, many of which are beyond CIB Marine's control, include but are not limited to:

operating, legal, and regulatory risks;
economic, political, and competitive forces affecting CIB Marine's banking business;
the impact on net interest income and securities values from changes in monetary policy and general economic and political conditions; and
the risk that CIB Marine's analyses of these risks and forces could be incorrect and/or that the strategies developed to address them could be unsuccessful.
These factors should be considered in evaluating the forward-looking statements, and undue reliance should not be placed on such statements. Forward-looking statements speak only as of the date they are made. CIB Marine undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are subject to significant risks and uncertainties and CIB Marine's actual results may differ materially from the results discussed in forward-looking statements.

Source: CIB Marine Bancshares, Inc.

[10 bagger]

#2.. CPHMF.. $3.65..

About Cipher Pharmaceuticals Inc.

Message Board..
http://www.stockhouse.com/companies/bullboards/t.dnd/cipher-pharmaceuticals-inc.

News Releases..
http://micro.newswire.ca/55305-0.html

Cipher Pharmaceuticals (TSX: DND) (OTC: CPHMF) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners. For more information, please visit www.cipherpharma.com.

Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was approved by the FDA in May and was launched in the United States in Q4 2012 as Absorica™. The product was also recently approved by Health Canada and Cipher expects to launch it as Epuris™ in Canada in early Q3 2013.

Mississauga-based Cipher Pharmaceuticals is a spinoff of CML Healthcare, a more than three-decades old medical imaging company that shed its drug development division, which was burning cash, when it decided to convert to an income trust. The resulting spinoff, Cipher, transitioned from being defined by its relative risk to being notable for its comparative safety. Unlike many of its newfound peers, Cipher has carved out a sweet spot in the middle of the drug development process, identifying late stage product candidates with near term market potential.

Last year was a good one for Cipher Pharma, especially after May when the company announced it had received FDA approval for acne treatment Absorica. Absorica was the third Cipher product to receive regulatory approval. Since 2007, the company has derived most of its revenue from cholesterol treatment drug Lipofen, and in Q3 of last year it began to market ConZip, a Tramadol treatment for moderate to moderately severe chronic pain.

Cipher management, however, believes Absorica could be the first Cipher product to be truly differentiated from its competition.

While Lipofen and Conzip have found niche markets, the products were not first to market and competed in relatively crowded spaces. Loe points out that in the first two months alone, Absorica achieved 3.6% prescription market share against lower-priced generic alternatives.
Absorica is a trademark of Ranbaxy Laboratories Limited

Lidose is a registered trademark of SMB Laboratories.

Accutane is a registered trademark of Hoffman-La Roche

CONTACTS:
Charles M. Caprariello
Robert Ferris

Vice President, Corporate Communications
RF Binder Partners Inc.

Ranbaxy Inc.
[phone]
[phone]

http://www.cipherpharma.com/files/DND%20-%20Q4%202012%20Report_v001_s9py6c.pdf

[10 bagger]

KLYG.. $0.0562..

Kelyniam is a Medical Device Manufacturing Company that specializes in the production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The company's Engineering Division is constantly working with medical professionals by allowing them to operate more effectively, improving patient care, and reducing health care cost by providing the highest quality products available with today's technology. Kelyniam is continually researching and developing new products and processes to help patients live more active and productive lives.
Our Engineering Division has recently made significant advancements in the use of Bio-CADCAM technology such as providing near perfect replicated Cranial implants to replace damaged bone structures. Similarly to our most recent acquisitions, Kelyniam is constantly in search of value enterprises and investment opportunities in North and South America. The company's long term business goals are to advance our existing technology and capabilities, and to acquire or invest in High Technology industries which management has extensive experience in order to consistently add shareholder value.

KELYNIAM LATEST NEWS:
Kelyniam Custom Cranial Implants Receive Endorsement From Skull Based Neurosurgeon Dr. Ammirati of The Ohio State University Wexner Medical Center,
February, 01

Kelyniam Global Inc. Announces Record Revenues,
January, 15

============================================================

Kelyniam Custom Cranial Implants Receive Endorsement From Skull Based Neurosurgeon Dr. Ammirati of The Ohio State University Wexner Medical Center

Canton, CT, Jan. 29, 2013 (GLOBE NEWSWIRE) -- (OTC: KLYG) Kelyniam Custom Cranial Implants, designed to fill the boney void in a patient's skull, have been endorsed by Mario Ammirati, MD, Director of Skull Based Surgery, Stereotactic Radiosurgery and the Dardinger Microneurosurgical Skull Based Laboratory, Wexner Medical Center, at the Ohio State University. This is the first product Dr. Ammirati has ever endorsed.

Dr. Ammirati stated: "As a neurosurgeon specializing in skull based surgery and brain tumors, I am encouraged with the advancements Kelyniam has made in patient customized cranial implants. I am extremely happy with the precision fit and the fast service I receive with every case. Complex cranial defects resulting from trauma or oncologic resection present reconstructive challenges. No matter how complex the defect, Kelyniam's implant design team is very responsive to my needs. They understand the surgical plans and are quick to respond to my design requirements. The end result is a product that fits very well and is quick to implant, thereby reducing O.R. time and providing the patient with excellent aesthetic results."

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

Source: Kelyniam Global Inc.
2013 GlobeNewswire, Inc.
===================================================

Kelyniam Global Inc. Announces Record Revenues

Canton, CT, Jan. 15, 2013 (GLOBE NEWSWIRE) --

Third Quarter

Kelyniam is pleased to announce record quarterly revenues of $382,177 for the third quarter ending September 30th 2012. This represents almost double the product revenue produced in the second quarter 2012. The company continues to penetrate the custom cranial implant marketplace and has sold implants to medical institutions in more than 20 different states. Furthermore, the company has sold the first maxiofacial implants in the fourth quarter as a result of the recent FDA 510k approval in late third quarter.

Fourth Quarter

The debut of Kelyniam maxiofacial implants in the fourth quarter was met with orders. These orders combined with existing custom cranial implant orders propelled revenues to approximately $400,000 for the fourth quarter, exceeding internal expectations of a slow quarter due to multiple holidays and fewer surgeries. Final fourth quarter numbers will be released once a full accounting is complete.

"The final two quarters of the year demonstrate that both the custom cranial and maxiofacial implant markets have capacity for a product of superior design. Management has worked hard to right the ship in 2012 and looks to build on the momentum in 2013" stated President and CEO Tennyson Anthony. "Kelyniam not only has created a product that fills the patient's cranial void, but is filling the void in the marketplace for a timely-delivered well-fitting product."

Upcoming Conference

Kelyniam will be exhibiting once again at the North American Skull Base Society (NASBS) February 15th - 17th, in Miami, FL.

Financial tables can be found on the company's website www.kelyniam.com

About Kelyniam Global, Incorporated

Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

Source: Kelyniam Global Inc.
2013 GlobeNewswire, Inc.

=======================================================
Kelyniam Global Inc. Announces Second Quarter 2012 Revenues
Released October 15, 2012
Second Quarter Results
For the quarter ending June 30th 2012 Kelyniam Global reported a loss of $45,692 on custom cranial product revenue of $196,435, compared to a net loss of $149,000 on revenues of $210,000 in the first quarter 2012. The company attributes the slight reduction in revenue to a slow April. Kelyniam expects the tepid sales of the spring to become robust with the arrival of “trauma season”. Trauma season is the seasonal variation in trauma cases during the warmer weather months, according to the American College of Surgeons. http://www.facs.org/trauma/ntdb/fantus/0906.pdf

In addition to the product revenue, the company realized $100,000 of grant revenue from the Connecticut Department of Economic Development (DECD) in the second quarter.

Professional costs were greater in Q2 from several one-time events; the line-of-credit with Westfield Bank and the DECD funding. The company also incurred higher legal fees defending a lawsuit filed by former employee John Mastoloni. The company expects to incur additional legal costs in the coming quarters as the lawsuit continues and therefore will no longer pursuit fully reporting status. Other one-time expenses for the quarter were costs associated with filing the 510k for craniofacial implant approval with the FDA.

Kelyniam had a productive quarter with its emergence as a multiproduct company with the filing of the 510k to manufacture and market craniofacial implants made from PEEK-OPTIMA. In order to facilitate the anticipated growth of several product lines the company took steps to shore up the financials with the line-of-credit and the DECD aid package.

Recent Business Developments
September - Kelyniam received FDA approval to market craniofacial implants in the United States.

September – Kelyniam President and CEO Tennyson Anthony recently traveled to Kuwait to sit down with government officials to discuss their purchasing of Kelyniam products. Mr. Anthony returned very optimistic that a first order will be coming in the near future. During the visit Mr. Anthony met with various doctors and surgeons interested in using the company’s current products and others who were excited about the company’s future products. Ministry of Health officials were quoted as saying to Mr. Anthony, “[O]ur country puts a priority on our healthcare system and has been rapidly developing it since the liberation, therefore we are only interested in the best products. Kelyniam will be a great fit.”

Research & Development
The company continues to allocate resources on improving efficiencies with the manufacturing process. Currently the company is working on prototypes of 2 products that do not yet exist in the medical device marketplace.
==============================================================
KELYNIAM GLOBAL, INC.
Kelyniam Files 510(k) for Custom Craniofacial Implants & Closes Financings....

CANTON, Conn., June 20, 2012 (GLOBE NEWSWIRE) — Kelyniam Global, Inc. (KLYG), a medical device company focused on the design and manufacturing of custom cranial implants, has filed a 510(k) application with the Food and Drug Administration (FDA) for clearance to market a custom craniofacial implant product made from the Invibio PEEK Optima material. The application has been received and is currently in the FDA approval process 510(k) (FDA# K121755).

Financings

Kelyniam has secured a line-of-credit from Westfield Bank (MA). The company recently closed this financing which will give the flexibility to facilitate the custom cranial business as well as expand in other markets and products.

Kelyniam has also closed on an aid package with the State of Connecticut Department of Economic Development. The aid package is designed to assist the company with asset purchases and hiring local skilled workers in support for an expansion plan laid out by management.

“Kelyniam is pleased to have filed this new application for clearance of its custom craniofacial implant, and look forward to the FDA’s review of the application,” said Tennyson Anthony, President/ CEO of Kelyniam. Mr. Anthony went on to say “Management has worked tirelessly this year to put the company on a greater financial footing. We are ecstatic both institutions are confident in the technology behind the manufacture of Kelyniam Custom Skull Implants and the execution of our business plan. We are excited to have the support of a quality financial institution such as Westfield Bank. Shareholders should find great comfort that both financings are non-dilutive.”

About Kelyniam Global, Incorporated

Kelyniam Global Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today’s technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.